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SUMMARY 
The erythroblastic leukemia viral oncogene homolog (ERBB) system consists of the four 
receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR), ERBB2 (HER2, 
neu), ERBB3 (HER3) and ERBB4 (HER4). The receptor family has eleven ligands causing 
receptor homo- or hetero-dimerization, and transphosphorylation of mainly tyrosine residues 
in the cytosolic receptor domains. Thus, numerous signaling cascades are induced, which 
associate the ERBB receptors with functions in development, tissue homeostasis and 
diseases. Betacellulin (BTC) is an ERBB ligand with binding affinities for EGFR and ERBB4. It 
was first identified in murine pancreatic insulinoma-derived cell lines and apparently plays a 
role in many tissues, e.g. in pancreatic islets of Langerhans, in the stomach and in the 
mammary gland, as well as in tumors, e.g. in sarcoma, in breast cancer and many others. BTC 
is synthesized as a single-transmembrane precursor, which requires cleavage by A disintegrin 
and metalloproteinase 10 (ADAM10), in order to induce paracrine or autocrine signaling with 
the soluble extracellular domain. Membrane-bound BTC can also induce juxtacrine signaling. 
Additionally, BTC is able to differentiate many different cell types and it acts as a potent 
mitogen in epithelial and smooth muscle cells. Furthermore, BTC was associated with 
resistance to EGFR therapy in breast cancer cells. Despite its abundance and multiple 
functions, the ubiquitous depletion of BTC in mice showed no overt phenotype. On the 
contrary, its ubiquitous overexpression results in numerous phenotypes, and it was shown, 
that BTC transgenic mice were protected against experimental induced acute pancreatitis 
(AP). 
AP is an inflammatory disease of the pancreas, induced by gall stones or alcohol abuse. 
Digestive enzymes are activated prematurely and released into the interstitium of the 
pancreas, where they auto-digest the membranes of different cell types constituting the 
pancreas. This is accompanied by an inflammatory reaction, which manifests as severe pain, 
signs of inflammatory response syndrome (SIRS) and frequently multi-organ failure and death.  
Regarding the ERBB receptor network, EGFR and its ligand EGF were associated with 
an ameliorated course of AP, previously, but follow-up studies were missing. The remaining 
ERBB family members have not been investigated until our group revealed that BTC 
overexpression has a protective effect in AP, which was shown not to be meditated by EGFR 
but associated with increased SAPK activity. However, the mechanisms behind this finding 
were revealed in the following study.  
In the first study of this thesis ‘The protective effect of betacellulin against acute pancreatitis is 
ERBB4-dependent’, ERBB4 was characterized as the transmitting receptor of BTC-mediated 
protection against AP. Here, the ERBB4 receptor was deleted in Btc transgenic (Btc tg) mice 
specifically in the pancreas under the promoter Pancreas associated transcription factor 1A 
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(Ptf1a) using the Cre-loxP system (Erbb4fl/fl;Ptf1aCre/+;Btctg/+). Also, Btc tg mice were crossed 
into a kinase-dead Egfr background (EgfrWa5/+;Btctg/+). Erbb4fl/fl;Ptf1aCre/+;Btctg/+mice and 
EgfrWa5/+;Btctg/+ mice were subjected to caerulein- and L-arginine induced AP. Serum lipase 
and serum amylase levels and histological parameters, such as pancreatic apoptosis, necrosis 
and edema were determined to grade the AP. Btc tg mice were protected from AP. While 
EgfrWa5/+;Btctg/+ mice presented like Btc tg mice in all parameters, the loss of Erbb4 inhibited 
the BTC-mediated phenotype with Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice presenting with parameters 
like their wildtype littermates. Btc tg mice showed less fibrosis upon AP induction compared to 
wildtype animals. Microarray and Western blot analyses revealed the enhanced expression of 
the extracellular matrix (ECM)-regulating proteins matrix metalloproteinase 2 (MMP2), MMP3, 
periostin (POSTN), and matrix-gla protein (MGP) in BTC transgenic mice and in EgfrWa5/+;Btctg/+ 
littermates but not in Erbb4fl/fl;Ptf1aCre/+;Btctg/+ animals upon AP induction. BTC induced the 
regulated intramembrane proteolysis (RIP) of ERBB4, which was associated with trafficking of 
the intracellular domain (ICD) of ERBB4 into the cytosol and nucleus, where it is known to act 
as transcriptional co-activator. This suggests that the ERBB4 ICD enhances the expression of 
ECM-proteins and -modifiers as a transcriptional regulator, in order to remodel the pancreatic 
microenvironment. Furthermore, BTC enhanced SAPK signaling via ERBB4, which could be 
associated with increased apoptosis rates. In summary, we suggest that BTC induces a dual 
mechanism in order to prevent AP development in mice, comprising tissue remodeling and 
increasing apoptosis. These data strongly recommend an inclusion of BTC in the development 
of novel therapeutic strategies or at least to investigate further mechanisms of the ERBB4-BTC 
signaling axis to uncover more suitable targets for AP treatment.  
The second study ‘Unraveling the ERBB network upon betacellulin signaling in 
pancreatic ductal adenocarcinoma in mice‘ shows that a high BTC expression is not always 
beneficial for pancreatic diseases. High BTC levels in pancreatic cancer have been reported 
previously and being a growth factor, it is not surprising that BTC also functions as a mitogen 
in pancreatic cancer cell lines. Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease 
which is only treated using resection and toxic chemotherapy, and it remains the cancer with 
the lowest survival rate (5-year survival: 8%). The only targeted therapy affects EGFR, albeit 
with marginal clinical relevance and the frequent development of resistance.  
The aim of the study was to reveal the role of BTC in PDAC and to investigate, which 
ERBB receptors are involved. To address these questions, an established mouse model was 
used. We used mice expressing constitutively active KRAS under the pancreas-specific 
promoter Ptf1a (Ptf1aCre/+;KrasG12Dl+,herein referred to as KC mice). These mice mimic human 
PDAC development, yet, showing a slow progression and incomplete penetrance of invasive 
carcinoma. However, the development of premalignant lesions, called pancreatic intraepithelial 
metaplasia (PanIN) and their subsequent progression into pancreatic cancer imitates the 
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human condition very well. Prior to PanIN development, induced by the activating mutation 
KRASG12D, acinar cells transdifferentiate to duct cells (acinar-ductal metaplasia, ADM). Some 
ERBB ligands have been implicated in PDAC development, the role of BTC as a ligand of 
EGFR and ERBB4 was however unknown before we performed our study.  
In this study, we found BTC expression in human PDAC specimen, human pancreatic 
cancer cell lines and in pancreatic premalignant lesions of KC mice. Upon the deletion of BTC 
in KC mice by CRISPR/Cas9 (Btc-/-;Ptf1aCre/+;KrasG12Dl+), PDAC development and progression 
were decelerated, which might be associated with the decreased EGFR expression and 
phosphorylation, we observed. Concordant with this observation, the overexpression of BTC 
in KC mice (Btctg/+;Ptf1aCre/+;KrasG12Dl+, herein referred to as BKC mice) accelerated PDAC 
development and progression and led to the decrease of the median survival by approximately 
nine months compared to KC mice. In BKC mice, not only EGFR was activated, but also 
ERBB4 and ERBB2 (the latter at least by hetero-dimerization with EGFR). BTC enhanced RAS 
activity very early, which was exclusively mediated by EGFR, shown by the pancreas-specific 
deletion of the designated receptors, using the Cre-loxP system 
(Btctg/+;Ptf1aCre/+;KrasG12Dl+;Egfrfl/fl (EGFR KO;BKC), Btctg/+;Ptf1aCre/+;KrasG12Dl+;Erbb2fl/fl 
(ERBB2 KO;BKC), Btctg/+;Ptf1aCre/+;KrasG12Dl+;Erbb4fl/fl (ERBB4 KO;BKC)). Beyond RAS 
activation, BTC induced ADM in isolated murine acinar cell clusters in 3-D cell culture. The 
deletion of Erbb2 and Erbb4 in BKC mice resulted in a drastically prolonged survival. This 
finding fitted to the observation that PDAC development was decelerated in ERBB2 KO;BKC 
mice, while the lack of ERBB4 showed no overt difference when compared to the 
histopathology of BKC mice. The deficiency of each receptor led to a decreased EGFR 
activation, and the loss of ERBB4 resulted in concomitantly decreased ERBB2, MAPK and 
SAPK activation. Interestingly, the depletion of EGFR rescued the BKC phenotype to an almost 
normal appearing pancreas, which was associated with prolonged survival, but the 
development of sporadic ADM could not be prevented. These ADM lesions were 
immuno-positive for ERBB2, ERBB3 and ERBB4, but Western blot analysis revealed that the 
same receptors were down-regulated in expression and activity. However, increased ERBB4 
ICD signaling could be detected in the pancreas of EGFR KO;BKC mice, indicating a 
compensatory mechanism by ERBB4 upon the loss of EGFR.  
These data are in line with the common view of the PDAC research community that 
EGFR is a crucial player in PDAC development. However, we could show that ERBB2 and 
ERBB4 are significantly involved in the survival of BKC mice and should be considered in 
further studies to reveal the mechanisms. Importantly, the loss of EGFR also decreased the 
impact of ERBB2 and ERBB3, which shows that targeting EGFR is the right way for treatment 
since EGFR inhibition is accompanied by the inhibition of further oncogenic receptors. 
However, we provide evidence that upon the loss of EGFR, a compensatory induction of the 
 
VII 
 
ERBB4 ICD occurs which suggests ERBB4 to be involved in the development of resistances 
in EGFR-targeted therapies. This study strongly indicates that instead of targeting EGFR only, 
the complete ERBB family should be considered for inhibition in PDAC therapies.  
 
The projects presented in this thesis reveal novel aspects of the spectrum of BTC 
signaling. Being beneficial on the one hand, it can cause detrimental effects on the other hand. 
Furthermore, we confirm that ERBB4 signaling has two faces, as well. In one setting, 
BTC-mediated ERBB4 signaling is beneficial to the outcome of disease, as observed in in AP. 
In a different setting, the activation of ERBB4 by the same ligand has dreadful consequences 
for the course of the disease, as observed in pancreatic cancer. Moreover, we showed that 
BTC prefers ERBB4- over EGFR-binding in AP, whereas in PDAC, BTC activates three out of 
four of the available ERBB receptors, revealing the predominant participation of EGFR 
signaling. This indicates that, regarding the ERBB family, the key to the outcome of diseases 
might be determined by receptor involvement after ligand binding. The bias in ligand-receptor 
interactions within the ERBB system needs to be further investigated. This is the point where 
the therapeutic benefit of BTC becomes questionable and must be qualified. BTC might be 
beneficial in AP, however, as soon as it encounters a cell with oncogenic KRAS, it has a 
detrimental effect, potentially enhancing RAS activity and causing ADM, thereby providing the 
basic component of PDAC development. Importantly, future studies of the ERBB receptor 
system should be regarded in a context-dependent manner and should implicitly consider the 
whole ERBB family. 
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ZUSAMMENFASSUNG 
Das ERBB (erythroblastic leukemia viral oncogene homologs) System besteht aus vier 
Rezeptor-Tyrosinkinasen (RTKs): epidermal growth factor receptor (EGFR), ERBB2- (HER2, 
neu), ERBB3- (HER3) und ERBB4-Rezeptor (HER4). Die Rezeptoren der ERBB-Familie 
können von elf Liganden gebunden werden, was zu einer Homo- oder Hetero-Dimerisierung 
der Rezeptoren führt, sowie zu einer anschließenden Transphosphorylierung, hauptsächlich 
von Tyrosin-Resten in der zytosolischen Rezeptordomäne. Die ERBB-Rezeptoren induzieren 
zahlreiche Signalkaskaden, die bei der Embryonalentwicklung, Gewebehomöostase und auch 
bei der Entstehung von Krankheiten beteiligt sind. Betacellulin (BTC) ist einer der ERBB-
Liganden mit Bindungsaffinitäten für EGFR und ERBB4. Er wurde erstmals in einer murinen 
Pankreas-Insulinom-Zelllinie identifiziert, spielt aber in zahlreichen Geweben und Organen, 
z.B. in den Langerhans-Inseln des Pankreas, in der Brustdrüse, dem Magen, im Gehirn, aber 
auch in Tumoren, z.B. im Sarkom, in Brustkrebs und vielen anderen Krebsarten eine 
bedeutende Rolle. BTC wird als membrangebundenes Vorläuferprotein synthetisiert, und 
durch das Enzym a disintegrin and matrix 10 (ADAM10) gespalten, um freigesetzt als 
Wachstumsfaktor parakrin oder autokrin zu wirken. Membrangebundenes BTC kann auch 
juxtakrin mit Nachbarzellen kommunizieren. BTC ist in der Lage, verschiedenste Zellen zu 
differenzieren und es fungiert als potentes Mitogen in Epithel- und in glatten Muskelzellen. In 
Brustkrebszellen wird die BTC-Expression mit der Resistenzbildung in der EGFR-Therapie 
assoziiert. Der Knockout (KO) von BTC zeigte in Mäusen keinen offensichtlichen Phänotyp. 
Hingegen kommt es bei einer ubiquitären Überexpression von BTC zu einem ausgeprägten 
Phänotyp der transgenen Mäuse. BTC transgene (tg) Mäuse sind z.B. vor experimentell 
induzierter akuter Pankreatitis (AP) geschützt. 
AP ist eine entzündliche Erkrankung der Bauchspeicheldrüse (Pankreas), die durch 
Gallensteine oder Alkoholmissbrauch verursacht wird. Verdauungsenzyme werden vorzeitig 
aktiviert und in das Interstitium des Pankreas freigesetzt, wo sie die Membranen 
verschiedenster Pankreas-bildender Zelltypen verdauen (Auto-Digestion). Begleitet wird dies 
von einer Entzündungsreaktion, die sich als heftiger Schmerz äußert und häufig zum signs of 
inflammatory response syndrome (SIRS), Multiorganversagen und zum Tod führt.  
Es konnte bereits gezeigt werden, dass EGFR und die Applikation seines Liganden 
epidermal growth factor (EGF) zu einer Verbesserung der AP führten, jedoch wurden die 
zugrundeliegenden Mechanismen nicht untersucht. Die übrigen ERBB-Familienmitglieder 
wurden erst untersucht, als unsere Gruppe zeigen konnte, dass BTC die Entwicklung einer AP 
verhinderte. Dieser Schutzmechanismus wird aber nicht durch den EGFR vermittelt, allerdings 
wurde eine erhöhte SAPK-Aktivität im Zusammenhang mit dem BTC vermittelten Schutz 
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festgestellt. Die zugrundeliegenden Mechanismen wurden erst in dieser Doktorarbeit 
untersucht.  
In der ersten Studie dieser Arbeit „The protective effect of betacellulin against acute 
pancreatitis is ERBB4-dependent’, wurde ERBB4 als entscheidender Vermittler des BTC-
induzierten Schutzes vor AP identifiziert. Dazu wurde der ERBB4-Rezeptor in BTC tg Mäusen 
spezifisch im Pankreas unter dem Promotor pancreas-associated transcription factor 1A 
(Ptf1a) mit Hilfe des Cre-loxP-Systems (Erbb4fl/fl;Ptf1aCre/+;Btctg/+) ausgeschaltet. Zusätzlich 
wurden die Btc tg Mäuse in ein Knockdown Mausmodel für den EGFR eingekreuzt 
(EgfrWa5;Btctg/+). Erbb4fl/fl;Ptf1aCre/+;Btc-Mäusen und EgfrWa5;Btctg/+-Mäusen wurde mittels 
Caerulein oder L-Argininin eine AP induziert. Um die Schwere der AP zu bestimmen, wurden 
klinische Parameter wie Lipase- und Amylase-Spiegel im Serum, sowie histologische 
Parameter wie Apoptose, Nekrose und Ödem im Pankreas bestimmt. Btc tg Mäuse blieben 
von der AP-Induktion unbeeinflusst. Während sich die EgfrWa/+5;Btctg/+ Mäuse in sämtlichen 
Parametern wie Btc tg Mäuse verhielten, verhielten sich die Erbb4fl/fl;Ptf1aCre/+;Btctg/+ Mäuse 
wie Wildtyp-Tiere. Zusätzlich zeigten Btc tg Mäuse nach AP-Induktion weniger Fibrose im 
Vergleich zu Wildtyp-Tieren. Microarray- und Western-Blot-Analysen ergaben eine erhöhte 
Expression der extrazellulären Matrix-(ECM)-Proteine matrix-metalloproteinase 2 (MMP2), 
MMP3, periostin (POSTN) und matrix-gla-protein (MGP) in Btc tg Mäusen und in 
EgfrWa5/+;Btctg/+ Kontrollen, aber nicht in Erbb4fl/fl;Ptf1aCre/+;Btctg/+-Tieren nach AP-Induktion. 
BTC verursachte die regulierte intramembran-Proteolyse von ERBB4 mit anschließendem 
Transport der intrazellulären Domäne (ICD) von ERBB4 in das Zytosol und den Zellkern, wo 
diese bekanntlich als Co-Aktivator der Transkription wirkt. Dies deutet darauf hin, dass die ICD 
von ERBB4 die Expression von ECM-Proteinen und -Modulatoren auf transkriptioneller Ebene 
reguliert, um die Mikroumgebung des Pankreas positiv zu beeinflussen. Die zuvor beobachtete 
Erhöhung von BTC-induziertem SAPK-Signaling war ebenfalls ERBB4 vermittelt und 
korrelierte mit einer erhöhten Apoptose-Rate. Zusammenfassend vermuten wir, dass BTC 
einen zweifachen Mechanismus induziert, bestehend aus dem Umbau des umliegenden 
Gewebes und einer erhöhten Apoptose-Rate, um die AP-Entwicklung bei Mäusen zu 
verhindern. Diese Daten legen nahe, BTC zukünftig als neues Medikament in der AP-Therapie 
einzusetzen. Ebenfalls könnte es therapeutisch sinnvoll sein den ERBB4-Rezeptor zu 
aktivieren, um die Behandlung der AP zu unterstützen. 
Die zweite Studie "Unraveling the ERBB network upon betacellulin signaling in 
pancreatic ductal adenocarcinoma in mice" zeigt, dass sich eine hohe BTC-Expression nicht 
nur vorteilhaft auf Erkrankungen des Pankreas auswirkt. Es ist bekannt, dass BTC im 
Pankreaskarzinom exprimiert wird, was nicht verwunderlich ist, da BTC stark mitogen wirkt.  
Allerdings wurde die Rolle dieses Liganden im Pankreaskarzinom nicht näher charakterisiert. 
Das duktale Adenokarzinom des Pankreas (PDAC) ist eine Erkrankung mit einer sehr hohen 
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Mortalität, die nur durch Chemotherapie und Resektion behandelt wird, und nach wie vor ist 
PDAC der Tumor mit der niedrigsten Überlebensrate (5-Jahres-Überlebensrate: 8%). Die 
einzige gezielte Therapie involviert EGFR, wenn auch nur mit geringer klinischer Relevanz und 
häufiger Resistenzentwicklung.  
Ziel dieser Studie war es, die Rolle von BTC im PDAC aufzuklären und zu untersuchen, 
welche Rezeptoren an der BTC-Aktivierung beteiligt sind. Um diese Fragen zu beantworten, 
wurde ein etabliertes PDAC-Mausmodell verwendet. Wir haben Mäuse verwendet, die unter 
dem pankreas-spezifischen Promotor Ptf1a konstitutiv aktives KRAS exprimieren 
(Ptf1aCre/+;KrasG12Dl+, im Weiteren als KC-Mäuse bezeichnet). Diese Mäuse tragen die gleiche 
Mutation, wie sie auch hauptsächlich beim humanen PDAC vorkommt, jedoch schreitet die 
Erkrankung langsamer fort und die Penetranz des invasiven Karzinoms ist unvollständiger als 
beim humanen PDAC. Die Entwicklung prämaligner Läsionen, der so genannten pancreatic 
intraepithelial metaplasia (PanIN), und ihr anschließendes Fortschreiten in das Pankreas-
Karzinom, imitiert jedoch sehr gut den pathophysiologischen Verlauf, wie er in PDAC-
Patienten zu beobachten ist. Vor der PanIN-Entwicklung transdifferenzieren Azinus-Zellen in 
Duct-Zellen (acinar-ductal metaplasia, ADM), die sich durch die initial aktivierende Mutation 
KRASG12D in Pankreas-Zellen entwickelt. Einige ERBB-Liganden wurden bereits mit der 
PDAC-Entwicklung assoziiert, allerdings ist noch nichts über die Funktion von BTC in PDAC 
bekannt. In dieser Studie konnten wir die BTC-Expression in humanen PDAC-Proben, in 
humanen PDAC-Zelllinien und in prämalignen Läsionen des Pankreas von KC-Mäusen 
nachweisen. Nach der Deletion von BTC in KC-Mäusen durch CRISPR/Cas9 
(Btc-/-;Ptf1aCre/;KrasG12Dl+) wurden sowohl die PDAC-Entwicklung, als auch die PDAC-
Progression verzögert, was mit einer verminderten EGFR-Expression und Phosphorylierung 
einherging. In Übereinstimmung mit dieser Beobachtung beschleunigte die Überexpression 
von BTC bei KC-Mäusen (Btctg/+;Ptf1aCre/+;KrasG12Dl+, weiterhin als BKC-Mäuse bezeichnet) die 
Entwicklung und Progression von PDAC und führte zu einer Abnahme der mittleren 
Überlebensrate um etwa neun Monate im Vergleich zu KC-Mäusen. In BKC-Mäusen wurde 
nicht nur EGFR aktiviert, sondern auch ERBB4 und ERBB2 (letzteres zumindest durch die 
Hetero-Dimerisierung mit EGFR). BTC erhöhte die RAS-Aktivität, was ausschließlich über 
EGFR vermittelt wurde. Dies konnte mittels pankreasspezifischer Deletion der jeweiligen 
Rezeptoren unter Verwendung des Cre-loxP-Systems gezeigt werden 
(Btctg/+;Ptf1aCre/+;KrasG12Dl+;Egfrfl/fl (EGFR KO;BKC), Btctg/+;Ptf1aCre/+;KrasG12Dl+;Erbb2fl/fl 
(ERBB2 KO;BKC), Btctg/+;Ptf1aCre/+;KrasG12Dl+;Erbb4fl/fl (ERBB4 KO;BKC)). Neben der 
RAS-Aktivierung induzierte BTC ADM in isolierten murinen Azinus-Zell-Clustern in der 
3-D-Zellkultur. Die Deletion von Erbb2 bzw. Erbb4 in BKC-Mäusen führte zu einer stark 
verlängerten Überlebensrate der jeweiligen KO-Mäuse. Dieser Befund passte zu der 
Beobachtung, dass die PDAC-Entwicklung bei ERBB2 KO;BKC-Mäusen verlangsamt war, 
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während der Verlust von ERBB4 in der Histopathologie keinen offensichtlichen Unterschied im 
Vergleich zu BKC-Mäusen zeigte. Der Verlust beider Rezeptoren führte zu einer verminderten 
EGFR-Aktivierung. Der Verlust von ERBB4 führte zusätzlich zu einer Verminderung der 
ERBB2, MAPK- und SAPK-Aktivierung. Interessanterweise hat die Deletion von EGFR den 
BKC-Phänotyp fast komplett kompensiert, was mit einer verlängerten Überlebensrate 
verbunden war, jedoch konnte die Entwicklung von sporadischer ADM nicht verhindert werden. 
Diese ADM-Läsionen waren positiv für ERBB2, ERBB3 und ERBB4, aber die Western-Blot-
Analyse ergab, dass sowohl die Expression, als auch die Aktivität dieser Rezeptoren 
herunterreguliert waren. Allerdings konnte eine erhöhte Phosphorylierung der ERBB4 ICD im 
Pankreas von EGFR KO;BKC-Mäusen detektiert werden, was darauf hinweist dass ERBB4 
beim Verlust von EGFR eine kompensatorische Rolle einnimmt.  
Diese Daten stehen im Einklang mit der gängigen Meinung in der PDAC-
Forschungsgemeinschaft, dass EGFR ein entscheidender Akteur in der PDAC-Entwicklung 
ist. Wir konnten jedoch zeigen, dass die Bedeutung von ERBB2 und ERBB4 nicht unterschätzt 
werden darf, da sie maßgeblich an der Überlebensrate von BKC-Mäusen beteiligt sind, 
allerdings müssen deren Mechanismen noch genauer untersucht werden. Bemerkenswert ist, 
dass der Verlust von EGFR die Aktivität von ERBB2 und ERBB3 verringert, was zeigt, dass 
EGFR auch weiterhin ein wichtiges Target in der PDAC-Therapie sein sollte. Die 
kompensatorische Induktion der ERBB4-ICD in EGFR KO-Mäusen weist darauf hin, dass 
ERBB4 an der Entwicklung von Resistenzen in EGFR-gezielten Therapien beteiligt ist. Diese 
Studie zeigt deutlich, dass die Hemmung der kompletten ERBB-Familie bei PDAC-Therapien 
berücksichtigt werden sollte.  
Die in dieser Arbeit vorgestellten Projekte zeigen neue Aspekte des Spektrums des BTC-
Signaling. Einerseits hat BTC eine vorteilhafte Wirkung, wie in der AP beobachtet, andererseits 
kann es großen Schaden anrichten, indem es die PDAC-Entwicklung stark beschleunigt. 
Darüber hinaus bestätigen wir, dass ERBB4-Signaling ebenfalls zwei Seiten hat. In AP ist eine 
BTC-vermittelte ERBB4-Aktivierung vorteilhaft, in der Tumorgenese des Pankreaskarzinoms 
hat die Aktivierung von ERBB4 durch denselben Liganden gravierende Folgen für den Verlauf 
der Erkrankung. Darüber hinaus haben wir gezeigt, dass BTC die Bindung von ERBB4 
gegenüber des EGFR in AP bevorzugt, während BTC im PDAC drei von vier der verfügbaren 
ERBB-Rezeptoren aktiviert, was mit einer hohen Beteiligung des EGFR einhergeht. Dies 
deutet darauf hin, dass die Auswirkungen des Signaling des ERBB-Netzwerks auf den Verlauf 
von Krankheiten dadurch bestimmt werden, welche Rezeptor-Beteiligungen der jeweiligen 
Liganden induziert werden. Was ERBB-Liganden beeinflusst, welche Liganden-Rezeptor- und 
Rezeptor-Rezeptor-Interaktionen innerhalb des ERBB-Systems bevorzugt werden, ist noch 
nicht genau verstanden. An diesem Punkt wird der therapeutische Nutzen von BTC fragwürdig 
und muss qualifiziert werden. BTC-Behandlung könnte in AP vorteilhaft sein, aber sobald der 
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Ligand auf eine Zelle mit onkogenem KRAS trifft, dreht sich seine Wirkung in das Gegenteil 
um, da es dort wahrscheinlich die RAS-Aktivität erhöht, somit ADM verursacht und den 
Grundbaustein für die PDAC-Entwicklung legt. Wichtig ist, dass zukünftige Studien des ERBB-
Rezeptorsystems kontext-abhängig betrachtet werden sollten und unbedingt die ERBB-
Familie in ihrer Gesamtheit untersucht werden sollte. 
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PROLOGUE 
This thesis consists of two research projects, which both investigate the ERBB receptor system 
in pancreatic diseases as acute pancreatitis and pancreatic cancer. Chapter 2 comprises the 
manuscript ‘The protective effect of betacellulin against acute pancreatitis is 
ERBB4-dependent’, which has been re-submitted after major revisions to ‘Journal of 
Gastroenterology’ in July, 2019 (addendum: The manuscript has been accepted and published 
in ‘Journal of Gastroenterology’ in August, 2019.). Chapter 3 comprises the manuscript 
‘Unraveling the ERBB network upon betacellulin signaling in pancreatic ductal 
adenocarcinoma in mice’, which is in the process of submission. Both chapters include a 
separate introduction referring to the disease, the state of literature on ERBB network 
involvement in the disease, an aim and the study. A summary with the major conclusions and 
outlook on the whole chapter is provided afterwards. The thesis starts with an extensive 
introduction about the ERBB receptor system.  
A further project, which I was involved in during my PhD studies, can be found under chapter 4. 
This comprises the manuscript ‘Sex-specific programming effects of parental obesity in pre-
implantation embryonic development’, which has been re-submitted after major revisions to 
‘International Journal of Obesity’ in July, 2019 (addendum: The manuscript has been accepted 
for publication in ‘International Journal of Obesity’ in October, 2019.). A summary of the 
manuscript prefaces chapter 4.  
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1 INTRODUCTION 
1.1 ERBB NETWORK 
The erythroblastic leukemia viral oncogene homolog (ERBB) network, a highly complex 
signaling system, transmitting extracellular stimuli into the cell, encompasses a family of four 
receptors, as well as eleven ligands. The receptors epidermal growth factor receptor (EGFR, 
ERBB1, HER1), ERBB2 (HER2; neu), ERBB3 (HER3) and ERBB4 (HER4) are controlled by 
the ligands: epidermal growth factor (EGF), transforming growth factor alpha (TGFA), 
amphiregulin (AREG), epigen (EPGN), epiregulin (EREG), heparin-like epidermal growth 
factor (HBEGF), betacellulin (BTC), and the neuregulins1-4 (NRG1-4). 
1.1.1 THE RECEPTORS 
The ERBB receptors of the EGFR family are essential RTKs for the mammalian body. The 
ubiquitous deletion of only one of the receptors is lethal in mice. EGFR loss in mice results in 
either peri-implantational, mid-gestational or postnatal lethality (depending on the genetic 
background) due to epithelial dysfunction1-3. Mice lacking ERBB2, ERBB3 or ERBB4 die during 
mid-gestation due to severe defects in neuronal and cardiac development4-6.  
All family members are type I transmembrane proteins containing a highly glycosylated 
extracellular ligand binding domain, a short single transmembrane region and a large 
cytoplasmic part containing the tyrosine kinase domain which is flanked by a tyrosine-rich tail. 
Ligand binding induces a conformational change in the receptors which enables them to 
dimerize. This event is required for the activation of the tyrosine kinase domain and for the 
subsequent induction of the reciprocal transphosphorylation of mainly tyrosine (Tyr) residues 
of the C-terminal tail7. This process leads to the exposure of docking sites which then provide 
a platform for the interaction of the receptor with signaling molecules as SRC proto-oncogene 
non-receptor tyrosine kinase (scr)-homology (SH2) or phospho-Tyr binding (PTB) domains, 
such as phosphatidylinositol 3-kinase (PI3K), signal transducers and activators of transcription 
(STAT) or adapter molecules which forward signals phosphorylation-independently, e.g. 
growth factor receptor bound protein (GRB)8 (Figure 1.1). These signaling molecules, in turn, 
induce various cascades, thereby mediating intracellular responses which are involved in cell 
division, migration, apoptosis, differentiation and adhesion9. Hence, the ERBB receptors play 
an essential role in embryonic development and adult homeostasis, as well as in pathological 
processes, such as carcinogenesis7. Receptor dimerization includes homo- and 
hetero-dimerization of 28 possible combinations. However, the affinity between the family 
members varies. The preferred dimerization partner of all receptors is ERBB210,11. ERBB3 
lacks the intrinsic kinase activity12, which prevents the initiation of Tyr-phosphorylation. Thus, 
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for proper activation ERBB3 requires a hetero-dimerization partner. ERBB2 activation also 
depends on receptor hetero-dimerization due to the lack of ERBB2-specific ligands9,13. These 
features make the ERBB2/ERBB3 dimer a perfect couple because they compensate each 
other’s disabilities. Indeed, the hetero-dimer is frequently involved in carcinogenesis being a 
very potent oncogenic dimer14-17. Nevertheless, ligand-independent ERBB2 signaling also 
occurs: Upon ERBB2 overexpression, predominantly as a consequence of ERBB2 gene 
amplification, it can build homo-dimers and signal autonomously, an event frequently observed 
in breast cancer. This led to the development of the ERBB2 specific antibody trastuzumab 
which is successfully used in breast cancer therapy18-21. The choice of the ligand, as well as 
the composition of the receptor-dimer determines which signaling cascade will be initiated22,23. 
EGFR and ERBB4 have a variety of cytosolic interaction partners, while ERBB2 has the fewest 
of all members and ERBB3 predominantly acts through PI3K signaling. All receptors share 
binding motifs for GRB2 and SHC8. A common downstream target of all members of the ERBB 
family is the RAS/RAF/MAPK signaling pathway as well as phospholipase C (PLC) signaling24. 
Another very important player in the ERBB network is the PI3K/activated protein kinase B 
(PKB/AKT) pathway, either through direct or indirect interaction of PI3K with the receptors24,25.   
 
Figure 1.1: Scheme of ERBB receptors 
EGFR (1) and ERBB4 (4) are fully functional receptors. ERBB2 (2) has no known ligand and ERBB3 (3) has no 
intracellular Tyr-kinase domain. Upon ligand binding, ERBB receptors dimerize and auto-phosphorylate the Tyr-rich 
cytosolic domain of their dimerization partner. Phospho-Tyrosines (P) serve as docking sites for adapter proteins. 
 
1.1.2 ERBB4 
1.1.2.1 BINDING SITES 
Like all family members ERBB4 is a 180 kDa glycoprotein consisting of a single 
transmembrane domain which separates the glycosylated extracellular ligand-binding domain 
from the intracellular domain (ICD)26. ERBB4 is an autonomous RTK, able to either operate as 
a homo-dimer or to serve as a binding partner for each of its relatives in order to form 
hetero-dimers. BTC27,28, EREG29,30, HBEGF10,28,31 and the neuregulins NRG132-35, NRG235-38, 
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NRG339,40 and NRG441 activate the receptor. Along with all other family members it provides 
binding sites for SHC and GRB28, adapter proteins which, when bound to RTKs, induce the 
activation of the RAS signaling cascade, which results in a mitogenic cell response. Like EGFR 
and ERBB2, ERBB4 provides a binding site for the cytosolic tyrosine phosphatases SH1 and 
SH2 (PTP-2c)8. In common with ERBB3 is the ability of ERBB4 to associate with PI3K31,42, 
which links the AKT/PKB pathway to ERBB4 signaling, thereby implicating a role for ERBB4 
in the regulation of cell growth and survival. As EGFR, ERBB4 provides a binding site for 
STAT5 enabling it to bind this transcription factor8,43,44, and thereby associating ERBB4 to gene 
expression regulation. Moreover, it also affects gene expression regulation in a direct manner 
by acting as a transcriptional co-activator44-49.  
1.1.2.2 REGULATED INTRAMEMBRANE PROTEOLYSIS 
After undergoing regulated intramembrane proteolysis (RIP), ERBB4 can send its intracellular 
domain (ICD) into the nucleus. Through binding of NRG or the induction of 
12-O-tetradecanoylphorbol-13-acetate (TPA), RIP is initiated. In a first step, a disintegrin and 
metalloproteinase domain-containing protein 17 (ADAM17) cleaves off the 120 kDa 
extracellular fragment (ECD) of ERBB4 and leaves the remaining part of the receptor 
associated to the cell membrane50,51. At the cytosolic juxtamembrane region, the ICD is 
subsequently cleaved by gamma secretase and released into the cytosol as a soluble fragment 
of 80 kDa (ICD) (Figure 1.2). The ICD is also able to interact with other transcription factors or 
transcriptional regulators and translocate into the nucleus where it activates the transcription 
of a variety of target genes44-49. All other members of the ERBB family have also been found 
in the nuclei of cells52-57, however, RIP has only been observed to occur in ERBB4.  
 
Figure 1.2: Regulated intramembrane proteolysis 
After RIP induction, ADAM17 cleaves off the extracellular domain (ECD) of ERBB4. Subsequently, gamma 
secretase cleaves off the intracellular domain (ICD) of ERBB4, enabling it to enter the nucleus. 
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1.1.2.3 ALTERNATIVE SPLICING 
ERBB4 possesses another unique feature. It can undergo alternative mRNA splicing, thereby 
producing four functionally distinct isoforms. The first isoforms were found to differ in their 
juxtamembrane (JM) region where exon 16, encoding for 23 amino acids (JM-a), is replaced 
by exon 15b, encoding for 13 alternative amino acids (JM-b). The two mutually exclusive 
isoforms have distinct expression patterns in the mouse. Since ERBB4 JM-b lacks the 
proteolytic cleavage site for ADAM17, it is protected from RIP and lacks ICD signaling58. 
Elenius et al. also discovered a cytosolic splice form which was unable to bind and thus, also 
to activate PI3K due to a lack of exon 26, which encodes for a sequence of 16 amino acids. 
They called this functional isoform CYT-2, compared to the full-length cytosolic domain CYT-1 
and found it to be predominantly expressed in neural tissues of the mouse59. In summary, there 
are four functionally different isoforms: CYT-1 JM-a, CYT-1 JM-b, CYT-2 JM-a, CYT-2 JM-b.  
1.1.2.4 FUNCTIONAL CONSEQUENCES OF ERBB4 SINGULARITY 
While the JM isoforms promote different cellular responses, the cytosolic isoforms also activate 
different signaling pathways and differ in their stability. In vitro experiments revealed that the 
expression of CYT-2 JM-a led to the survival of fibroblasts, while the expression of CYT-2 JM-b 
promoted cell death of the same cell type, indicating opposing effects of the same gene60. 
Furthermore, also the cytosolic variants were revealed to function oppositely: While the 
expression of CYT-2 was found to result in hyperplasia of the mammary epithelium in vivo, the 
expression of CYT-1 rather resulted in the differentiation of the same61. These were only two 
examples of the contradictory face of ERBB4, owing to its splice isoforms. This and its 
capability of independent ICD signaling might be the reason for the contradictory face of 
ERBB4 in different types of cancer. In bladder cancer, increased levels of ERBB4 correlated 
with a better prognosis62 and in colitis-associated cancer, Ni et al. reported a protective role of 
ERBB4 by negatively regulating the cholesterol metabolic pathway63. And while ERBB4 acts 
as a tumor suppressor in the development of hepatocellular carcinoma64, its activation in 
glioblastoma was associated with a poor prognosis65. ERBB4 is frequently mutated in 
metastatic melanoma and provides a promising target in developing novel melanoma drug 
therapies66,67. The CYT-1 isoform was revealed to be an independent prognostic factor on the 
time to progression in malignant melanoma, while total ERBB4 or CYT-2 had no influence on 
the time to progression68. A multivariate analysis demonstrated that the cytosolic ICD of 
ERBB4 is a positive prognostic factor in lymph-node negative invasive breast cancer patients69. 
In another study, high overall ERBB4 levels correlated with a significantly longer survival in 
estrogen-positive breast cancer patients, while the exclusive nuclear ICD immunostaining was 
associated with a shorter survival than membrane-bound ERBB4 staining70. The Janus face of 
ERBB4 is especially prominent in breast cancer, which is probably attributed to the great 
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research interest in ERBB4 in this field, while it is neglected in a variety of other diseases. 
Many studies attribute ERBB4 an oncogenic role in breast cancer71-74, however, as many 
publications match ERBB4 a rather favorable role75-78.  
These examples show that investigations on ERBB4 must be carried out very thoughtfully. 
Alternative splicing and the question whether ICD signaling occurs biases ERBB4-mediated 
responses.  
1.1.3 CANONICAL SIGNALING OF THE ERBB FAMILY 
A typical MAPK activation cascade is illustrated as follows: BTC binds to EGFR and ERBB4, 
thereby inducing receptor dimerization and autophosphorylation. P-Tyr-1068 of EGFR serves 
as a docking site for GRB2, which is in complex with and thereby recruits the intracellular 
adapter molecule son of sevenless homolog 1 (SOS1) to the receptor dimer via its SH3 domain 
and concomitantly, it brings SOS1 into close proximity to membrane-bound RAS. SOS1 is a 
GEF which promotes GDP/GTP exchange in the RAS molecule, thereby inducing a 
conformational change and activating it79,80. Active RAS, in turn, binds RAF, thereby 
transforming it into an active state. RAF is a Serine/Threonine (Ser/Thr) kinase which positively 
regulates mitogen-activated protein kinase kinase 1 (MAPKK/MEK1) by the phosphorylation 
of Ser residues in its catalytic domain. MEK is a Tyr- and Ser/Thr-dual specific kinase, which, 
in turn, phosphorylates mitogen-activated protein kinase (MAPK/ERK), enabling it to enter the 
nucleus in order to activate numerous transcription factors by Ser- or Thr-phosphorylation 
resulting in the regulation of proliferation, differentiation and apoptosis81.  
1.1.4 SILENCING THE ERBBS 
There are several ways to down-regulate the ERBB signal. Since phosphorylation is the major 
way to start the cascade and to keep it running, dephosphorylation of Tyr, Ser and Thr is one 
way to stop the cascade. Phosphatases can hydrolyze phosphates either from receptors or 
signaling molecules in the cytosol. Another way to turn off the signal is the removal of the 
receptor from the cell surface, called internalization. After internalization, the receptor can 
either undergo recycling or degradation. The exact mechanism how internalization is initialized 
is not revealed yet. However, in the case of EGFR, endocytosis is promoted by mono- and 
polyubiquitination of lysines (Lys) in the kinase domain of the receptor, mediated by GRB2 and 
the E3 ubiquitin ligase CBL. This highly complex process depends on many other factors. After 
endocytosis, the receptor is sorted in the early endosome and will either be transported to the 
lysosome in order to be degraded according to its ubiquitination pattern or it will be recycled 
back to the cell surface, while the latter is the default pathway for EGFR. The ligand occupancy 
is crucial to determine EGFR internalization towards recycling or degradation. At the 
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dominating pH in the endosome, EGF binding to the receptor is stable, whereas TGFA 
dissociates from EGFR very fast. Since continuous ubiquitination is believed to depend on 
persistent ligand binding, EGF signaling predisposes the receptor to degradation, while TGFA 
stimulation results in fast receptor recycling, thereby maintaining a steady signal. ERBB2, 
ERBB3 and ERBB4 are impaired to endocytic downregulation, however, little is known about 
the differences in their susceptibilities to ligand-induced internalization compared to the EGF 
receptor82.  
1.1.5 THE LIGANDS 
1.1.5.1 AN OVERVIEW 
In the absence of any ligand, all ERBB members are present in a tethered conformation 
preventing them from dimerization. Upon ligand binding, the receptors undergo a 
conformational change, exposing the dimerization arm in order to interact with another family 
member83. The ERBB family recognizes several structurally similar growth factors including 
EGF, HBEGF, TGFA, AREG, BTC, EPGN, EREG, as well as NRG1-47. All ligands are 
transmembrane proteins, which share a conserved EGF-like motif and are synthesized as 
large precursors. They are activated upon the proteolytic cleavage by ADAM10 and 17, 
resulting in the release of their ectodomain84,85. This soluble extracellular domain can diffuse 
over a short distance and act in a paracrine way, affecting nearby cells. It can also act in a 
juxtacrine manner, affecting neighboring cells or in an autocrine manner, impacting the cell it 
originated from24. The ligands have different binding specificities and affinities for the ERBB 
receptors, i.e. all ligands, except for the NRGs, bind EGFR and all NRGs bind the ERBB4 
receptor but not EGFR. ERBB growth factors are ambivalent, but for ERBB2 no ligand exists7. 
According to their receptor specificity, it is common practice to categorize them into groups: 
Group I is built by the EGFR specific ligands: EGF, TGFA, AREG and EPGN; group II consists 
of ligands which recognize EGFR and ERBB4: HBEGF, EREG and BTC; group III is formed 
by growth factors which bind to ERBB3 and ERBB4: NRG1 and NRG2; and group IV consists 
of NRG3 and NRG4 with affinities for ERBB4 only86. Interestingly, although triggering the same 
receptor, group I ligands induce different responses in the cell. The mechanisms for this 
phenomenon are not understood. One solution might be, in part, that the EGF receptor 
chooses different dimerization partners with different kinetics in a ligand-dependent manner 
thereby providing binding sites for different signaling molecules, thus, ending in different 
signaling cascades. A study revealed that EGF and TGFA biased EGFR to rather dimerize 
with ERBB2 than with another EGFR monomer, while BTC and AREG produced equal 
amounts of EGFR homo-dimers and hetero-dimers with ERBB2. AREG was only able to 
produce half as many dimers compared to all other EGFR ligands, independent of the dimer-
type87. These results suggest that the choice of the dimerization partner and the corresponding 
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kinetics are the keys to the question which answer is favorably given by the cell. Possibly, this 
is achieved by conformational or steric changes in the receptor. Also important is the fact that 
ERBB ligands can cross- and auto-induce further ERBB ligands. BTC, AREG, EREG and 
EPGN are often co-expressed due to their spatial proximity on the chromosome locus, which 
makes the signaling network even more complex and also difficult to investigate23.  
1.1.5.2 BTC – THE LIGAND OF INTEREST 
CHARACTERISTICS OF BTC 
BTC is synthesized as a precursor protein, consisting of 178 amino acids with an extracellular 
region, comprising an EGF-like domain, a transmembrane region, and a cytoplasmatic tail101. 
In addition to the three di-sulphide bridges in the EGF-like domain, BTC is the only EGFR 
ligand possessing an extra cystein-cystein (Cys) bond in its extracellular part, which does not 
affect EGFR binding affinity, but of which the function remains to be solved102. Its ectodomain 
is predominantly cleaved by ADAM1085, ready to induce paracrine or autocrine signaling via 
EGFR or ERBB4. Thus, BTC is able to mediate signals through every member of the ERBB 
family by receptor hetero-dimerization. Also, unshed BTC can interact with adjacent cells in a 
juxtacrine manner103. Together with HBEGF, BTC has the biggest potential among all EGFR 
ligands to induce receptor internalization and degradation. This is due to the ability of BTC to 
resist low pH levels, thereby, ensuring steady ubiquitination of the receptor after 
internalization. Compared to its relatives, BTC and HBEGF rarely induce EGFR recycling 
back to the cell surface, indicating a rather fast shut down of the induced signal than signal 
amplification104. This points to an internalization mechanism that is different from the canonical 
pathway and which might not end in receptor degradation105.  
BTC was identified in the conditioned medium of murine pancreatic insulinoma derived cell 
lines. Btc mRNA was expressed in mouse sarcoma cell lines, but also in many other tissues, 
including murine pancreatic islets of the pancreas. Additionally, human BTC mRNA was found 
to be detected in the breast cancer cell line MCF-7. Early, BTC was found to be a potent 
mitogen for retinal pigment epithelium and vascular smooth muscle cells100.BTC can convert 
exocrine cells of the rat pancreas into insulin-producing cells when combined with activin A106. 
It also converts murine glucagon producing alpha-cells107, rat intestinal crypt-like cells108, 
human hepatoma cells109, and rat mesenchymal stem cells110 into insulin producing beta-cells, 
strongly indicating a role for the growth factor in differentiation, thus providing a great 
therapeutic potential in diabetes research. BTC acts mitogenic on undifferentiated human 
pancreatic epithelial cells111 and on rat insulinoma cells112, as well as on fetal rat pancreatic 
ductal epithelial cells, which correlates with high EGFR expression113. BTC plays a role in 
human hepatocellular carcinoma, endometrial adenocarcinoma, head and neck squamous 
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cell carcinoma and prostate cancer metastasis103. In one breast cancer study, BTC expression 
was found to be associated with a poor clinical outcome, whereas the effect was even worse, 
when HBEGF was overexpressed concomitantly114. Furthermore, BTC was associated with 
resistance to EGFR treatment in breast cancer cell lines. The treatment with tyrosine kinase 
inhibitors (TKI) led to the acute expression of BTC, induction of ERBB2/ERBB4 dimers and 
ERBB4 cleavage, thereby evading EGFR inhibition and reactivation of EGFR mediated 
signaling cascades115. This mechanism could also be important in other tumors.  
BTC OVEREXPRESSION IN MICE 
While the BTC KO in mice revealed no apparent phenotype with mice being viable and 
fertile116, the overexpression of BTC bares numerous alterations. BTC transgenic (tg) mice 
display stunted growth, pulmonary haemorrhage syndrome, defects in the eyes and high 
post-natal mortality117. BTC is required for female reproduction and its ubiquitous 
overexpression in mice lead to delayed blastocyst implantation into the uterus due to impaired 
fertilization, resulting in a reduced litter size118. Interestingly, the relative weight of the vast 
majority of organs was increased in BTC tg mice, except for the pancreas. Although BTC has 
a proliferative effect on beta-cells, the pancreas weight in BTC tg mice was significantly 
decreased, indicating an adverse effect of BTC on the exocrine part117. However, BTC tg 
pancreata displayed increased proliferation rates, but also increased apoptosis rates, 
suggesting an increased turnover of pancreatic cells upon BTC signaling. It was revealed that 
the retarded growth of the pancreas in BTC tg mice was mediated by ERBB4, while all other 
BTC-related organ weight changes were dependent on the EGF receptor. Another very 
intriguing feature of BTC, revealed by our group, is its protective effect in acute pancreatitis 
(AP) upon overexpression suggesting increased apoptosis and decreased necrosis rates 
possibly induced by enhanced SAPK signaling and thereby ameliorating the AP clinical 
course119.  
Apparently, there are many levels in the complex ERBB hierarchical structure - from receptor 
activation via the signaling cascade and the final response of the cell to the fate of the receptor 
- that provide a platform for aberrant signal transduction allowing them functions in pathological 
processes. The impact of the ERBB receptors and their ligands on pancreatic cancer and acute 
pancreatitis will be reviewed in this work.   
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2 BTC IN ACUTE PANCREATITIS 
2.1 INTRODUCTION 
2.1.1 ACUTE PANCREATITIS 
2.1.1.1 DEVELOPMENT AND INCIDENCE  
AP is an inflammatory disease with many causes. In principal, pancreatic duct obstruction or 
acinar cell injury lead to the release of active digestive enzymes into the interstitial space, 
instead of into the lumen of the pancreatic ducts in order to be transported to the duodenum. 
This deregulation results in the protease-induced damage of cell membranes (auto-digestion) 
of the pancreas, which, in turn, causes an inflammatory response within the pancreatic 
parenchyma120. Gall stones and alcohol abuse are the main causes of pancreatitis (70-80%), 
followed by uncommon causes, e.g. infections, abdominal trauma, drug-induced adverse 
reactions, pancreatic tumors (10-15%) and idiopathic causes (10-20%)121. With an annual 
incidence of 13-45/100.000 in the U.S. and Europe, AP is one of the most common gastro-
intestinal causes for contacting the emergency services and for hospitalization and incidences 
are increasing122,123. 25% of all AP patients develop insufficiency of the exocrine pancreas124 
and up to 40% develop pre-diabetes or diabetes after the first episode of AP125. Recurrence 
occurs in 18% of AP patients and 8% of the patients develop chronic pancreatitis (CP), which 
coincides with a drastic decrease in the quality of life126. Symptoms of AP include persistent 
abdominal epigastric pain and nausea. The diagnosis is made, if at least two of the following 
criteria are fulfilled: severe abdominal pain radiating to the back, enhanced serum lipase (or 
amylase) activity, at least three-fold compared to normal serum, and hallmarks of AP in 
computer tomography or magnetic resonance imaging120.  
2.1.1.2 CLASSIFICATION 
The severity of the disease is represented by the mortality rates that are as high as 36-50% in 
high grade AP (severe AP), which is characterized by persistent (>48 hours) single or multiple 
organ failure. Mortality is declining with the decrease of AP severity. Moderately severe AP is 
accompanied by transient (<48 hours) organ failure and/or local or systemic complications, 
while mild AP shows no signs of complications or the involvement of other organs. The 
determinant of the risk of developing organ failure is the immune response of the host to local 
pancreatic injury during the first week of AP. This immune response results in the increase of 
heart and respiration rate, a deregulated body temperature and an unbalanced white blood 
count. These symptoms are all summarized in the term “Signs of systemic inflammatory 
response syndrome” (SIRS). Persistence of SIRS in the early phase of AP increases the risk 
of developing organ failure and severe AP127. While these parameters classify the clinical 
severity of AP, the distinction between interstitial or edematous pancreatitis and necrotizing 
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AP (NAP) defines the morphological severity, with the former being the milder type of AP. NAP 
affects 5-10% of all patients127. It is further sub-divided into three groups: NAP with necrosis 
affecting exclusively the pancreatic parenchym (very rare), NAP with necrosis affecting 
peri-pancreatic tissues only and NAP affecting both compartments, representing the most 
common type of NAP121.   
2.1.1.3 THERAPY 
Analgesic therapy is administered in the first place. The administration of opiates is often 
inevitable, although opiates enhance the paralytic ileus, which frequently accompanies AP. 
However, opiates are an appropriate analgesic for AP, since they affect the clinical outcome 
of AP as bad as other analgesics, however, they also reduce the need for supplementary pain 
treatment128. In order to increase the chance of preserving as much tissue as possible, patients 
receive fluid replacement, of which the volume and rate are crucial. The right balance must be 
found and the patient requires constant monitoring. In this way, optimal organ perfusion can 
be ensured and typically fast developing hypovolemia can be prevented129. It is discussed 
controversially, whether enteral or parenteral nutrition ameliorates the outcome of the AP 
course. Food or fluid ingestion leads to an intensification of pain, classifying nutrition therapy 
as pain management. The current consensus is that nutrition support should only be provided 
in severe AP or when required, and that enteral nutrition should be preferred over parenteral 
nutrition130. While it is discussed controversially whether early endoscopic retrograde 
cholangiopancreatography (ERCP) affects mortality and complications of AP, an overview of 
randomized controlled trials revealed no adverse effect of ERCP on the course of AP. 
However, the common sense is that indication for ERCP is given in patients with coexisting 
cholangitis or biliary obstruction or when remaining pancreatic or bile duct obstructions are 
expected131. NAP is also predominantly treated in a conservative manner, being effective in 
two thirds of the patients. Approximately one third of the patients develops infectious necrosis, 
making them subject to surgery or endoscopic drainage techniques in order to target the 
necrotic tissue. Due to high mortality rates of 11-39%, open necrosectomy has been replaced 
by minimally invasive approaches132. In summary, AP treatment only consists of symptomatic 
treatment. No therapies exist affecting the physiopathology of the disease.  
2.1.1.4 PATHOGENESIS 
The two most common types of AP differ in their pathological mechanism. While gall stones 
and the exposure of duct cells to bile acid lead to ductal obstruction and associated pressure 
on the tissue, the exposure of acinar cells to ethanol and bile acids is toxic. These events, 
independent of the cause, result in the deregulation of trypsinogen activation, mitochondrial 
function, calcium signaling and endoplasmic reticulum (ER) stress126.  
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PREMATURE TRYPSINOGEN ACTIVATION 
In the acinar cell of a normal pancreas, chymotrypsin and trypsin are stored as inactive 
precursors (zymogens) in granules. Upon a physiological stimulus, zymogens are secreted 
into the lumen of the pancreatic duct and transported to the duodenum, where 
enteropeptidases cleave off N-terminal amino acids in order to activate trypsin. Active trypsin, 
in turn, cleaves and thus, activates chymotrypsinogen133.  
Pancreatic ductal obstruction blocks the apical release of zymogen granules (containing the 
inactive precursors chymotrypsinogen and trypsinogen) into the lumen, leading to the fusion 
of such granules with acinar lysosomes. Products of this fusion are autophagic vacuoles, 
where lysosomal cathepsin B activates the proteolysis of trypsinogen to trypsin. This event 
starts a cascade of zymogen activation with the subsequent release of active digestion 
enzymes into the interstitial space where they damage cellular membranes by auto-digestion. 
Intracellular proteases also break down the lysosomal membrane, thereby triggering 
mitochondrial cytochrome c release and inducing Caspase 3-mediated apoptosis126.  
ER STRESS 
The ER is the organelle within the eukaryotic cell where protein modification takes place and 
where the delivery of these proteins to their target sites is determined. In the ER, proper protein 
folding and post-translational modification is carried out in order to send the correctly folded 
protein to the Golgi apparatus.  
Incomplete or improper folding results in the retention of the protein in the ER in order to repair 
the misfolded protein or to target it for degradation. A deregulation of any of these processes 
is called ER stress and induces the unfolded protein response (UPR)134. UPR is initially 
activated to adapt to the altered environment and to restore physiological ER function by 
changing the transcriptome in favor of enhanced protein folding and degradation capacity of 
the ER135. Since acinar cells produce an enormous amount of protein, they are particularly 
sensitive to ER stress. In AP, toxins like ethanol induce an increased need of acinar cell 
products, thereby stressing the ER. The UPR enhances the transcription of ER chaperone and 
factors required for ER expansion and ER-dependent protein degradation. Also, autophagy is 
induced for the removal of incorrectly folded proteins. However, if the UPR is overwhelmed, it 
induces cell death as the last response126.  
DISTURBED CA2+ SIGNALING 
With a concentration of 5 mM, the ER is also the major deposit of Calcium ions (Ca2+) in the 
cell (compared to 0.1 µm in the cytosol). Upon physiological triggers, Ca2+ is released into the 
cytosol for a transient cytosolic Ca2+ increase, and is then transported back into the ER or out 
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of the cell by two adenosine triphosphate (ATP)-dependent Ca2+ channels. Disturbed Ca2+ 
signaling is a major incident during AP126.  
In normal acinar cells, Ca2+ influx induces zymogen exocytosis and stimulates ATP production 
in the mitochondria. Ethanol, bile acids and cholecystokinin disturb the physiological Ca2+ cycle 
in acinar cells, initially, by the induction of inositol 1,4,5- trisphosphate receptor signaling. This 
further results in the potentiation of cytosolic Ca2+ by the activation of the Ca2+-dependent 
Ca2+-influx into the cell from the outside, leading to permanently high cytosolic Ca2+ 
concentrations which causes mitochondrial membrane permeability and the loss of the 
mitochondrial membrane potential to generate ATP. The resulting ATP depletion even 
potentiates the cytosolic Ca2+ increase due to the ATP-dependence of channels which are 
responsible for transporting Ca2+ back into the ER or outside of the cell. Constitutive Ca2+ 
elevation results in mitochondrial dysfunction and necrosis, as well as in premature zymogen 
activation. Premature zymogen activation due to disturbed Ca2+ signaling is also the 
mechanism that underlies the experimental mouse model, that was used for this work. 
Caerulein is an analogue of cholecystokinin. It triggers the increase of cytosolic Ca2+ and the 
release of active zymogens into the interstitial space, thereby inducing AP136.  
2.1.2 THE ERBB FAMILY IN ACUTE PANCREATITIS 
The EGFR ligand EGF was early found to be implicated in AP. More than 20 years ago, the 
exogenic administration of human recombinant EGF in caerulein-inducible AP in rats did not 
alter gross or histologic morphology of the pancreas, but it ameliorated septic complications 
by protecting the intestinal mucosa from damage, thereby preventing rats from secondary 
infections in acute necrotizing pancreatitis137. Also in rats, exogenous EGF decreased the 
severity of caerulein-induced AP by possibly increasing the pancreatic blood flow and cell 
proliferation and by decreasing the activation of the immune response138. Another role was 
attributed to EGF only shortly after, when Dembinski et al. demonstrated accelerated recovery 
of pancreatic cells during AP regeneration, which they also associated with an improved 
pancreatic blood flow139. However, despite all of these promising characteristics of EGF, it was 
never tested in clinical trials to treat AP.  
Also, for its designated receptor EGFR, similar findings were made a few years later. EGFR 
was associated with the protection against necrosis upon exogenous regenerating protein 4 
(Reg4) administration in mice. Reg4 enhanced the expression of the anti-apoptotic proteins 
B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra-large (Bcl-xL), which, in turn, stimulated 
EGFR-induced AKT signaling and which was inversely correlated with necrosis140. However, 
caerulein-induced AP in mice with EGFR-depleted acinar cells showed no signs of altered 
severity in AP, indicating that EGFR plays no overt role in AP141. A more recent study evaluated 
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data obtained from a gene expression database and found EGFR to be upregulated in AP 
samples of caerulein-treated mice. The consequences of increased EGFR levels were not 
evaluated142. These data indicate that EGFR does not play a role in the development of AP, 
but might be abundantly expressed as a reaction of AP development to exert a protecting role.  
A study from a time, when the presence of ERBB4, the last member of the ERBB family, was 
not revealed, yet, found differential expression pattern of the remaining ERBB receptors in AP, 
compared to normal tissue, indicating a role for the ERBB system in this disease143.  
AP is associated with fibrosis early in disease development144,145. The ERBB ligands TGFA 
and HBEGF were found to induce fibrosis, when overexpressed in the pancreas of mice146-148, 
while the overexpression of AREG did not149. Thus, the generation of fibrosis in the pancreas 
is ligand-specific and possibly, also receptor-specific, since HBEGF has affinities for EGFR 
and ERBB4. Indeed, for HBEGF, it was shown that it mediates its fibrosis-promoting effect 
through EGFR. However, pancreatic fibrosis of HBEGF transgenic mice was not completely 
abrogated in all mice (only in 38%) after crossing them into mice with an EGFR hypomorphic 
Wa2 background. This suggests either remaining EGFR activity150, or the involvement of 
ERBB4 as the second binding partner of HBEGF. 
The most striking finding about ERBB receptor family involvement was discovered by our 
group. We revealed that BTC transgenic mice were protected from AP in caerulein- and 
L-arginine-inducible pancreatitis models of AP. The overexpression of BTC led to a significant 
reduction of pancreatic weights, which was limited to the exocrine pancreas, possibly mediated 
by an enhanced cell-turnover in BTC transgenic mice. The crossing of BTC transgenic mice 
with mice expressing a kinase-dead EGFR did not rescue the pancreatic weight indicating no 
EGFR involvement in regard to the pancreas weight. Upon AP induction, BTC transgenic mice 
presented with significantly reduced serum lipase and amylase levels, decreased necrosis, 
edema and inflammation which was possibly due to increased SAPK activity, resulting in 
enhanced apoptosis and proliferation rates119. But not only prevented BTC from developing 
AP, it was also possible to treat mice suffering from AP with intraperitoneally administered 
BTC. 
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2.2 AIM OF THE STUDY 
AP is a common disease with rising incidences, which is frequently life-threatening to patients 
in the severe disease stage. Once overcome, AP frequently results in secondary diseases, 
e.g. insufficiency of the exocrine pancreas, chronic pancreatitis or diabetes mellitus. Thus, the 
quality of life often decreases drastically. The current treatment is only symptomatic and aims 
to decrease the pain, to save pancreatic tissue and prevent hypovolemia. However, these 
standard therapies still need optimization. Although clinical trials are performed testing 
therapeutics, e.g. targeting Ca2+ trafficking, there is an urgent need to find better targets 
amenable to therapy, and also to find biomarkers to diagnose the disease in pre-clinical stages. 
There is increasing evidence that the ERBB system is involved in AP development and might 
carry out a protective role, but the mechanisms underlying this protection remain to be 
revealed. Since BTC, among all ERBB ligands, appears to have the most protective effect on 
the course of AP, we aimed to study the role of BTC in AP pathophysiology in more detail, 
including the identification of the ERBB receptors involved. This is particularly important for the 
development of therapeutic agents against AP and the reduction of possible side-effects.  
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2.3.1 ABSTRACT 
Background  
The EGFR ligand betacellulin (BTC) has been previously shown to protect mice against 
experimentally-induced acute pancreatitis (AP). BTC binds both autonomous ERBB receptors 
EGFR and ERBB4. In this study, we evaluated the mechanism underlying the protection from 
AP-associated inflammation in detail.  
Methods 
AP was induced with caerulein or L-arginine and investigated in a pancreas-specific ERBB4 
knockout and in an EGFR knockdown mouse model (EgfrWa5/+). Pancreatitis was evaluated by 
scoring inflammation, necrosis, and edema, while microarrays were performed to analyze 
alterations in the transcriptome between mice with AP and animals which were protected 
against AP. The intracellular domain (ICD) of ERBB4 was analyzed in different cell 
compartments.  
Results 
While the pancreas of BTC transgenic mice in the background of EgfrWa5/+ is still protected 
against AP, the BTC-mediated protection is no longer present in the absence of ERBB4. We 
further demonstrate that BTC activates the ICD of ERBB4, and increases the expression of 
the extracellular matrix (ECM) proteins periostin and matrix gla protein as well as the ECM 
modulator matrix metalloproteinases 2 and 3, but only in the presence of ERBB4. Notably, the 
increased expression of these proteins is not accompanied by increased ECM amount.  
Conclusions 
These findings suggest that BTC derivates, as a drug, or the ERBB4 receptor, as a druggable 
target protein, could play an important role in modulating the course of AP and even prevent 
AP in humans. 
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2.3.2 INTRODUCTION 
Acute pancreatitis (AP), a frequent inflammatory disease of the exocrine pancreas, is often 
caused by gallstone migration into the bile duct or alcohol abuse. Patients develop a severe, 
extremely painful inflammatory disease with multisystem organ failure151. During AP pancreatic 
acinar cells activate digestive enzymes like trypsinogen and chymotrypsinogen, resulting in 
autodigestion followed by interstitial edema, inflammation and acinar necrosis152. In spite of 
intense research, the etiology and the progress of this potentially lethal disease remain poorly 
understood.  
Growth factors are important regulators of gene transcription, and transcriptome alterations 
are a powerful cell answer to environmental changes, challenges, or to diseases like 
inflammation or cancer. One of the most potent signaling systems in eukaryotic cells is the 
tyrosine kinase epidermal growth factor receptor (EGFR, ERBB1, HER1) and its family 
members ERBB2 (HER2, NEU), ERBB3 (HER3), and ERBB4 (HER4). All four receptors are 
expressed in the exocrine pancreas and play important roles in pancreatic homeostasis and 
during pancreatic tumorigenesis, as pancreatic ductal adenocarcinoma (PDAC)153,154. EGFR 
is a main receptor for initiating PDAC155,156, and several EGFR ligands have been implicated 
in neoplastic changes of the pancreas: overexpression of transforming growth factor alpha 
(TGFA)157 in mice induces acinar-to-ductal metaplasia; amphiregulin (AREG)158 
overexpression increases proliferation of duct cells; and overexpression of heparin-binding 
epidermal growth factor-like growth factor (HBEGF) leads to proliferation of metaplastic duct 
epithelium and fibrosis159. Our previous studies revealed that mice overexpressing the EGFR 
and ERBB4 ligand betacellulin (BTC) are protected against caerulein- and L-arginine induced 
AP 160. Although it is known that EGFR, ERBB2161, and ERBB3162 are involved in PDAC or AP, 
potential roles of ERBB4 in the exocrine pancreas and its associated diseases remain 
unknown. 
The autonomous ERBB4 receptor can be expressed in four different isoforms. Alternative 
splicing results in the JM-b isoform lacking the juxtamembrane cleavage site for regulated 
intramembrane proteolysis (RIP), which is present in the predominantly expressed JM-a 
isoform163. Additionally, exon skipping results in the deletion of the PI3K binding site (CYT-2), 
compared to the full length and functionally fully active cytoplasmic CYT-1 form164. 
Furthermore, ERBB4 is able to undergo gamma-secretase-dependent regulated 
intramembrane proteolysis (RIP), releasing its intracellular domain (ICD) to the cytosol, or to 
the nucleus165,166. The ICD is able to interact with other proteins and migrate into the nucleus 
and then act as a transcriptional co-factor/regulator167,168. These different possibilities result in 
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an ambiguous function of ERBB4, depending on isoform expression and/or intramembrane 
proteolysis.  
In our current study, we investigated in detail how BTC protects the pancreas against 
inflammation and which receptor mediates this effect. Therefore, we deleted ERBB4 
specifically in the pancreas of BTC transgenic mice (Btc) or crossed Btc mice with a mouse 
line carrying a dominant negative EGFR (EgfrWa5/+).  
2.3.3 METHODS 
2.3.3.1 ANIMALS 
Transgenic mouse lines overexpressing BTC ubiquitously under the control of the chicken-
beta-actin gene promoter have been described previously169. EgfrWa5/+ (Wa5) mice expressing 
an antimorphic Egfr allele170 were donated by the Medical Research Council (Oxfordshire, UK) 
via Dr. David Threadgill (University of North Carolina, NC, USA). B6;129-Erbb4tm1Fej/Mmucd 
(Erbb4fl/fl) mice171 were purchased from the Jackson Laboratory (Bar Harbor, ME, US), and 
Ptf1atm1(cre)Hnak transgenic mice expressing cre recombinase under the control of the pancreas 
specific transcription factor 1 alpha (Ptf1aCre/+)172 have been described previously. We 
generated Erbb4fl/fl; Ptf1aCre/+ mice to delete the Erbb4 gene pancreas-specific by using the 
Cre-loxP-system. All mice were maintained in the C57BL/6N background and housed under 
specific pathogen-free conditions in the closed barrier facility of the Gene Center Munich at 
23°C, 50% humidity and with a 12-h light/dark cycle (lights on at 7 AM), and had free access 
to a standard rodent diet (V1534, Ssniff, Soest, Germany) and water. All animal experiments 
were approved by the author’s institutional committee on animal care and carried out in 
accordance with the German Animal Protection Law with permission from the responsible 
veterinary authority. 
2.3.3.2 CAERULEIN-INDUCED PANCREATITIS IN TRANSGENIC MICE 
Pancreatitis experiments were performed as previously described160. Briefly, after fasting for 
18 h, all animals received hourly intraperitoneal applications (i.p.) of 50 µg/kg body weight 
caerulein (Merck, Darmstadt, Germany) in saline. One experimental group of mice was killed 
3 h after the first injection. A second group received eight consecutive caerulein injections and 
animals were killed 24 h after the first application. Blood samples were centrifuged at 4°C at 
1000xg, and serum was stored at -80°C for further studies. The pancreas was removed and 
samples were either frozen on dry ice and stored at -80°C for expression analysis or fixed in 
4% PFA for histological studies. One pancreas sample was immediately homogenized in RLT 
buffer (Qiagen, Hilden, Germany) buffer supplemented with 1% beta-mercaptoethanol and 
snap frozen in liquid nitrogen for RNA analysis. 
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2.3.3.3 L-ARGININE INDUCED PANCREATITIS 
The L-arginine model of pancreatitis in non-fasted mice was induced by i.p. application of 
4 g/kg L-arginine as described previously160. In brief, a sterile solution of L-arginine 
hydrochloride (8%) (Merck) was prepared in normal saline and the pH was adjusted to 7.0. 
Mice received two hourly injections of L-arginine (4 g/kg), while controls were administered 
saline. 24, 48, 72 hours after the first injection mice were sacrificed. Tissue and blood samples 
were removed and processed as described above. 
2.3.3.4 PANCREAS PREPARATION AND IMMUNOHISTOCHEMISTRY 
Immunohistochemistry was employed for determining apoptosis, proliferation and the ERBB4 
receptor in formalin-fixed, paraffin-embedded pancreatic tissue. Anesthetized mice were killed 
by exsanguination and blood was collected. The pancreas was removed immediately, carefully 
trimmed free of adjacent tissues, weighed to the nearest mg, fixed in 4% paraformaldehyde (in 
phosphate-buffered saline, PBS, pH 7.4), and embedded in paraffin. Antibodies and dilutions 
are listed in Suppl. Table S 2.1. For the immunostaining of ERBB4 and Ki67 the slides were 
sub-boiled in a water bath for 20 min at 97°C in 10 mM sodium citrate buffer pH 6.0 and for cl. 
Caspase 3 the slides were boiled in a pressure cooker for 30 min. The primary antibody was 
incubated over night at 4°C. After washing the slides three times in PBS the sections were 
incubated with an appropriate secondary antibody for one hour at room temperature. 
Diaminobenzidine (Merck) was used as the chromogen in all immunohistochemical 
experiments and the immunolabeled sections were counterstained with hematoxylin.  
2.3.3.5 DETERMINATION OF PROLIFERATION AND APOPTOSIS RATES 
All immunostained cell nuclei present in the pancreas sections from one individual were 
counted. The numerical area density of immunostained exocrine pancreas cell nuclei was 
obtained by dividing the total number of immunostained cell nuclei by the cross-sectional area 
of the exocrine pancreas. The proportion of immunostained exocrine cell nuclei was obtained 
by dividing the numerical area density of immunostained cell nuclei by the numerical area 
density of exocrine cell nuclei. For determination of the numerical area density of exocrine cell 
nuclei, every 25th visual field covering exocrine pancreas tissue was selected for counting of 
cell nuclei using an unbiased counting frame173. Cell proliferation and apoptosis indices were 
defined as the number of immunolabeled cell nuclei divided by the number of cell nuclei 
counted, and expressed as the number of immunolabeled cell nuclei per 105 cell nuclei. 
2.3.3.6 DETERMINATION OF THE NECROTIC AREA IN PERCENT 
Every 25th visual field covering exocrine pancreas tissue was selected for determining the total 
area and the necrotic area using an unbiased counting frame173. 
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2.3.3.7 SERUM AMYLASE AND LIPASE CONCENTRATIONS 
Serum was diluted 1:10 in sterile water to a volume of 100µl. Amylase and lipase were 
measured by Modular-P + ISE (Roche, Mannheim, Germany) at the Institut für Klinische 
Chemie, Klinikum rechts der Isar, Munich, Germany.  
2.3.3.8 HISTOPATHOLOGICAL SCORE 
Coded, H&E-stained histological sections were graded according to the severity of pancreatitis 
using a scoring criteria described previously173. The connective tissue score was performed on 
Masson’s Trichrome stained paraffin sections of paraformaldehyde-fixed (4%) pancreas using 
a scoring criteria described previously173. Lung histopathology score were performed on H&E 
stainings as described previously174.  
2.3.3.9 WESTERN BLOT ANALYSIS 
Protein was prepared from mouse pancreas by homogenization in extraction buffer as 
described previously175. Protein samples with equal concentrations were electrophoresed on 
12% polyacrylamide-sodium dodecyl sulfate gels and then blotted to PVDF-membranes (GE 
Healthcare, Munich, Germany). Incubation with primary antibodies was carried out overnight 
at 4°C. Antibodies and dilutions (either in 5% dry milk or in 5% BSA) are listed in Suppl. Table 
S 2.1. Afterwards the membranes were incubated with an appropriate horseradish peroxidase-
conjugated secondary antibody. Immunoreactive bands were visualized by 
chemiluminescence with ECL kit (GE Healthcare). 
2.3.3.10 FRACTIONATION OF PANCREATIC CELLS 
To fractionate pancreatic cells into nucleus, membrane, and cytosol, the QIAGEN Qproteome® 
Cell Compartment Kit was used according to the manufacturer’s instructions. To verify the 
purity of each fraction, a Western blot experiment was performed. ERBB2 was chosen as a 
specific membrane protein marker, GAPDH as a marker of the cytosol fraction and histone H3 
as a specific protein marker for the nucleus fraction. Western blot experiments were performed 
as descript previously.  
2.3.3.11 REAL-TIME-PCR 
RNA was extracted from shock-frozen pancreatic tissues with RNeasy kit (Qiagen, Hilden, 
Germany) and cDNA was synthesized with RevertAid reverse transcriptase (Thermo Scientific, 
Schwerte, Germany) according to the manufacturer’s instructions. For qualitative mRNA 
expression of Erbb4, reverse transcription-PCR (RT-PCR) was performed by using reagents 
from Qiagen. The final reaction volume was 20 µl, and cycle conditions were 94°C for 5 min 
followed by 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min. The primers 
employed are listed in Suppl. Table S 2.2. 
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Quantitative mRNA expression analysis was performed by real-time quantitative RT-PCR 
(qRT-PCR) using the LightCycler-480-system and the LightCycler-480-Probes-Master (Roche, 
Mannheim, Germany) as described previously176. Primers (Thermo Fisher Scientific) and 
probes (Roche) for the evaluated transcripts are listed in Suppl. Table S 2.2. 
2.3.3.12 STATISTICS 
Results are expressed as means+SEM and the significance of differences between two groups 
was tested using the two-tailed unpaired Student’s t-test and, in the case of more than two 
groups by analysis of variance (ANOVA) and Tukey’s multiple comparison test. The qRT-PCR 
values were related to the mean of the control group, data were presented as box plots with 
medians and analyzed with two-tailed Mann-Whitney U-test. All data were analyzed with 
GraphPad Prism (GraphPad Prism version 5.0 for Windows, GraphPad Software, San Diego, 
CA, USA). P-values below 0.05 were considered statistically significant.  
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2.3.4 RESULTS 
2.3.4.1 PROTECTION AGAINST AP IS NOT MEDIATED BY EGFR  
First, BTC expression in the exocrine pancreas was evaluated. BTC was detected by 
immunofluorescence and Western blot in the exocrine pancreas of control mice, with increased 
levels in Btc transgenic animals (Suppl. Fig. S 2.1 A,D,F). All four ERBB receptors were 
expressed and phosphorylated during AP with the exception that ERBB3 was not 
phosphorylated (Suppl. Fig. S 2.1 D). BTC, as a ligand of EGFR and ERBB4, showed 
significantly increased ERBB phosphorylation levels in Btc mice with 3h-AP compared with 
control animals (Suppl. Fig. S 2.1 D,F). To determine whether the protective effect of BTC is 
EGFR-dependent, we crossed Btc transgenic mice in the Wa5 mice background. Wa5 mice 
have an antimorphic Egfr allele with a dead kinase activity, and they represent a well-accepted 
EGFR knockdown mouse model. With this mouse model we performed a caerulein-induced 
AP and sacrificed the animals 24 hours after caerulein injection. The histological severity score 
demonstrated significantly reduced inflammation, necrosis, and edema in Btc mice, and this 
effect was still present in Wa5+Btc double mutant mice compared to Wa5 and control mice 
(Figure 2.1 A-D). Additionally, Wa5 mice and control littermates showed significantly increased 
serum amylase and lipase levels compared with Btc mice and Wa5+Btc animals (Figure 
2.1 E,F). A significantly higher apoptosis-rate was identified in the exocrine pancreas of Btc 
mice and double mutants compared to control littermates and Wa5 mice (Figure 2.1 G).  
2.3.4.2 ERBB4 IS DISPENSABLE FOR PANCREAS DEVELOPMENT AND HOMEOSTASIS 
To analyze its potential function, we deleted ERBB4 in the pancreas using a genetic approach. 
For this purpose, we crossed animals carrying a floxed Erbb4 allele with transgenic mice 
expressing cre recombinase under the control of the pancreas-specific transcription factor 1 
alpha (Ptf1aCre/+) promoter. Recombination of the Erbb4 allele and the resulting pancreas-
specific loss of ERBB4, with unchanged receptor levels in the remaining organs were 
confirmed by RT-PCR (Suppl. Fig. S 2.1 E) and immunohistochemistry (Suppl. Fig. S 2.1 B), 
respectively. Erbb4fl/fl; Ptf1aCre/+ mice were viable and showed no macroscopic phenotype. 
H&E-stained sections of Erbb4fl/fl; Ptf1aCre/+ exocrine pancreata (Suppl. Fig. S 2.1 C) showed 
unchanged histological structure and normal islets of Langerhans (data not shown). Body 
weight of male and female mice evaluated up to 12 weeks was unchanged in Erbb4fl/fl; Ptf1aCre/+ 
mice compared with control littermates (data not shown). Absolute and relative pancreas 
weights of female (Suppl. Fig. S 2.1 G,H) and male (Suppl. Fig. S 2.1 I,J) mice were not altered.  
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Figure 2.1: Investigation of Wa5+BTC mice during caerulein-induced AP  
A Representative H&E staining of 24-h-lasting AP in 12 weeks old male mice. BTC and Wa5+BTC mice show less 
severe B inflammation, C necrosis, and D edema histological scores 24 hours after caerulein injection compared 
to control and Wa5 mice. During 24 h caerulein-AP E serum amylase and F lipase levels were significantly reduced 
in BTC and Wa5+BTC mice compared to control and Wa5 animals. G Quantitative evaluation revealed a 
significantly higher number of cleaved caspase 3-positive cells in the pancreas of BTC and Wa5+BTC animals 
compared to control and Wa5 mice. Controls n=7, Wa5 n=7, BTC n=8, and Wa5+BTC n=8. Scale bars in a represent 
200 µm. Data in B-G are presented as mean+SEM (standard error of the mean), and were analyzed by ANOVA 
followed by Tukey’s post hoc test. *P<0.05; **P<0.01, ***P<0.001. 
2.3.4.3 PROTECTION AGAINST AP IS ERBB4-DEPENDENT 
As BTC is also able to bind and activate ERBB4, we next performed a caerulein-induced 24h 
AP experiment in Btc mice with a pancreas-specific deletion of ERBB4 
(Erbb4fl/fl;Ptf1aCre/+;Btctg/+). A histological score revealed no difference in the severity of 
pancreatitis between Erbb4fl/fl;Ptf1aCre/+ mice, Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice, and control 
littermates regarding necrosis, inflammation, and edema; only Btc animals showed significantly 
reduced scoring values (Figure 2.2 A-D). Serum amylase and lipase levels were also 
significantly reduced only in Btc mice compared with Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice, control 
mice, and Erbb4fl/fl;Ptf1aCre/+ mice (Figure 2.2 E,F). Because apoptosis plays a crucial role in 
pancreatitis, we investigated apoptotic cells in Erbb4fl/fl;Ptf1aCre/+;Btctg/+ animals 3h after 
caerulein-induced AP. While cleaved caspase-3-positive cells were only sporadically visible in 
the pancreas of Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice and the other control groups, a large number of 
apoptotic cells were detectable in the pancreas of Btc animals (data not shown). Quantitative 
evaluation confirmed a significantly higher number of apoptotic cells in the exocrine pancreas 
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of Btc animals as compared to control groups (Figure 2.2 G). Western blots for stress activated 
protein kinase (SAPK) (Figure 2.2 H) revealed that SAPK, a pro-apoptotic kinase, was 
significantly stronger phosphorylated in Btc mice compared with the control groups (Figure 2.2 
I).  
 
Figure 2.2: Investigation of Erbb4del+Btc mice during caerulein induced AP 
A Representative H&E staining of 24-h-lasting AP in 12 weeks old male mice. Scale bars represent 200 µm. Only 
BTC mice show less severe B inflammation, C necrosis, and D edema in histological scores 24 hours after caerulein 
injection compared to control, Erbb4del, and Erbb4del+Btc mice. During 24 h caerulein-AP E serum amylase and F 
lipase levels were only significantly reduced in Btc mice compared to control, Erbb4del, and Erbb4del+Btc animals. 
G Quantitative evaluation revealed a significantly higher number of cleaved caspase-3-positive cells in the pancreas 
of Btc animals compared to control, Erbb4del, and Erbb4del+Btc mice. H Western blot analysis of phospho-SAPK 
and SAPK 3 hours after an induced caerulein-AP. TUBA1A was used as a loading control. I Densitometric analysis 
revealed a significantly increased level of phospho-SAPK in BTC mice only. Data in B-G are related to a number 
of: n=6/group. Data (B-G; I) are presented as mean+SEM, and were analyzed by ANOVA followed by Tukey’s post 
hoc test. *P<0.05; **P<0.01, ***P<0.001. 
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To confirm that our results are not associated with a caerulein-specific mechanism we 
employed L-arginine as a second AP-model. Consistent with our data so far, 
Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice showed no differences in the histological scoring of the necrotic 
area, edema, and infiltration of the pancreas compared with Erbb4fl/fl;Ptf1aCre/+ and control mice 
(Figure 2.3 A-D). Again, only in pancreata of Btc mice, we observed less necrosis, edema, and 
infiltration compared to the other three groups (Figure 2.3 A-D). The increase in serum amylase 
levels in Btc mice at 24 h, 48 h, and 72 h was significantly less pronounced compared to the 
other three groups (Figure 2.3 E). In addition, we detected only minor pancreatitis-associated 
lung inflammations in Btc mice compared to the other three groups, which all developed lung 
inflammation 72h after L-arginine pancreatitis (Figure 2.3 F,G). Although ERBB4, per se, does 
not play a role in AP, we could demonstrate with two independent models of AP induction that 
the BTC mediated protection against AP is ERBB4-dependent.  
2.3.4.4 THE ERBB RECEPTORS AND BTC ARE EXPRESSED IN NORMAL PANCREAS (NP) AND IN 
CHRONIC PANCREATITIS (CP) 
To evaluate the expression of the ERBB receptors and BTC in the pancreas and to investigate 
whether the receptors and BTC are expressed during pancreatitis, we performed 
immunohistochemistry stainings (Suppl. Fig. S 2.2). Due to the inaccessibility of human AP 
samples and due to the relationship of the two diseases, we performed our investigations in 
CP. All receptors and BTC were expressed in NP and CP. EGFR and ERBB4 were 
predominantly expressed in acinar cells, but not in the ducts of NP. ERBB2 and ERBB3 were 
expressed in both, acinar and duct cells of NP. BTC staining was most prominent in the islets 
of Langerhans, but also detected in the acinar and duct cells. In CP, EGFR was expressed in 
all acinar cells and reactive ductal structures, but not in normal duct cells. ERBB2 was detected 
in acinar cells and strongly in normal and reactive ducts. ERBB3 distribution was similar to NP. 
ERBB4 was irregularly distributed in acinar cells in NP but, in CP very consistently in ductal 
structures. BTC distribution in CP was similar to NP. 
2.3.4.5 MICROARRAYS REVEALED SEVERAL UPREGULATED GENES ENCODING ECM PROTEINS IN 
THE PANCREAS OF BTC MICE DURING AP  
To identify regulated genes that could mechanistically explain the protection of BTC against 
AP we investigated the pancreatic transcriptome of Btc mice and control littermates using 
microarrays. 1009 genes were up-regulated in control animals with AP and 649 genes were 
up-regulated in Btc mice with AP, and 492 of these up-regulated genes are matching in both 
AP-groups. Both groups with AP share 728 down-regulated genes, and 350 genes were 
exclusively down-regulated in Btc animals with AP. The full microarray data set was uploaded 
at NCBI Gene Expression Omnibus and has the data accession number GSE121038. Several 
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of the most abundantly up-regulated genes during AP in Btc mice (the top 20 regulated genes 
are shown in Suppl. Fig. S 2.3 A) encode proteins of the ECM or for enzymes organizing the 
  
Figure 2.3: The protective effect of BTC is also lost in Erbb4del+Btc mice during L-arginine pancreatitis 
A H&E-stained histological sections revealed less pronounced tissue necrosis, edema, and infiltration in the 
pancreas of Btc mice as compared Erbb4del+Btc, Erbb4del, and control animals. Scale bars represent 200 µm. 
Histological scoring revealed that the increase severity score of B inflammatory cell infiltration, C acinar necrosis, 
and D edema was significantly less prominent in the pancreas of Btc mice as compared to the three other groups. 
E The increase in serum amylase levels in Btc mice at 24 h, 48 h, and 72 h was significantly less pronounced as 
compared to Erbb4del+Btc, Erbb4del and control mice. Data in A-D are at 72 h after L-arginine administration. F Lung 
histology score after 72h L-arginine pancreatitis. G H&E stainings revealed no lung inflammation of Btc mice as 
compared Erbb4del+Btc, Erbb4del, and control animals. Scale bars represent 100 µm. Data (B-F) are presented as 
mean+SEM, and were analyzed by ANOVA followed by Tukey’s post hoc test. *P<0.05; **P<0.01, ***P<0.001. 
 
ECM. The mRNA expression profiles were confirmed for 15 of the most interesting genes by 
quantitative RT-PCR in animals after 3h-AP (Suppl. Fig. S 2.3 B).  
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Figure 2.4: Analysis of ECM 
A Western blot revealed increased levels of MGP, POSTIN, MMP2, and MMP3 in Btc and Btc+Wa5 mice, compared 
to control and Erbb4del+Btc mice with 24h-AP. TUB1A1 was used as a loading control. B Densitometric analysis of 
Western Blots revealed significantly increased levels of MGP, POSTN, MMP3, and MMP2 in Btc and Wa5+Btc 
mice. C Representative pictures of Masson’s-Trichrome-Stain stainings. Scale bars represent 100µm. D 
Histological score demonstrates significantly reduced levels of connective tissue in Btc and Btc+Wa5 mice, 
compared to control, Wa5, Erbb4del, and Erbb4del+Btc mice with 24h AP (n=6/group). E Immunohistochemistry 
stainings of MGP, POSTN, MMP3, and MMP2 in Btc and control mice with 24h AP. Scale bars represent 50µm. 
Data (B,D) are presented as means+SEM, and were analyzed by ANOVA followed by Tukey’s post hoc test. 
*P<0.05; **P<0.01, ***P<0.001. 
2.3.4.6 BTC INCREASES ECM REMODELING PROTEINS IN AN ERBB4-DEPENDENT MANNER 
Next, we investigated whether changes in the most interesting transcripts up-regulated in Btc 
transgenic animals with and without AP are present at the protein level. Since we know that 
ERBB4 mediates the protective effect of BTC in AP, we analyzed Erbb4fl/fl;Ptf1aCre/+;Btctg/+mice 
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in more detail. Four of the up-regulated transcripts (Mgp, Postn, Mmp2, Mmp3) were validated 
to be significantly increased at protein level in Btc mice and Wa5+Btc animals with 3h-AP, but 
not in control animals and Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice (Figure 2.4 A,B). The fact that these 
proteins are increased only in mice without AP-phenotype (Btc and Wa5+Btc) and not in 
Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice, indicates that these proteins could be part of the BTC-induced 
protection mechanism.  
An increased amount of connective tissue and ECM is often associated with a higher severity 
of AP. To determine the amount of connective tissue, sections from animals with a 24-h-
caerulein-induced AP were stained by Masson’s-Trichrome-Stain (Figure 2.4 C). A histological 
score revealed that the amount of stained connective tissue was clearly lower in Btc and 
Wa5+Btc mice compared to controls (EgfrWa5/+, Erbb4fl/fl;Ptf1aCre/+, and 
Erbb4fl/fl;Ptf1aCre/+;Btctg/+mice) with AP (Figure 2.4 D). Immunohistochemistry stainings 
revealed that Btc mice express much more MGP and POSTN in their acinar cells compared to 
control animals during AP (Figure 2.4 E). MMP2 and MMP3 are also expressed in the acinar 
cells, but IHC showed no obvious differences between both groups. POSTN and MMP3 are 
highly expressed in the islets of Langerhans. These results show that Btc mice have less ECM 
and increased amounts of ECM modifier as MMP2, MMP3, POSTIN, and MGP, which could 
play an important role in the AP protection mechanism of BTC. 
2.3.4.7 BTC INCREASES INTRAMEMBRANE PROTEOLYSIS OF ERBB4  
To assess BTC-induced ERBB4 activity in the exocrine pancreas and to investigate whether 
the receptor plays a role in the progression and severity of pancreatitis, we investigated ERBB4 
phosphorylation. Increased ERBB4 phosphorylation was detected in the pancreas of Btc 
transgenic mice, while the AP status did not seem to influence phosphorylation (Figure 2.5 A). 
It is known that full-length ERBB4 and also the ICD of ERBB4 can migrate into the nucleus, 
where both proteins are able to act as transcriptional regulators. RT-PCR analysis revealed 
that the cleavable JM-a form and both CYT variants (Figure 2.5 B) are expressed in the 
pancreas. In a next step, we performed a cell fractionation of pancreas of AP-induced Btc and 
control mice. The fraction purity was analyzed by reference proteins: H3F3A (nucleus), 
GAPDH (cytosol), and ERBB2 (membrane) (Figure 2.5 E). Western blot analysis of ERBB4 
and densitometric evaluations revealed significantly increased ERBB4 in the nucleus fraction 
of Btc mice compared to controls, and we also found enriched levels of ERBB4-ICD in the 
nucleus and cytosol in Btc animals with AP (Figure 2.5 C,D).  
 
28 
 
 
Figure 2.5: Btc transgenic animals revealed increased levels of the ERBB4-ICD 
A Western blot analysis of phospho-ERBB4 and total ERBB4 in the pancreas of control and Btc mice with and 
without AP. GAPDH was used as a loading control. B RT-PCR showed that the JM-a isoform and both CYT isoforms 
of ERBB4 are expressed in the murine pancreas. P: Pancreas, K: kidney, S: spinal cord, C: cerebellum, H: heart. 
C ERBB4 and the ICD of ERBB4 were detected by Western blot in all three fractions of the pancreas after a 3 h 
caerulein-induced pancreatitis in BTC and control mice. ERBB2 (membrane), GAPDH (cytosol), and H3F3A (nuclei) 
were chosen as reference proteins. D Densitometric analysis revealed significantly more ERBB4 in the nuclei of 
Btc mice compared with control animals, and significantly increased levels of the ICD in the cytosol and nuclei of 
BTC animals. *P<0.05; ** P<0.01. E Western blot analysis confirmed the purity of the fractionated proteins. ERBB2 
is mainly expressed in the membrane-fraction, GAPDH only in the cytosol-fraction, and H3F3A exclusively in the 
nuclei-fraction. 
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2.3.5 DISCUSSION 
In a previous study, we showed that transgenic mice overexpressing the EGFR ligand BTC 
consistently failed to develop caerulein-induced and L-arginine-induced AP160. Before BTC can 
be considered as a therapeutic agent against AP, the mechanism behind its protective effects 
needs to be clarified. With this in mind we deleted both ERBB receptors that can be directly 
activated by BTC (EGFR and ERBB4) pancreas-specifically. Interestingly, while EGFR is 
dispensable for the development and homeostasis of the exocrine pancreas, it is an important 
proto-oncoprotein for tumor initiation155,156. Our data clearly indicate that EGFR does not 
mediate the protective effect against AP, as this effect is fully maintained in BTC;Egfr+/Wa5 mice. 
The fact that EGFR seems to be dispensable for the homeostasis of the exocrine pancreas 
indicates that EGFR is not the preferred ERBB receptor of BTC in this tissue.  
In light of these findings, we focused our investigations on the second autonomous ERBB 
receptor and binding partner of BTC, ERBB4. We used a pancreas-specific ERBB4 knockout 
model172 for further investigations of BTC mediated effects in the pancreas. Btc transgenic 
mice lost their protection against AP in the ERBB4 receptor knockout background, strongly 
indicating that the protective effect is mediated by ERBB4. We revealed previously, that the 
protective effect of BTC was associated with increased apoptosis and SAPK signaling160. In 
this work, we verified that this effect was also mediated by the ERBB4 receptor, since cleaved 
Caspase-3 levels were decreased and SAPK was less activated than in BTC mice. This 
indicates a role for ERBB4 as a driver of apoptosis. Previous studies in human breast cancer 
have also shown a significance of ERBB4 mediated SAPK activation, resulting in the delay of 
mitotic progression177. Therefore, the activation of SAPK via ERBB4 signaling could represent 
an interesting druggable target during AP.  
In addition to ligand-induced phosphorylation, ERBB4 can also undergo RIP to release its ICD 
into the cytosol and the nucleus, where it can act as transcriptional co-activator. We revealed 
significantly enhanced cytosolic and nuclear ICD presence in Btc transgenic animals 
concluding that BTC induces the ICD release, which has previously only been reported for the 
ligand NRG1178. In the nucleus, the ERBB4 ICD could bind to interaction partners, as YAP and 
MDM2168,178, and hence, serve as transcriptional co-regulator, enhancing the transcription of 
the ECM proteins MGP, POSTN, MMP2 and MMP3, we found to be upregulated on mRNA 
and protein levels in Btc and Wa5+Btc mice, but not in Erbb4fl/fl;Ptf1aCre/+;Btctg/+ mice upon AP 
induction, thereby altering the microenvironment and providing a favorable setting for AP 
protection.  
MGP and POSTN are proteins of the ECM179,180 and MMP2181 and MMP3182 are modulators of 
the ECM, able to prevent fibrosis. ECM remodeling is an important mechanism for cell 
differentiation and tissue homeostasis, but a deregulation can result in the development of 
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fibrosis and carcinogenesis183 and fibrosis has been associated with AP, previously144,145. 
MMPs and collagens are often increased in different tumors and the ECM can play a role in 
cancer initiation and progression. MMP2 and MMP3 are increasingly expressed by BTC 
overexpression, possibly in order to prevent early fibrosis, thereby contributing to the protection 
against AP.  The up-regulated ECM proteins, POSTN and MGP, also seem to have a positive 
effect on AP and is in line with previous findings. POSTN knockout mice showed significantly 
decreased regeneration after caerulein induced AP, suggesting that POSTN is essential for 
the recovery of the exocrine pancreas in AP184. MGP correlated negatively with pro-
inflammatory cytokines and acute phase proteins during AP in humans, and low levels of MGP 
correlated with a more severe inflammation185. A current study demonstrated that MGP is 
associated with a reduced cytokine production in T-cells and MGP reduces the clinical and 
histopathological severity of colonic inflammation in murine experimental colitis186. MGP, like 
other Gla-rich proteins, can act as an anti-inflammatory agent in monocytes and macrophages, 
also during chronic inflammation187. We propose that BTC overexpression in AP induces 
anti-inflammatory and pro-regenerative proteins by the activation of the ERBB4-ICD which 
alters transcriptional regulation of these targets.  
In summary, our report revealed that BTC protects the pancreas against AP through ERBB4. 
This is achieved possibly by SAPK signaling and subsequent caspase-3 activation, thereby 
increasing the apoptotic rate and by ICD trafficking with subsequent alteration of the 
transcriptome, favoring the expression of the anti-inflammatory and pro-regenerative proteins 
MGP, POSTN, MMP2, and MMP3. We identified the ERBB4 receptor as a promising druggable 
target to control AP; as a transmembrane receptor, ERBB4 represents an amenable 
therapeutic target. However, caution must be taken, since cellular responses are distinct and 
given in a ligand-dependent manner. Other ERBB4 ligands than BTC might bear unfavorable 
roles for the pancreas, such as HBEGF which leads to metaplastic duct proliferation when 
overexpressed. Our study rather suggests that the growth factor BTC, or synthetic analogs, 
could be used as a drug to treat AP or to support conventional AP treatment. In particular, 
because the overexpression of BTC does not show an adverse phenotype in the pancreas of 
mice, suggesting only low or even no side-effects, when locally administered. 
 
 
.  
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2.3.6 SUPPLEMENTARY FIGURES 
 
Suppl. Fig. S 2.1: BTC and ERBB receptor expression  
A Immunofluorescence staining for BTC in the pancreas of transgenic and control mice. B Immunohistochemical 
staining for ERBB4 in the pancreas of Erbb4fl/fl;Ptf1aCre/+ and control mice and D H&E staining. Scale bars in A 
represent 200 µm and in B,C 100 µm. D Western blot analysis of BTC expression and ERBB expression and 
phosphorylation of pancreas from transgenic and control animals with 3h-AP. GAPDH was used as reference 
protein. E RT-PCR of several organs from Erbb4fl/fl;Ptf1aCre/+ mice and control mice. Gapdh was used as reference 
gene. F Densitometrical analysis of Western blots. G Absolute and H relative pancreas weight of female 
Erbb4fl/fl;Ptf1aCre/+ and control animals and of I,J male mice showed no differences between genotypes. Data in F-
J are presented as mean+SEM and were analyzed by Student‘s t-test. *P<0.05, P<0.01. 
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Suppl. Fig. S 2.2: ERBB receptor and BTC expression in normal pancreas (NP) and human chronic 
pancreatitis (CP) 
Immunohistochemistry of NP and CP revealed, in NP, EGFR and ERBB4 were expressed in acinar cells, and not 
in the ducts, while in CP, both were additionally expressed in reactive ductal structures. ERBB2 expression was 
found in ducts and centroacinar cells and ERBB3 was detected in acinar cells and ducts in NP and BTC expression 
predominated the islets of Langerhans. In CP, ERBB2 was predominantly expressed in ductal structures. ERBB3 
and BTC expression in CP was similar to NP. Scale bars: 50 µm. 
 
Suppl. Fig. S 2.3: Changes in ECM remodeling proteins are associated with the AP-protective effect of BTC 
A The 20 most abundantly up-regulated transcripts of Btc mice with 3h AP compared with control littermates. For 
total RNA isolation the pancreas samples were freshly preserved in RNAlater solution. First, the pancreas was 
perfused by injection of 1 ml RNAlater. Then the perfused pancreas was incubated in 5 ml RNAlater at 4°C for 24h 
and subsequently frozen at -80 °C until further processing. The microarray analyses were performed with the Agilent 
SurePrint G3 Mouse GE 8x60K Microarray (G4852A; AMADID 028005) as previously described188. The RNA 
integrity values ranged from 7 to 9 and processed signals were filtered based on “Is well above background” flags, 
where two samples out of each experimental group must be above the background signal. Differentially abundant 
genes were determined using the limma189 package from BioConductor with a FDR ≤ 0.05 and at least a 2-fold 
change (log fold-change ≥ 1). The full microarray data set was uploaded at NCBI Gene Expression Omnibus and 
has the data accession number GSE121038. B RT-PCR of transcripts from Btc mice compared to control animals 
during 3h AP. Data in B are related to a number of: n= 4 males/group; age: 4 months, and were analyzed by 
Student’s t-test. *P<0.05; **P<0.01, ***P<0.001. 
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2.3.7 SUPPLEMENTARY TABLES 
Suppl. Table S 2.1: Antibodies employed for Western blots analysis and immunohistochemistry and their 
dilutions 
Western blot 
Antigen Antibody Host Dilution 
BTC R&D Systems, Minneapolis, MN, USA #AF1025 goat 1:500 
ERBB4 Cell Signaling, Boston, MA, USA, #4795 rabbit 1:1000 
p-ERBB4 
(Tyr 1284) 
Cell Signaling, #4757 rabbit 1:1000 
SAPK Cell Signaling, #9252 rabbit 1:1000 
p-SAPK Cell Signaling, #9251 rabbit 1:2000 
MGP LifeSpan BioSciences, Seattle, WA, USA, #LS-
C341793-100 
rabbit 1:1000 
POSTN LifeSpan BioSciences, #LS-C150337 rabbit 1:1000 
MMP2 Santa Cruz Biotechnology, #13594 (2C1) mouse 1:500 
MMP3 Santa Cruz Biotechnology, #6839 (C-19) goat 1:500 
ERBB2 Santa Cruz Biotechnology, Dallas, TX, USA #284 
(C-18) 
rabbit 1:500 
H3F3A Cell Signaling, #9717 rabbit 1:1000 
TUB1A1 Cell Signaling, # 2125 rabbit 1:5000 
GAPDH Cell Signaling, #2118 rabbit 1:5000 
Goat α Rabbit Cell Signaling, #7074 goat 1:2500 
Rabbit α Mouse Cell Signaling, #7076 rabbit 1:2000 
Donkey α Goat R&D Systems, #HAF109 donkey 1:2000 
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Immunohistochemistry 
Antigen Antibody Host Dilution 
ERBB4 Santa Cruz Biotechnology, #SC-283 rabbit 1:100 
cl. Caspase 3 Cell Signaling, #9664 rabbit 1:100 
Ki67 DAKO, #M7249, Hamburg, Germany rat 1:200 
EGFR R&D Systems, #AF231 goat 1:800 
ERBB2 Cell Signaling, #4290 rabbit 1:800 
ERBB3 Cell Signaling, #12708 rabbit 1:500 
ERBB4 Proteintech, Manchester, UK, #19943-1-AP  rabbit 1:500 
BTC R&D Systems, #AF261NA goat 1:300 
MGP Proteintech, #10734-1-AP rabbit 1:200 
POSTN Proteintech, #19899-1-AP rabbit 1:200 
MMP2 Santa Cruz Biotechnology, #13594 (2C1) mouse 1:200 
MMP3 Santa Cruz Biotechnology, #6839 (C-19) goat 1:200 
Rabbit α Goat DAKO, #E0466 rabbit 1:200 
Goat α Rabbit DAKO, #E0432 goat 1:200 
Goat α mouse DAKO, #E0433 goat 1:200 
 
Suppl. Table S 2.2: Primers and probes employed for RT-PCR 
Gene Forward Primer 
5’-3’ 
Reverse Primer 
5’-3’ 
Probe 
5’-3’ 
Mmp2 TAACCTGGATGCCGTCGT TTCAGGTAATAAGCACCCTTGAA GGTGGTGG 
Mmp3 TGCAGCTCTACTTTGTTCTTTGA AGAGATTTGCGCCAAAAGTG CCGGGGAG 
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Postn TGAGATAAAATATACCAGGATTTCCA TCTTCTTTGCAGGTGTGTCTTT TTTCCACA 
Col1a1 AGCAGGTTCACCTACTCTGTCC CTTGCCCCATTCATTTGTCT ATGGCTGC 
Fn1 CGGAGAGAGTGCCCCTACTA CGATATTGGTGAATCGCAGA CCTCCTCC 
Mgp TCACGAAAGCATGGAGTCCT GCTGAGGGGACATAAAGGTG CAACAGGA 
Lum CAGCAACATTCCGGATGAG TCATTGTGAGATAAACGCAGGT CTGGGCTG 
Cdh11 ACTGCCTGGCTCAACATCTC CTGGGACTTTGGTTTCCTGA GCAGCAGA 
Srpx CCGAAAGGGCTATGAGCTT AGGGTAGGACATCGCTTCTG AGCTGGGA 
Ctgf TGACCTGGAGGAAAACATTAAGA AGCCCTGTATGTCTTCACACTG CTGGCTGT 
Serpina6 CCACCAAAGACACTCCCTTG GGTGTACAGGAGGGCCATT CTGCTGCC 
Serpinf1 GGACTCTGATCTCAACTGCAAG AAGTTCTGGGTCACGGTCAG CTTCTTCC 
Aebp1 GGAGAAAAACAAGGACCACAAA ATCCCAATAGGTGGGCACT GGGTGAGG 
Clip4 AGGAGCCGTGAAAACCTTG GATCTGCCCTTTGTCATTCC AGCTGGGA 
Penk CCCAGGCGACATCAATTT GCAGGTCTCCCAGATTTTGA CACATTGG 
Actb CGTGAAAAGATGACCCAGATCA CACAGCCTGGATGGCTACGT TTTGAGACC
TTCAACACC
CCAGCCA 
Erbb4 CAGCAGTACCGAGCCTTGCG CAGAGTCATGTTGGAAGGCC  
Jm-Erbb4 AGATGGACTCCTCACATGCC GGGCTCACCAGCTCTGTC’  
Cyt-Erbb4 AGAATCTCTTGGATGAAGAGG CCATTACAGCAGGAGTCATCA  
Gapdh TCATCAACGGGAAGCCCATCAC AGACTCCACGACATACTCAGCACCG  
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2.4 CONCLUSIONS & OUTLOOK 
AP is a common disease with rising incidence, almost always leading to hospitalization due to 
persistent, severe pain and eventually becoming life-threatening with a mortality of up to 50% 
in severe AP. Causes for AP are divers, the major reasons being gall stones and alcohol 
abuse. The former leads to duct obstruction and increasing pressure on acinar cells which 
leads to the blockage of zymogens secretion into the lumen of the duct, whereas alcohol acts 
as a toxin on the exocrine pancreas. Both causes lead to pathological processes, involving 
ER-stress, disturbed Ca2+ signaling, mitochondrial dysfunction and premature trypsinogen 
activation resulting in apoptosis, necrosis and auto-digestion. Treatment of AP is only 
symptomatic and primarily includes analgesics, rehydration to preserve tissue and to prevent 
hypovolemia and lastly, a proper nutrition strategy, also for pain relief. But each of these 
attempts still requires concerted handling to prevent a more severe course of the disease or 
the occurrence of complications for the patient. In addition, none of these options target 
pathophysiological processes during development or progression of AP. Currently, clinical 
trials are ongoing using therapies, e.g. targeting Ca2+ channels, and the results are urgently 
awaited. Frequently, AP occurs more than once. This recurrent AP (RAP) affects 
approximately one in five patients (with an increased risk for smokers and alcohol consumers), 
eventually leading to chronic pancreatitis. Furthermore, pancreatic insufficiency belongs to the 
devastating long-term consequences of AP and every third survivor will end up with diabetes 
mellitus, alltogether decreasing quality of life tremendously and underlining the urgent need 
for an innovative, and particularly, for a pancreas-preserving treatment.  
The ERBB system has been partially investigated in AP research. It was revealed that EGF 
administration in AP mouse models had protective effects on the AP course and that EGFR 
expression also played a slightly protective role. Both ameliorated the outcome of AP but could 
not prevent it. A previous study from our lab revealed BTC to have a protective effect on AP, 
which was much more pronounced than in studies using EGF. Btc tg mice were subject to 
caerulein- and L-arginine-inducible AP whereas AP development in these mice was inhibited 
compared to wildtype mice. Crossing these mice into a kinase-dead EGFR background could 
not reverse this phenotype, thus, the BTC-mediated protection was suggested to be 
independent of EGFR. Instead, increased SAPK signaling is was activated.  
In this study, we investigated the role of ERBB4 in BTC-mediated protection against AP using  
caerulein-inducible and L-arginine-inducible AP mouse models. Btc tg mice were completely 
protected from AP development. We found that all ERBB receptors, expect for ERBB3 were 
activated in AP in mice and BTC overexpression enhanced the receptor phosphorylation of 
EGFR and ERBB4. The loss of ERBB4 in AP of wildtype mice had no effect on the course of 
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AP, neither had the loss of EGFR, as previously described. The expression of a kinase-dead 
EGFR in Btc tg mice had no effect on AP. But the pancreas-specific loss of ERBB4 resulted in 
the complete loss of AP protection, revealing ERBB4 as the mediator of the BTC-induced 
prevention of AP. In Btc tg mice lacking ERBB4, serum lipase, amylase and histological scoring 
of necrosis, apoptosis and edema changed back to the AP conditions as they were observed 
in wildtype mice. Further, the amount of fibrosis in ERBB4-depleted Btc tg mice was similar to 
control mice upon AP induction, while it was decreased in BTC transgenic AP induced mice. 
Microarray and quantitative PCR analyses revealed transcriptome changes in Btc tg mice 
compared to wildtype mice. The most upregulated transcripts derived from genes involved in 
extracellular matrix (ECM)-dynamics, Mgp, Postn, Mmp2 and Mmp3. The expression of these 
anti-inflammatory and pro-regenerative proteins was also proven to be different in 
ERBB4-depleted Btc tg mice from single Btc tg mice. This verifies that the expression of these 
genes is ERBB4-dependent. We detected RIP of ERBB4 and subsequent trafficking of its ICD 
into the cytosol and nucleus. Since the ERBB4 ICD also acts as a transcriptional co-regulator, 
we suggested that ERBB4 might be involved in the differentially regulated transcription of these 
ECM proteins, which have shown to be increased in expression in Btc tg mice. This mechanism 
could lead to an altered composition of the pancreatic microenvironment, which is resistant to 
AP development. MMP2 and MMP3 possibly prevent early fibrogenesis, while POSTN might 
activate early processes of regeneration and MGP inhibits a strong inflammatory response in 
AP upon BTC-mediated ERBB4 ICD signaling. A second consequence of BTC overexpression 
was the enhanced activation of SAPK in AP, which was associated with an increased 
apoptosis-rate, both of which were not observed in the ERBB4 depleted background. This 
indicates that ERBB4 is associated with apoptosis regulation.  
These data present BTC and ERBB4 as promising targets in AP therapy. However, since 
probably all ERBB-signaling is strongly ligand-dependent, caution should be taken about 
choosing ERBB4 as a therapeutic target. The overexpression of the EGFR/ERBB4 ligand 
HBEGF rather results in metaplastic duct proliferation, which could be triggered by ERBB4. 
BTC might be the better target for AP treatment. However, also BTC as therapeutic option 
should be considered carefully. Systemic treatment is rather adverse, since BTC transgenic 
mice have numerous health issues and since the administration of growth factors might 
generally increase the risk of tumor development. But BTC overexpression had no effects on 
the exocrine pancreas, thus, making a locally administered therapy attractive. Further studies 
must be carried out to investigate the complete mechanism of BTC-mediated protection 
against AP, to find therapeutic targets, which are possibly less difficult to target.  
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2.5 BRIDGE 
While chronic pancreatitis is established to be a risk factor for pancreatic cancer, there is rising 
evidence, that AP can also be correlated with an increased risk of developing pancreatic 
cancer190,191. One population-based, age- and sex-matched cohort study revealed that while 
within two years after the diagnosis of AP, the risk of developing pancreatic cancer was the 
highest. The chance to develop cancer decreased over time, however, after five and ten years, 
respectively, the risk was still twice as high compared to patients without AP192. Furthermore, 
patients who had AP have a chance of recurrence and recurrent APs, in turn, can develop into 
chronic pancreatitis, which emphasizes the association of AP and pancreatic cancer126. Since 
BTC ameliorated the outcome of AP drastically, we wondered whether BTC might also be 
beneficial in pancreatic cancer.  
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3 BTC IN PANCREATIC CANCER 
3.1 INTRODUCTION 
3.1.1 PANCREATIC CANCER 
3.1.1.1 NUMBERS & FACTS: A SURVEY 
PDAC is a malignant tumor of glandular origin arising from the ductal epithelium of the 
pancreas. It is the most common type of pancreatic cancer (and herein referred to as PDAC, 
pancreatic ductal adenocarcinoma or pancreatic cancer), followed by neuroendocrine 
tumors (5%)193 and acinar cell carcinoma (1-2% of exocrine tumors)194. With death cases 
reaching almost the incidences of approximately 460.000 globally, per year, PDAC is one of 
the deadliest cancers, worldwide. In Europe, North America and Australia/New Zealand, these 
rates are even three- to four-fold higher and researchers expect them to remain stable or even 
to increase in the near future. While we observe declining rates for breast cancer as the current 
third leading cause of cancer-related deaths in Europe, PDAC is projected to belong to the top 
three cancer killers after lung and colon cancer in the near future in the European Union and 
even to be in second place in the USA by the year 2030195-197. But why do mortality rates 
remain stable despite so many years of increasing advances of insights into the basic 
principles of PDAC? With a 5-year-survival of 8% (after combining all tumor stages) PDAC has 
the worst survival of all cancers198. Reasons for that can be found in the late clinical 
presentation due to the late onset of symptoms, the spread of metastases at the time of clinical 
presentation and the lack of early detection due to the poor availability of specific 
biomarkers199. Furthermore, amongst solid tumors, PDAC has the highest amount of stroma 
impeding therapeutics delivery to the cells of interest in order to be effective200. Moreover, the 
dense fibrotic tissue is further supported by hypovascularization which even worsens drug 
availability and penetration201,202. Another hallmark of PDAC is genomic instability which leads 
to the rapid development of resistance to targeted therapies203.  
3.1.1.2 DEVELOPMENT & PROGRESSION OF PDAC 
Preceding the development to a carcinoma in situ, the pancreas undergoes a few preneoplastic 
changes. In part, prior to the onset of premalignant lesions, acinar cells transdifferentiate into 
duct cells (acinar-ductal-metaplasia (ADM)) (Figure 3.1, asterisks)204. The pancreatic 
epithelium develops into three different major types of neoplastic precursor lesions, such as 
pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasia (MCN) and intraductal 
papillary mucinous neoplasia (IPMN), all of which have the potential to progress into invasive 
carcinoma205, however, the former are the most common and best studied lesions and will be 
the predominant lesions in the underlying work. PanIN are microscopic flat or papillary lesions, 
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smaller than 0.5 centimeters (cm), with a columnar epithelium expressing differing amounts 
of mucins and presenting with differing degrees of cellular, nuclear and architectural atypia205. 
PanIN develop through sequential stages of preneoplastic progression from low-grade lesions 
including PanIN1(A/B) and PanIN2 to the high-grade lesion PanIN3, the latter being highly 
associated with the progression to invasive carcinoma. Histologically, these lesions are 
described as follows:  
PanIN1A/B: While normal ducts present with a cuboidal epithelium and basally based 
nuclei (Figure 3.1, arrows), PanIN1A/B present with a flat columnar epithelium (Figure 3.1, 
white arrowheads) with basally located small round or oval nuclei and abundant supranuclear 
mucin. PanIN1B are identical to 1A with the exception that 1B has a papillary, pseudostratified 
epithelium (Figure 3.1, black arrowheads).  
PanIN2: These lesions are predominantly papillary with nuclear atypia, such as 
hyperchromatism, nuclear crowding or/and loss of polarity. Regular mitoses can be observed 
rarely (Figure 3.1, dotted line).  
PanIN3 (carcinoma in situ): These lesions are papillary. Budding off of epithelial cell 
clusters into the lumen is frequently observed. PanIN3 present with luminal necrosis. 
Dystrophic goblet cells with nuclei oriented towards the lumen can be detected and mitoses 
may occur more frequently and are atypical. Nuclear atypia are more prominent than in 
PanIN2 lesions and nucleoli are enlarged (Figure 3.1, dotted line).  
 
Figure 3.1: Development and progression of (pre)neoplastic lesions prior to PDAC development 
H&E (upper panels) and Masson’s trichrome stainings (lower panels) of murine pancreatic sections. Normal 
pancreas (NP) composed of predominantly acinar tissue, islets of Langerhans (LI) and normal ducts (arrows), ADM; 
acinar-ductal metaplasia (asterisks): Acinar cells transform into ductal structures, frequently accompanied by 
fibrosis, PanIN1A/B; the ductal epithelium becomes columnar, nuclei are still at the basal site of the cell. PanIN1A 
present with a flat epithelium (white arrowhead), PanIN1B depict a papillary structure (black arrowheads), PanIN2; 
papillary lesions with loss of polarity in some cells (demarcated line), PanIN3; Papillary lesions with the complete 
loss of polarity, and budding off of epithelial cell clusters into the lumen and luminal necrosis but with an intact basal 
membrane (demarcated line), PDAC; carcinoma with cancer cells disrupting the basal membrane of the lesion and 
migrating into the surrounding desmoplastic tissue.  
The carcinoma in situ (or PanIN3) is marked by an intact basal membrane that surrounds the 
epithelial tumor cells (Figure 3.1)206,207. During further progression, genetic and epigenetic 
changes allow a few epithelial cells to acquire mesenchymal features (epithelial-to-
mesenchymal transition, EMT) in order to disrupt the basement membrane and to become 
LI 
LI 
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invasive, the first crucial step of a cascade of events required for metastatic dissemination. 
Once, the cancer cells have reached the stromal compartment, they migrate through the 
stroma and proceed to intravasation, subsequent circulation through the blood stream, 
extravasation and finally, the formation of micro-metastases and colony formation at the target 
site208, preferably at liver, peritoneum and lungs209. EMT is facilitated by the destruction of 
adherens junctions between cells, of cell-ECM contacts mediated by integrins and by the loss 
of E-cadherin (CDH1) and concomitant upregulation of N-cadherin (CDH2)208. Once, the tumor 
has metastasized, the patient is inevitably sentenced to death. Systemic treatment by 
chemotherapy certainly does not only target the primary tumor, but also metastatic lesions, 
however, investigations suggest that metastases are similarly resistant to drug delivery as to 
the primary tumor due to a similar desmoplastic environment making it challenging to control 
metastatic burden in PDAC201. Genetically, metastases are clones of the primary tumor and 
do not display a specific genomic imprint210. 
3.1.1.3 MICROENVIRONMENT 
A hallmark of PDAC is the microenvironment of the tumor cells. The cancer cells are 
surrounded by an excessive desmoplastic reaction which provides an environment that 
comprises predominantly activated pancreatic stellate cells (PSC) secreting and storing 
extracellular matrix (ECM) and immune cells ensuring an inflammatory reaction200,201. PSCs 
are quiescent under physiological conditions and are only activated upon injury and 
inflammation of the pancreas, or by cytokine and growth factor stimulation. Once activated, 
they acquire myofibroblast-like characteristics, which is marked by the expression of the 
PSC-specific marker alpha-smooth muscle actin (ACTA2). PSCs change their morphology, 
start to proliferate and migrate, secrete ECM and maintain an excessive cross-talk with the 
ECM. These characteristics make them one of the key players of PDAC211,212. They also 
communicate with the cancer cells in order to propagate their invasion by remodeling the dense 
tumor stroma213. These pro-tumorigenic properties made them a promising target in the search 
for PDAC treatment, however, surprisingly, the depletion of PSCs or PSC-driven pathways in 
pancreatic cancer resulted in increased invasiveness and in a worse prognosis of PDAC in 
quite a few in vivo studies214, suggesting a protective response of PSCs upon tumor 
development and indicating a rather ambivalent role of PSCs. Whether this is due to differential 
epigenetic regulation, different responses to microenvironmental cues or due to different 
sub-populations within the PSCs has to be determined. PSCs deserve a lot more attention and 
caution since their role(s) in PDAC development still have to be revealed.   
3.1.1.4 GENOMIC LANDSCAPE OF PANCREATIC CANCER 
Over 90% of all PDAC patients present a point mutation in the KRAS gene215-218, 
predominantly resulting in the replacement of amino acid 12 or, less frequently, of codon 13 
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or 61 in the resulting protein sequence219. Regarding codon 12, numerous sequencing studies 
revealed that in 41% to 48% of all cases, glycine is replaced by an aspartic acid (KRASG12D), 
more variably, in 11% to 33% glycine is substituted by valine (KRASG12V), in 15% to 20% by 
arginine (KRASG12R) and the remaining mutations in codon 12 are the substitution of glycine 
by alanine (Ala), cysteine (Cys) or Ser220-222. KRAS mutations are the initiating mutations in 
PDAC tumorigenesis as they are the first mutations to be detected already in low grade 
PanIN30. These mutations do not lead to the immediate development of neoplastic cells. 
Instead, there is a long latency period until cells harboring mutated KRAS transform into 
invasive carcinoma, and also, the penetrance is below 100%, meaning that not all cells 
develop invasiveness. In fact, further mutations are required to proceed to higher dysplastic 
lesions. The further progression to the PanIN2 stage is permitted by the loss of tumor 
suppressor cyclin-dependent kinase inhibitor 2A (CDKN2A). The further loss of tumor 
suppressor (TP53) and Mothers Against Decapentaplegic Homolog 4 (SMAD4) is observed 
only in high grade lesions and in invasive carcinoma. Additionally, genomic instability by 
telomere shortening is another hallmark that is observed already in over 90% of low grade 
PanIN and which deteriorates with the grade of lesions. Other genomic aberrations are copy 
number alterations, as well as chromothripsis, a phenomenon by which up to thousands of 
chaotic chromosomal rearrangements occur in a single event223.   
3.1.1.5 KRAS 
KRAS is one of the RAS family proteins. RAS proteins are G-proteins cycling between a 
guanine-diphosphate (GDP) and guanine-triphosphate (GTP) bound state determining the 
activity of the binary molecular switch. They possess a weak intrinsic GTPase activity capable 
of hydrolysing GTP, thereby switching into the inactive state which is strongly stimulated by 
GTPase activating enzymes (GAPs). Upon the interaction with guanine nucleotide exchange 
factors (GEFs), GTP is loaded back onto the RAS protein providing it with the capability to 
interact with further intracellular signaling molecules. Oncogenic mutations, such as 
frequently detected in the KRAS gene in PDAC, impair the intrinsic GTPase function, as well 
as the interaction with GTPases which results in the permanent loading of GTP and thus, in 
a constitutively active RAS protein219,224. Oncogenic KRAS is responsible for enhanced 
proliferation, suppression of apoptosis, a dysregulated metabolism, a reorganized 
microenvironment, evasion of the immune response and enhanced metastatic spread in 
pancreatic cancer225. The three major pathways by which KRAS signaling is transduced in 
PDAC, are the canonical rapidly accelerated fibrosarcoma (RAF)/MEK/MAPK and the PI3K, 
3-phosphoinositide-dependent protein kinase-1 (PDK1)/ protein kinase-B (PKB/AKT) 
pathways and the RalGEFs pathway226.  
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3.1.1.6 THERAPY 
SYSTEMIC THERAPY 
Due to the late diagnosis, only 15-20% of all pancreatic cancer cases are local, and thus, 
eligible to surgical resection227 improving the 5-year-survival up to 12-19%228-230. Those and all 
remaining patients who suffer from locally advanced or metastatic pancreatic cancer, are 
treated with either adjuvant or neoadjuvant systemic therapy, respectively227. More than 20 
years ago, gemcitabine monotherapy was regarded as the standard-of-care treatment for 
pancreatic cancer. Today, FOLFIRINOX, and still, gemcitabine are the two standard-of-care 
therapies for good performance status patients, while gemcitabine is almost exclusively 
administered in combination with nab-paclitaxel231. Gemcitabine is a synthetic fluoridated 
nucleoside prodrug. It is incorporated into the DNA as a masquerade cytosine, thereby eluding 
the repair mechanisms of the cell and inhibiting the replication process232. Nab-paclitaxel 
(albumin-bound paclitaxel) is an anti-mitotic drug which stabilizes microtubule formation 
through binding and therefore disrupting microtubule-spindle dynamics during mitosis resulting 
in apoptotic cell death233. The combination of those two drugs prolonged the median survival 
of the patients by almost two months (8.5 vs. 6.7 months), the 1-year-survival by almost 60% 
(35% vs. 22%) and the 2-year-survival by 100% (9% vs. 4%) compared to the administration 
of gemcitabine alone. Furthermore, the progression-free survival and the response rate were 
significantly improved234. FOLFIRINOX is a combinatorial therapy of folinic acid (vitamin B 
derivative), 5-fluoruracil (5-FU, pyrimidine analog), irinotecan (topoisomerase inhibitor) and 
oxaliplatin (platinum-based DNA-crosslinker). 5-FU inhibits the thymidylate synthase (TS) 
resulting in the lack of (for DNA replication essential) deoxythymidine triphosphate and also in 
the incorporation of TS metabolites into RNA and DNA235. A study comparing FOLFIRINOX 
combination therapy to gemcitabine monotherapy revealed that FOLFIRINOX treatment 
prolonged the median survival by 4.3 months (11.1 vs. 6.8 months), more than doubled the 
1-year-survival (48.4% vs. 20.6%) and tripled the 18-month-survival (18.6% vs. 6%). However, 
the improvements of FOLFIRINOX are accompanied by a higher incidence of adverse events 
which must be considered for every single patient when weighing up the right chemotherapy236.  
TARGETED THERAPY 
Targeted therapies aim to battle the culprit on a molecular level very specifically. The tumor is 
attacked where it develops and ideally, the side effects are reduced. A few oncogenes involved 
in the pathogenesis of PDAC development are known and have already been targeted in 
clinical trials, such as EGFR, ERBB2, vascular endothelial growth factor/receptor 
(VEGF/VEGFR), platelet derived growth factor receptor (PDGFR), BRAF, RAS, PI3K, MEK1/2, 
poly (ADP-Ribose) polymerase 1 (PARP1), sonic hedgehog (SHH) and more. Some of these 
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seem to be promising targets231. In the following, therapies targeting members of the ERBB 
family are summarized.  
EGFR is frequently overexpressed in human pancreatic cancers237-239 and EGFR expression 
levels correlate with a poor prognosis, fast progression or aggressiveness of pancreatic 
cancer237,240,241. So, EGFR has been an attractive target in search of a therapeutic agent. There 
are two ways to inhibit the RTK, in particular, either with monoclonal antibodies (mABs) or 
small molecule inhibitors. The two most prominent and promising mABs which progressed to 
clinical trials were Cetuximab and Panitumumab. Both bind to the extracellular domain of 
EGFR, thereby competing with the ligand, inhibiting receptor dimerization and activation, and 
instead, inducing receptor internalization. Cetuximab additionally induces immune responses 
in the host potentiating its anti-tumorigenic effect242. Another way to inhibit EGFR activity 
effectively is achieved by a small molecule, named erlotinib. It competes with ATP for the 
ATP-binding site of the tyrosine kinase domain of the receptor in a reversible manner resulting 
in the inhibition of autophosphorylation and thus, activation of the same243.  
The expression levels of ERBB2 in PDAC vary from low and modest to high. However, most 
of the investigations are consistent with the finding that ERBB2 overexpression is rather 
observed in premalignant lesions than in invasive carcinomas238,240,244-248. These findings were 
sufficient to target the receptor with the mAB trastuzumab, hitherto successfully used for the 
treatment of metastatic breast and gastric cancer249.  
However, several meta-analyses revealed that targeted therapies in PDAC have no benefit 
over conventional mono-chemotherapies250,251. Although erlotinib treatment combined with 
gemcitabine leads to a significantly (but marginally) increased overall survival, it has no clinical 
relevance252. Also, trastuzumab had either no or only negligibly beneficial effects on the overall 
or progression-free survival in combination with chemotherapy compared to conventional 
monotherapies253,254. So still, after more than 20 years of intense research and after the 
enormous advances in pancreatic cancer research, systematic treatment with toxic 
chemotherapy is the standard-of-care therapy for patients.  
3.1.2 THE ERBB FAMILY IN PANCREATIC CANCER 
There is an urgent need to overcome the limited understanding of the biology of EGFR 
signaling since so many therapeutic approaches failed to target EGFR and EGFR signaling. 
This includes the understanding of the complete ERBB family and their designated ligands 
instead of one single member of the family. The ERBB receptors and ligands play crucial roles 
in pancreatic cancer, however, certainly, there is still much in the hidden which will be 
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discovered in the future. In the following, it is summarized what is known about the ERBB 
network in PDAC, beginning with the ligands.  
3.1.2.1 THE LIGANDS 
GROUP I LIGANDS 
The overexpression of TGFA in the pancreas of mice results in ADM, which is accompanied 
by a fibrotic response and which can further progress into malignant carcinoma147. TGFA was 
verified to be responsible for early events in PDAC development, since primary murine acinar 
cells undergo ADM in 3-D tissue culture after TGFA stimulation255. According to the Human 
Protein Atlas (pathology atlas) database, high TGFA mRNA levels are considered as a bad 
prognostic factor in PDAC patients256. Amphiregulin (AREG) overexpression leads to a 
different response in the pancreas. Compared to TGFA, no fibrosis and no complex tubular 
formation is observed, however, AREG induces increased proliferation of duct cells, 
exclusively, leaving acinar cells untouched149. Other studies found AREG to be involved in the 
PDAC outcome. In one study, AREG was expressed in more than 50% of PDAC samples and 
its expression was correlated with a poor prognosis257. High AREG expression levels in PDAC 
were associated with the hetero-dimerization of EGFR with ERBB3, resulting in enhanced ERK 
and AKT signaling258. The Human Protein Atlas (pathology atlas) database also suggests to 
treat AREG as a bad prognostic marker in pancreatic cancer, since high mRNA levels 
significantly coincided with a shorter survival in PDAC patients256. EGF is overexpressed in 
pancreatic cancer compared to normal pancreatic tissue259 and EGF co-expression together 
with its designated receptor EGFR is associated with increased tumor aggressiveness260. 
Taken together, for all growth-factors uniquely binding EGFR applies that their expression 
together with a concomitant expression of the EGF receptor in pancreatic cancer is related to 
a poor prognosis261.  
GROUP II LIGANDS 
However, the remaining ligands of the ERBB family also play a role in PDAC. Starting with 
another, according to the Human Protein Atlas database (pathology atlas)256 unfavourable 
prognostic marker, EREG. EREG is overexpressed in human PDAC as well as in human 
pancreatic cancer cell lines (hPaCaCells) where it carries out growth-stimulatory effects after 
further exogenic EREG stimulation262. One study revealed that a down-regulation of MUCIN4 
(MUC4), a transmembrane protein upregulated in premalignant lesions, in pancreatic cancer 
and hPaCaCells, and which was shown to be involved in the pathogenesis of PDAC, inhibits 
tumorigenicity and metastasis of pancreatic cancer cells. This observation coincided with the 
down-regulation of EREG263, also assigning a tumorigenic role to EREG. HBEGF was found 
to be expressed in early lesions of human pancreatic cancer264. It also promoted KRAS driven 
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oncogenesis in a genetically engineered mouse model (GEMM) and the stimulation of 
wildtype murine acinar cells in three-dimensional (3-D) cell culture resulted in ADM265, 
indicating that HBEGF is involved in the carcinogenesis of the exocrine pancreas.  
GROUP III/IV LIGANDS 
Another ERBB ligand family, the NRGs, which activate ERBB3 and ERBB4, also play a role 
in PDAC. NRG1 was found to be detected in 75% of the cancer cells and in 90% of metastatic 
lesions of human pancreatic cancer tissues. Stimulatory experiments with NRG1 on 
pancreatic cancer cell lines resulted in growth stimulatory and growth inhibitory outcomes 
which was in part explained by receptor availability of ERBB2 and ERBB3 (particularly by the 
ratio of ERBB2/ERBB3) and by the availability of NRG1 splice forms. While NRGβ1 acted as 
a mitogen, NRGα1 attenuated the growth of the cell lines. The same study observed a 
decreased survival for patients with high NRGβ1 levels (not significant), while there was no 
difference for patients with high NRGα1 levels266 indicating that NRGβ1, but not NRGα1 might 
play a tumor-promoting role in PDAC. Another study found NRG1 expression over 50% of 
pancreatic cancer specimen promoting tumor growth by activating the ERBB3 receptor267,268. 
Interestingly, very recently, fusions of the NRG1 gene were found in 100% of PDAC patients 
with wildtype KRAS alleles269, indicating aberrant ERBB signaling in order to evade 
constitutive KRAS activation. So far, NRG1 seems to be the only NRG ligand that was 
revealed to play a role in PDAC270.  
BTC 
BTC (Group II ligand) mRNA was expressed in many pancreatic cancer cell lines and in 90% 
of human pancreatic cancers. There was a 7.5-fold BTC expression in human PDAC tissues 
compared to the levels detected in normal pancreas. This increase was due to high BTC 
mRNA levels in the duct-like cancer cells. Also, BTC mRNA expression was inducible by EGF 
and HBEGF stimulation in one cancer cell line indicating a cross-induction mechanism for 
BTC by those two EGFR and EGFR/ERBB4 ligands, respectively271. Further, BTC is a potent 
mitogen which was shown by stimulation experiments in human pancreatic cancer cells and 
also in vivo by a cell line inoculated mouse model. BTC can also regulate its expression 
through an auto-induction mechanism in pancreatic cancer cells272. All these features make 
BTC appear to be involved in pancreatic cancer development or progression, however, after 
the year 2000, no further investigations of the role of BTC in PDAC were carried out. Another 
characteristic of BTC is its ability to trans-differentiate various cell types into insulin-producing 
cells103. Trans-differentiation plays a crucial role in PDAC development, and the ERBB ligands 
TGFA and HBEGF are known to be involved in ADM. With the trans-differentiation potential 
of BTC, it might also be implicated in ADM and thus, PDAC development.  
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3.1.2.2 THE RECEPTORS  
EGFR 
EGFR is highly expressed in human PDAC. Its pharmacological, as well as its genomic 
depletion resulted in the inhibition of tumor initiation in mice with pancreas-specific oncogenic 
KRASG12D or KRASG12V. This was, in the KRASG12D model, attributed to a decreased activation 
of the MAPK pathway156,273. But since EGFR is upstream of KRAS, and MAPK is a 
downstream target of KRAS, how can EGFR manage to regulate a downstream target of a 
constitutively active KRAS molecule? The same groups reported that a depletion of the tumor 
suppressor TP53, KRAS-induced oncogenesis is possible, albeit with reduced efficiency 
indicating that EGFR plays an essential role during tumorigenesis in KRAS driven GEMMs in 
a TP53 depleted background156,273. Pharmacological inhibition of EGFR in the clinic by 
erlotinib in combination with gemcitabine only provided marginal benefit in a subset of patients 
compared to gemcitabine mono-treatment252. This suggests that in late stages, the cancer 
cells possibly escape EGFR dependency. This theory would also be in line with the 
observation that the loss of differentiation in pancreatic cancers correlated with the decrease 
of EGFR expression and that human PDAC cell lines with a quasi-mesenchymal subtype were 
more resistant to erlotinib treatment than cell lines with a classical (milder) phenotype204,273,274. 
However, it has been shown very recently, that EGFR inhibition in combination with the 
inhibition of one of its downstream targets, CRAF, led to the prevention of premalignant 
lesions development, to the regression of advanced PDAC in a GEMM and to the inhibition 
of the proliferation of tumor cells in a patient-derived xenograft (PDX) model275. It will be very 
interesting, whether combinatorial therapies targeting EGFR and CRAF will progress to 
clinical trials in the near future.   
ERBB2 
While EGFR is highly important for KRAS induced oncogenesis, the role of ERBB2 in 
pancreatic cancer is less well understood. There are studies showing the expression of 
ERBB2 mRNA in 100% of PDAC samples with increased (but not significant) ERBB2 
expression compared to normal pancreatic tissue266. On the other hand, there are studies 
finding variable, but rather low frequencies of ERBB2 overexpression in PDAC ranging from 
2% to 29%, in part due to the amplification of the gene locus. Mutations in the ERBB2 gene 
indicating aberrant signaling were not found276. A meta-analysis considering six investigations 
performed by FISH analyses revealed that ERBB2 gene amplification did not correlate with 
clinical parameters of pancreatic cancer277. However, another study correlated ERBB2 
overexpression in 25% of PDAC samples with an aggressive phenotype278. Targeting the 
ERBB2 receptor in clinical trials was also disappointing. However, a recent study revealed 
that targeting ERBB2 in a PDAC xenograft model with a combination of trastuzumab and a 
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homemade murine ERBB2-specific mAB was more effective than targeting EGFR with an 
equivalent mAB combination, although expression levels of ERBB2 were 15-fold lower than 
EGFR levels279. This indicates that ERBB2 might play a less apparent but still, a highly 
important role. These contradictory findings show that more effort has to be put into the 
investigation of ERBB2 involvement in PDAC development and progression. 
ERBB3 
ERBB3 was expressed in 100% of PDAC samples with a statistically significant increase in 
mRNA abundance266. ERBB3 was also elevated in more than 50% of PDAC tissues compared 
to normal pancreas, which was not due to gene amplification. This was associated with 
advanced tumor stages and shorter survival of the patients162. Another study found ERBB3 to 
be expressed in many hPaCaCells and in 90% of PDAC samples which was not correlated 
with the outcome of the disease280. But the inhibition of ERBB3 by miRNA decreased the 
proliferation and migration of cancer cells by down-regulating AKT and MAPK signaling, 
thereby also allocating ERBB3 a role in pancreatic cancer277.  
Promising experiments revealed that the dual targeting of the hetero-dimer ERBB2/ERBB3 
(both with different abundance) with two monoclonal antibodies resulted in pronounced 
anti-tumor effects in hPaCaCells and xenograft models. In particular, the therapy delayed 
tumor growth of xenografts arising from cells harbouring KRAS mutations, and which are 
poorly sensitive to erlotinib treatment281.   
ERBB4 
One of the few studies about ERBB4 in PDAC revealed weak to moderate ERBB4 mRNA 
levels in normal pancreas and in 83% of PDAC samples, detected by real-time (RT)-PCR and 
immunohistochemistry (IHC). However, ERBB4 levels were significantly decreased in 
non-metastatic PDAC compared to tumors that had already spread into lymph nodes or built 
distant metastases and also compared to normal pancreas. But no correlation between 
ERBB4 levels and the survival of the patients could be observed282. Only two years later, it 
was published that ERBB4 expression in pancreatic cancer was exclusively found in 
non-metastatic tumors278, which is the exact opposite. Other detected ERBB4 mRNA in 64% 
of PDAC specimen but with a significant decrease in ERBB4 abundance compared to normal 
pancreas. They also detected very low or no levels of ERBB4 in common human pancreatic 
cancer cell lines266 also indicating a rather favourable role for ERBB4 in PDAC. Other 
investigations suggested a context-specific role for ERBB4 in PDAC which can either be 
tumor suppressive or oncogenic. Mill et al. observed that a mutant, constitutively active, 
ERBB4 homo-dimer was able to inhibit colony formation in a human pancreatic cell line, while 
the stimulation of wildtype ERBB4 with NRG1B was not. However, they have linked ectopic 
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ERBB4 expression to enhanced anchorage-independent growth induced by NRG1B 
stimulation in MIAPaCa cells, which was in turn reduced by the inhibition of ERBB4 kinase 
activity283. As also observable in other tumors than the pancreas, ERBB4 seems to play a 
controversial role in tumorigenesis. It provides features to either act as a tumor suppressor or 
as tumor driver, and thus, the function of ERBB4 in pancreatic cancer still has to be revealed. 
3.2 AIM OF THE STUDY 
Almost all ligands of the ERBB family are associated with pancreatic cancer development or 
progression. Most of them were found to be overexpressed in human PDAC, as well as in 
hPaCaCells and an increased expression often goes along with an unfavourable prognosis 
for patients. However, functional studies revealed that every ligand has a unique role in PDAC. 
While the overexpression of TGFA and HBEGF induced fibrosis and ADM, AREG transgenic 
mice showed an increased duct proliferation. NRG1 had a dual role, dependent on the 
presence of its splice isoforms and BTC was a potent mitogen but further information is 
missing. Certainly, many basic mechanisms have been revealed by the investigation of ERBB 
ligands, but there are still gaps of knowledge, e.g. which receptors mediate these 
ligand-induced processes? Beyond the designated receptors of the ligands, further receptors 
can be activated by hetero-dimerization of the ERBBs. This factor should not be 
underestimated, in particular, because targeting of only one receptor in a hetero-dimer might 
not be as efficient as targeting both partners. Furthermore, not all ligands of the family, which 
were found to be expressed or overexpressed in PDAC specimen were profoundly investigated 
in animal models. 
The expression levels of the ERBB receptors in pancreatic cancer are controversial. Only 
EGFR was frequently overexpressed, which consistently, coincided with a poor outcome for 
the patient. Targeting EGFR, however, resulted in disappointing outcomes. ERBB2 
overexpression was observed less frequently in PDAC and also to rather low to moderate 
levels. ERBB3 expression, on the other hand is frequently expressed or overexpressed in 
PDAC. The prognostic value of the abundance of both receptors, ERBB2 and ERBB3, remains 
controversial. However, targeting of ERBB2 in combination with EGFR or ERBB3 in 
hPaCaCells or xenograft models enhances anti-tumor effects, independently of ERBB2 
expression levels. ERBB4 expression is rather decreased in human PDAC, but functional 
studies revealed ambivalent roles for this outliner of the ERBB family. Responses to erlotinib 
treatment (an EGFR-inhibitor) in patients are independent of the pancreatic EGFR expression 
levels. In pre-clinical studies, it was also observed that the response rate to ERBB2-targeted 
combination therapies was not dependent on the ERBB2 expression levels of the responders. 
ERBB4 also carries out a role that is possibly not correlated to ERBB4 expression levels in 
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PDAC. In conclusion, it is crucial to investigate the activity of the receptors, rather than just the 
abundance. Increasing evidence shifts treatment options to combinatorial instead of 
mono-therapies. Presumably, a wide range of information on pancreatic cancer is still hidden 
inside the complex ERBB network. With the following study, we will stimulate the ERBB family 
in mice by applying a ligand with binding affinities for both, EGFR and ERBB4. Beyond receptor 
expression levels, we will investigate the ERBB receptor activation and the activation of 
corresponding pathways with the aim to reveal the roles of the ERBB receptors in PDAC 
development, progression and survival.  
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3.3.1 ABSTRACT 
Background & Aims 
Pancreatic ductal adenocarcinoma (PDAC) will soon belong to the top three cancer killers. The 
only approved targeted therapy targets the epidermal growth factor receptor (EGFR). Although 
EGFR is a crucial player in PDAC development, EGFR therapy is rather disappointing. In this 
study we evaluated the role of the EGFR ligand betacellulin (BTC) in PDAC.  
Methods 
With CRISPR/Cas9 technology we generated a BTC knockout mouse model and a transgenic 
overexpression model. Both models were crossed with a tumor mouse model for PDAC 
(Ptf1aCre/+;KRASG12D/+) . To investigate the ERBB receptors, we deleted each receptor 
pancreas-specific by using the Cre-loxP system.  
Results 
B-/-KC mice have decelerated PDAC development, associated with decreased EGFR 
activation. BKC mice developed severe PDAC with a poor survival rate. The dramatically 
increased BTC-mediated tumor burden is EGFR-dependent, but also ERBB4 and ERBB2 are 
involved in PDAC development. A depletion of EGFR, ERBB2 or ERBB4 improves the survival 
rate of BTC-mediated PDAC significantly.    
Conclusions 
A deletion of BTC reduces the tumor burden and BTC overexpression accelerates PDAC 
development in KRASG12D mice, involving EGFR-, ERBB2- and ERBB4-signaling.  
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3.3.2 INTRODUCTION 
With a 5-year-survival rate of 8% the pancreatic ductal adenocarcinoma (PDAC) is worldwide 
one of the deadliest cancers. While mortality rates are declining for many cancers due to early 
detection and improved treatment, rates for PDAC are still rising198 promoting PDAC to the top 
three cancer killers, within the next decade197. The standard of care treatment is surgical 
resection and adjuvant chemotherapy. FOLFIRINOX or gemcitabine in combination with 
nab-paclitaxel provided the most promising results203. However, they do not differentiate 
between cancerous and normal cells, and as systemic therapies are often associated with 
unacceptable side effects. There is an urgent need to find customized therapies targeting 
aberrantly regulated molecules in PDAC. Over 95% of PDAC patients harbor an activating 
point mutation in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene284. Being 
detected in over 90% of pancreatic intraepithelial neoplasia (PanIN), KRASG12D is the initiating 
mutation in PDAC. However, the progression of PanIN into invasive PDAC comes along with 
the subsequent loss of the tumor suppressors CDKN2A, TP53 and SMAD4223. Attempts to 
target aberrant KRAS in PDAC were promising in cell and animal models. However, they 
rather ended disappointing in clinical trials285 and so, numerous downstream effectors of 
KRAS are in the focus of ongoing trials. A striking finding was made, when Ardito et al. and 
Navas et al. revealed that the epidermal growth factor receptor (EGFR), acting upstream of 
KRAS, was required for oncogenic KRAS-driven PDAC tumorigenesis in mice, but only in a 
TP53 stable background156,273. Indeed, EGFR is the only molecule approved for targeted 
PDAC therapy in the clinic, although with marginal improvement in survival with only a small 
subset of patients responding. Surprisingly, the response rate to erlotinib in PDAC patients is 
independent of the pancreatic EGFR expression status252. Thus, many questions concerning 
EGFR signaling in PDAC remain to be addressed. EGFR is one of four members of the 
complex family of the ERBB receptors. Together with ERBB2 (HER2, neu), ERBB3 (HER3) 
and ERBB4 (HER4), EGFR belongs to the receptor tyrosine kinases (RTK). The ERBB 
receptors homo- or hetero-dimerize after ligand-dependent activation in order to induce 
cellular responses like proliferation, migration, apoptosis, differentiation and adhesion9 and 
with 28 possible receptor combinations (including spliced receptors) and eleven ligands, the 
family is able to induce 611 different active receptor/ligand combinations24. ERBB ligands like 
epidermal growth factor (EGF)259,260, transforming growth factor alpha (TGFA)147,255, 
amphiregulin (AREG)149,257, heparin-binding EGF-like growth factor (HBEGF)264,265 and 
epiregulin (EREG)262,263 have been associated with PDAC. While all of them bind EGFR, the 
latter two also bind ERBB4 indicating that EGFR might not be the only candidate to mediate 
their effects in PDAC. Another EGFR- and ERBB4-binding ligand, betacellulin (BTC) has also 
been implicated in PDAC. BTC mRNA was not only detected in human pancreatic cancer cell 
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lines (hPaCaCells) and elevated in human PDAC tissues271, BTC was also revealed to be a 
potent mitogen in human pancreatic cancer cell lines272 but it is not known through which 
receptor BTC signaling occurred. This is particularly interesting, since its designated receptor 
ERBB4 plays controversial roles in PDAC development and progression266,282,283. The role of 
ERBB4 seems to be context-dependent, in particular, probably due to its - in contrast to its 
ERBB relatives - exceptional nature to signal in a splice-form dependent manner affecting 
either its cytoplasmic (CYT-1, CYT-2) or juxtamembrane region (JM-a, JM-b) or in form of its 
soluble intracellular domain (ICD80) after undergoing regulated intramembrane proteolysis 
(RIP)286. There is an urgent need to unravel the complex ERBB system in pancreatic cancer 
to understand not only the role of EGFR better, but also to show the potential significance of 
its relatives in order to establish more effectively targeted therapies when it comes to 
anti-EGFR treatment. To investigate BTC in pancreatic cancer, we generated a BTC knockout 
mouse model (BTC-/-) and overexpressed BTC in a transgenic mouse model (Btc). Both 
models were crossed in a PDAC mouse model and additionally to include the receptor 
mediation we deleted pancreas-specific EGFR, ERBB2, or ERBB4. Survival rate was 
recorded, pancreata were characterized histologically and were investigated on molecular 
level to evaluate the role of BTC and the ERBB receptors.  
3.3.3 METHODS 
Mice carrying floxed Egfr fl/fl (Egfrtm1Dwt)287, Erbb2 fl/fl 288, Erbb4fl/fl (B6;129-Erbb4tm1Fej/Mmucd)171, 
KrasG12D/+ (B6.129S4-Kras tm4Tyj/J)289 alleles or expressing cre recombinase under the 
pancreas specific transcription factor 1 alpha (Ptf1a-Cre) (Ptf1atm1(cre)Hnak)172 promoter have 
been described previously. Transgenic mouse lines overexpressing BTC ubiquitously under 
the control of the chicken-beta-actin gene promoter (Btctg/+) have been described, elsewere169. 
We cross mated Btctg/+;Ptf1aCre/+;KrasG12D/+ (herein referred as BKC) mice and  
Btctg/+;Ptf1aCre/+;KrasG12/+D;Egfrfl/fl, and Btctg/+;Ptf1aCre/+;KrasG12D/+;Erbb2fl/fl and 
Btctg/+;Ptf1aCre/+;KrasG12D/+; Erbb4fl/fl mice (herein referred to as EGFR KO;BKC, 
ERBB2 KO;BKC and ERBB4 KO;BKC, respectively) to delete the designated ERBB receptor 
pancreas-specific using the Cre-loxP-system. Mice were maintained in the C57BL/6N 
background and housed under specific pathogen-free conditions in the closed barrier facility 
of the Gene Center Munich at 23°C, 50% humidity and with a 12-h light/dark cycle (lights on 
at 7 AM). They had free access to water and a standard rodent diet (V1534, Ssniff, Soest, 
Germany). All animal experiments were approved by the author’s institutional committee on 
animal care and carried out in accordance with the German Animal Protection Law with 
permission from the responsible veterinary authority. Mice were weighed weekly until the age 
of 6 months and afterwards still weekly or every two weeks. Mice were sacrificed at the 
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designated time points or, for survival analysis, were left alive and redeemed as soon as they 
became moribund.  
3.3.3.1 GENERATION OF BTC KNOCKOUT MICE (BTC-/-) 
For CRISPR/Cas assisted Btc gene disruption using a single guide RNA (sgRNA) specific for 
exon 2 sequence 5’-GTCTTGCAATTCTCCACTGTG-3’, a corresponding oligonucleotide was 
cloned into the pEX-A-U6-gRNA vector as described previously290. Cas9 mRNA and sgRNA 
were in vitro transcribed by using the Ambion Maxiscript SP6 kit (Thermo Fisher Scientific). 
C57BL/6N zygotes were injected with Cas9 mRNA (50 ng/µl) and sgRNA (100 ng/µl) and 
embryos were transferred into recipient NMRI mice. Potential founders were identified by PCR 
using the following primers: sense primer: 5´-GCTTACATGACTTCTAGCCATG-3´, antisense 
primer: 5´-GCTAATCATGGAGGCACAGAAA-3´. Based on the detected mutations, a PfiMI 
restriction fragment length polymorphism assay was established, yielding fragments of 210 bp 
and 290 bp for wild-type Btc and a single fragment of 500 bp for the mutated Btc sequence. 
Two founder animals with the same frameshift mutation were identified (Suppl. Fig. S 3.1).    
3.3.3.2 REVERSE TRANSCRIPTASE-PCR 
RNA was extracted from different organs with TRIZOL reagent (Invitrogen, Darmstadt, 
Germany) and 3 µg RNA were reverse-transcribed in a final volume of 30 µL using RevertAid 
reverse transcriptase (Thermo Scientific, Schwerte, Germany) according to the manufacturer’s 
instructions. To show the qualitative mRNA expression of the Btc-KOs, reverse transcription-
PCR (RT-PCR) was performed by using reagents from Qiagen (Hilden, Germany). The final 
reaction volume was 20 µl, and cycle conditions were 94°C for 5 min followed by 35 cycles of 
94°C for 1 min, 58°C for 1 min, and 72°C for 1 min using the following primers: forward: 5`-
GTTCTGGGTGACACTGGAGC-3´, reverse:  5-CCTTTCTCACAGATGCAGGAG-3´. The 
amplicon was digested by PflMI (NEB, Frankfurt, Germany) for 90 min at 37°C and subject to 
agarose electrophoresis to reveal the mutation side. Gapdh was used as reference mRNA and 
amplified with the following primers: forward: 5’-GTGGAAGGGCTCATGACCAC-3’, reverse: 
5’- GCCCACAGCCTTGGCAGCA-3’. 
3.3.3.3 PANCREAS PREPARATION  
Mice were sacrificed by cervical dislocation at the age of 8 weeks, 12 months or when 
moribund. The pancreas was isolated, blotted dry and weighed to the nearest milligram., Parts 
of the head, tail and central part of the pancreas were dissected, pooled, frozen on dry ice and 
stored at -80°C. The remaining tissue was incubated in 4% para-formaldehyde (PFA, in 
phosphate-buffered saline, PBS, pH 7.4) overnight and embedded in paraffin. From mice 
sacrificed at the age of 1 week, the whole pancreas was either frozen on dry ice, or immediately 
homogenized in total in RLT buffer (Qiagen), freshly supplemented with 1% 
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beta-mercaptoethanol (BME, Roth, Karlsruhe, Germany) and shock-frozen in liquid nitrogen 
for RNA isolation, or incubated as a whole in 4% PFA overnight and embedded in paraffin.  
3.3.3.4 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) was performed detecting murine (m) mBTC, mTGFA, mAREG, 
mEREG, mACTA2, mEGFR, cleaved Caspase 3 and human (h) hBTC, hEGFR, hERBB2, 
hERBB3, hERBB4 on PFA-fixed, paraffin-embedded pancreatic tissue. For all 
immunostainings, the slides were boiled in a pressure-cooker for 15 minutes (min) in 10 mM 
sodium citrate buffer pH 6.0 or EDTA pH 9, blocked in 3% H2O2 for 30 min and in 5% of the 
appropriate serum for another 30 min. The primary antibody was incubated over night at 4°C. 
After washing in PBS the slides were incubated with the appropriate secondary antibody for 
one hour at room temperature and the signal was amplified using Vectastain® ABC HRP kit 
(Vector, Burlingame, CA, USA) for 30 min at room temperature. As chromogen, ImmPACTTM 
DAB peroxidase substrate kit (Vector) was used and the sections were counterstained with 
hematoxylin (Roth) for 3 min. A list of primary and secondary antibodies with the corresponding 
dilutions is provided in Suppl. Table S 3.1. 
3.3.3.5 HEMATOXYLIN AND EOSIN (H&E) AND MASSON’S TRICHROME STAINING 
H&E and Masson’s trichrome stainings were performed on PFA-fixed, paraffin-embedded 
sections of the pancreas using standard protocols. 
3.3.3.6 QUANTIFICATION OF REACTIVE TISSUE IN PANCREATA  
PFA-fixed, paraffin-embedded pancreas was serially sectioned and four sections per 
pancreas, each taken after every 10th section, H&E stained and evaluated under the light 
microscope by two researchers, independently. Pictures covering the total pancreas area were 
taken with a 100x magnification lens using a Leica DFC425C digital camera (Leica 
Microsystems, Wetzlar, Germany). The ratio of the measured area of reactive tissue, 
consisting of fibrosis, inflammation, pre-neoplastic lesions and scattered lymph nodes was 
recorded with LAS software version 3.8.0 (Leica Microsystems) and calculated to the 
measured whole pancreatic area of the section for each animal (n=4). Data were analyzed by 
Student’s t-test and plotted as column bar plots in GraphPad Prism (GraphPad Prism version 
5.0 for Windows, GraphPad Software, San Diego, CA, USA).  
3.3.3.7 RAS ACTIVITY ASSAY 
To evaluate RAS activity in the pancreata, the Active Ras Detection Kit (Cell Signaling) was 
used according to the manufacturer’s instructions. In brief, dissected, frozen pancreas was 
homogenized in lysis/binding/wash buffer, freshly supplemented with phenylmethanesulfonyl 
fluoride, and 500 mg of the lysate were incubated with the GST-Raf1-Ras binding domain for 
one hour at 4° C, washed and eluted under denaturing conditions and object to an SDS-gel 
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electrophorese using Mini-PROTEAN® TGX Stain-Free™ Precast Gels (BIORAD, Hercules, 
California, USA) and subsequent Western blot analysis detecting mRAS. Total protein was 
quantified using Image Lab 6.0.1 (Bio-Rad) and the amount of active RAS was referenced to 
total protein and plotted in GraphPad Prism. Data were analyzed by Student’s t-test.   
3.3.3.8 CO-IMMUNOPRECIPITATION 
Pancreata were homogenized in a TRIS-based buffer (50 mM Tris, 150 mM NaCl, 1% NP40, 
10% glycerol, 1M EDTA; freshly supplemented with protease and phosphatase inhibitors) and 
350 µg of protein has been subject to immunoprecipitation targeting EGFR. For this, the lysate 
was incubated with 1 µg of EGFR antibody (Santa Cruz, SC-03) or 1 µg of normal IgG antibody 
(R&D Systems) at 4° C overnight and incubated with 50 µl of protein A magnetic beads (Cell 
Signaling) for 30 min at room temperature. After washing the precipitate was eluted under 
denaturing conditions and applied to a Western blot detecting ERBB2 (Santa Cruz, SC-284), 
ERBB3 (Santa Cruz, SC-285) and EGFR as control.  
3.3.3.9 HISTOPATHOLOGICAL GRADING 
The pancreatic sections were analyzed by two researchers, independently, in a blinded 
fashion. The area of acinar cells, ADM, PanIN1-3, PDAC and fibrosis was determined by point 
counting in five randomly selected areas of H&E and Masson’s trichrome stained sections of 
four mice using established histomorphological criteria205-207. For this, a grid of crosses was 
laid over stained sections using a netScope viewer software of the (Net-Base Software GmbH, 
Freiburg, Germany) and crosses hitting the appropriate structure were counted and calculated 
to the sum of crosses hitting the area of the pancreas. Data were analyzed by 2-way-ANOVA 
and plotted as column bar plots in GraphPad Prism.  
3.3.3.10 WESTERN BLOT ANALYSIS 
Pancreas of animals was homogenized in Laemmli-extraction buffer as described 
previously175. Protein samples with equal concentrations were electrophoresed on 10% 
polyacrylamide-sodium dodecyl sulfate gels and blotted to PVDF-membranes (GE Healthcare, 
Munich, Germany). The membranes were blocked with 5% milk and incubated with the primary 
antibodies overnight at 4°C. After washing, the membranes were incubated in the appropriate 
horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were 
visualized by chemiluminescence with an ECL kit (GE Healthcare or Thermo Scientific). 
Antibodies and dilutions are supplied in Suppl. Table S 3.2. Densitometrical analyses were 
performed with ImageJ 1.52a and plotted in GraphPad Prism (GraphPad Prism version 5.0). 
3.3.3.11 REAL-TIME-PCR 
RNA was extracted from shock-frozen pancreatic tissues with RNeasy kit (Qiagen) and cDNA 
was synthesized using RevertAid reverse transcriptase (Thermo Scientific) according to the 
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manufacturer’s instructions. Quantitative mRNA expression analysis was performed by 
quantitative real-time RT-PCR (qRT-PCR) using the StepOneTM Real Time PCR-Sytems 
(Applied BiosystemsTM, Waltham, Massachusetts, USA). 1 µL of cDNA in final reaction volume 
of 10 μl were used and the final primer concentration was 0.5 µM. Cycle conditions were 50 °C 
for 2 min, followed by 95 °C for 2 min followed by 40 cycles of 95 °C for 15 s, 60 °C for 15 sec, 
and 72 °C for 1 min. For Quantification the threshold cycle (CT) number was used. We 
performed no-template control and no-RT control assays, which produced negligible signals 
with CT values that were greater than 35. Experiments were performed in duplicates or 
triplicates for each sample. Primers used for qPCR are listed in Suppl. Table S 3.3. Transcript 
copy numbers were normalized to ribosomal protein L30 (Rpl30). 
3.3.3.12 CELL CULTURE AND STIMULATION EXPERIMENTS 
PANC-1 and BcPC-3 cells were purchased from CLS (Cell lines service, Eppelheim, Germany) 
four months before the experiments were performed. All human permanent cell lines in the 
CLS cell bank have been authenticated by using the STR DNA profiling analysis. Mycoplasma 
testing will be done every 6 months for all cultured cells using a mycoplasma detection kit 
(PlasmoTest, InvivoGen, Toulouse, France). Both cancer cell lines were maintained at 37 °C 
and 5% CO2. PANC-1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Merck), BxPC-3 cells in Roswell Park Memorial Institute 1640 medium (RPMI, Merck), both 
supplemented with 10% fetal bovine serum (FBS, Merck) and 1% Penicillin/Streptomycin 
(Merck). At a confluence of 90%, cells were starved overnight (1% FBS) and stimulated the 
next day with 50 ng/ml of recombinant human BTC (rhBTC, R&D Systems #261-CE) for 5 and 
15 min. Cells were then lysed in a TRIS-based buffer (50 mM Tris, 150 mM NaCl, 1% NP40, 
10% glycerol, 1M EDTA; freshly supplemented with protease and phosphatase inhibitors 
(Roche)) and subject to Western blot analysis detecting phosphorylation and total expression 
of the ERBB receptors.  
3.3.3.13 3-D PRIMARY CELL CULTURE 
For acini isolation 3-week-old wildtype mice were dissected, pancreata were washed twice in 
sterile ice-cold PBS and immediately minced and digested twice in collagenase P solution 
(Hanks Balanced Salt Solution (HBSS, Sigma, Taufkirchen, Germany), 5% FBS, 0.2 mg/mL 
soybean trypsin inhibitor (STI, Sigma), 0.2 mg/mL Collagenase P (Roche, Penzberg, 
Germany) at 37 °C for 10 min. The pancreatic tissue was gently pressed and washed through 
a 100 µm cell strainer and incubated in red blood cell lysis buffer (Roth) for 10 min at 37°C. 
The acini recovered for 1 hour in 3D-culture medium (RPMI 1640, 1% FBS, 1% 
Penicillin/Streptomycin, 001 mg/ml STI, 1 µg/ml dexamethasone (Sigma)). Prior cell seeding, 
the culture dishes were coated with a gel of rat tail collagen I (Invitrogen, Carlsbad, California, 
USA) and RPMI medium, supplemented with NaHCO3 to adjust the pH for at least 1 hour at 
 
58 
 
37°C. For seeding, the cell suspension was mixed with the collagen I coating gel in a ratio 1:3, 
gently placed into the coated dishes and solidified for 1 hour at 37 °C, 5% CO2. The matrix was 
then coated with warm 3D culture medium and stimulated or left untreated. This is a modified 
protocol of Qu et al.291. For stimulation experiments, 3D culture medium was supplemented 
with rhBTC or rhTGFA or left untreated and investigated under a light microscope at days 0, 4 
and 5 after treatment. The number of transdifferentiated cells was estimated by two 
researchers, independently.  
3.3.3.14 STATISTICS 
Data are presented as means±SEM and compared by two-tailed unpaired Student’s t-test, and 
in the case of more than two groups by analysis of variance (ANOVA) and Tukey’s multiple 
comparison test. All data were analyzed with GraphPad Prism (GraphPad Prism version 5.0 
for Windows, GraphPad Software, San Diego, CA, USA). P-values<0.05 were considered 
statistically significant.  
3.3.4 RESULTS 
3.3.4.1 THE LACK OF BTC IN KC MICE RESULTS IN A DECREASE OF TUMOR BURDEN AND 
DECREASED EGFR PHOSPHORYLATION. 
To evaluate the function of BTC in PDAC we generated a BTC knockout mouse (BTC-/-) by 
CRISPR/Cas9 technology. Two founder animals with monoallelic insertions of 1 bp were 
identified. The insertion of 1 bp leads to a shift in the reading frame in Btc exon 2. The mutant 
Btc transcripts encode 27 amino acids (aa) of the extracellular BTC domain, followed by 31 aa 
missense sequence and a premature termination codon after 58 aa (Suppl. Fig. S 3.1 A). 
BTC-/- mice were viable and showed no macroscopic phenotype, and bred in a Mendelian ratio 
(data not shown). RT-PCR analysis confirmed the mutated Exon2 of the Btc gene (Suppl. Fig. 
S 3.1 B) and an IHC confirmed the loss of BTC (Suppl. Fig. S 3.1 D). Crossed into the KC 
background B-/-KC mice showed at the age of eight weeks and twelve months no differences 
in body and relative pancreas weight were detected (Suppl. Fig. S 3.1 C). All B-/-KC animals 
were still vital at the time of dissection at 12 months while KC mice started deceasing already 
with seven months (Figure 3.2 A). Reactive tissue area of the pancreas (fibrosis, inflammation, 
ADM,) were determined at the age of eight weeks (Figure 3.2 B,C) revealing a 10-fold 
decrease in the amount of reactive tissue in B-/-KC mice compared to KC mice indicating a 
decelerated PDAC development. In pancreata of 12-month-old mice, we revealed decreased 
PDAC progression upon BTC depletion. More low-grade lesions and significantly less invasive 
carcinoma were identified compared to age-matched KC mice (Figure 3.2 F,G). Western blot 
analysis revealed reduced EGFR expression and phosphorylation in pancreata of 8-week-old 
and 12-month-old B-/-KC mice compared to age-matched KC mice (Figure 3.2 H,I). These data 
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indicate that the depletion of BTC attenuates tumor initiation and progression by 
downregulating EGFR signaling and resulting in a prolonged survival. 
 
Figure 3.2: Characterization of B-/-KC mice 
A Kaplan-Meier-Curve demonstrating the survival of KC and BKC mice. B Representative H&E stainings of 
pancreata of 8-week-old B-/-KC mice compared to age-matched KC littermates. C Morphometric analysis of reactive 
tissue in the pancreas of B-/-KC (3,8%) and (KC 31,8%) mice. Data were analyzed by Student’s t-test. D Western 
blot analysis and E corresponding densitometrical analyses showing EGFR expression and phosphorylation in 
pancreata of 8-week-old B-/-KC mice compared to age-matched KC pancreata. GAPDH served as reference protein. 
F Representative H&E stainings with G histopathological grading of pancreata of 12-month-old mice. H Western 
blot and I densitomtetrical analysis of pancreata of 12-month-old mice showing EGFR expression and 
phosphorylation in B-/-KC mice compared to KC mice. Scale bars: 100 µm. All data were generated as means±SEM. 
*P<0.05, **P<0.01. 
3.3.4.2 BTC IS EXPRESSED IN HUMAN PDAC SAMPLES, IN HUMAN PDAC CELL LINES AND IN 
PANCREATA OF KC MICE.  
By IHC, BTC was detected predominantly in the islets of Langerhans and in ducts and acini of 
human normal pancreas (NP) (Figure 3.3 A). In human PDAC samples (6/6) BTC was 
identified in PanIN and the adjacent stroma (Figure 3.3 A), and Western blot analysis revealed 
BTC expression in 5/6 human hPaCaCells (Figure 3.3 B). These data indicate a role for BTC 
in PDAC development. Since BTC has binding affinities for EGFR and ERBB4 and is also able 
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to indirectly activate the other ERBB receptors, we evaluated the phosphorylation status of all 
ERBB receptors upon BTC stimulation in two hPaCaCells. Stimulation of PANC-1 and BxPC-3 
cells with 50 ng/ml hBTC activated all receptors at 5 and 15 min, while ERBB3 was 
constitutively activated, basally, in both cell lines (Figure 3.3 D). In addition, we detected all 
ERBB receptors by immunostaining in human PDAC (Suppl. Fig. S 3.2). These data indicate 
that the ERBB system is involved in human PDAC. The pancreata of KC mice revealed a 
strong positive immunostaining for endogenous BTC expression in low- and high grade PanIN 
in 5/6 samples (Figure 3.3 D).  
 
Figure 3.3: BTC is expressed in human PDAC samples, in human PDAC cell lines and in pancreata of KC 
mice.  
A Immunohistochemistry staining against BTC in human normal pancreas (NP) and in human pancreatic cancer 
specimen. B Western blot analysis of BTC expression in 5/6 human pancreatic cancer cell lines. TUBA1A served 
as a reference protein. C PANC-1 (left panel) and BxPC-3 (right panel) were stimulated with BTC for 5 and 15 
minutes. Western blot analysis shows ERBB receptor expression and phosphorylation. GAPDH served as reference 
protein. D Immunohistochemistry stainings against BTC, TGFA, AREG, and EREG in PanIN of KC mice. Scale 
bars: 100 µm. 
3.3.4.3 THE OVEREXPRESSION OF BTC IN KC MICE LEAD TO EARLY ONSET OF PDAC AND HIGH 
MORTALITY. 
To investigate how BTC could influence PDAC, we overexpressed BTC in a murine PDAC 
model. We crossed ubiquitously overexpressing BTC mice117 into the KC background 
 
61 
 
(Ptf1acre/+;KrasG12D/+;Btctg/+, herein referred to as BKC mice). BKC mice developed cachexia 
after six weeks and lost up to 25% of their body weight within the following two weeks (Figure 
3.4 A). The major cohort of BKC mice (13/18) died at 2 months (median survival: 2.75 months), 
whereas KC mice had a median survival of 11 months (Figure 3.4 B). Up to the age of eight 
weeks, the relative pancreas weight of BKC mice was unchanged compared to the pancreas 
of KC mice, but at the age of 12 months the relative pancreas weight was significantly reduced 
in BKC mice (Figure 3.4 C). H&E stainings of the pancreata of 1-week-old mice of both groups 
appeared normal (Figure 3.4 D). Already at the age of four weeks up to two thirds of the BKC 
pancreata were interfused by inflammation, fibrosis, ADM and low-grade PanIN (Figure 3.4 D), 
while these structural abnormalities were hardly observed in age-matched KC pancreata 
(Figure 3.4 D). At the age of eight weeks, still more than 70% of the pancreata looked normal 
in KC mice (Figure 3.4 D). However, pancreata of age-matched BKC mice were completely 
replaced by low- and high-grade PanIN and invasive carcinoma and a massive amount of 
desmoplasia (Figure 3.4 D,F). Desmoplasia were indicated by alpha-smooth-muscle-actin 
(ACTA2) staining (Figure 3.4 E), detecting activated pancreatic stellate cells. A Masson’s 
trichrome staining revealed a massive amount of collagen fibers (Figure 3.4 F) in BKC animals 
compared to age matched KC mice (Figure 3.4 F). 75% of KC mice developed high grade 
PanIN and carcinoma during their lifetime (Figure 3.4 D), while 100% of BKC mice had 
developed carcinomas already at the age of eight weeks. BTC overexpression in the KC 
mouse leads to a very early onset of PDAC, cachexia and to a drastic increase in mortality.  
 
Figure 3.4: BTC induces adverse events in KC mice 
A Body weight curve of BKC mice compared to KC littermates. Data were analyzed by 2-way-ANOVA. 
B Kaplan-Meier-Curve depicting the survival of BKC mice (median survival: 2,75 months) compared to KC mice 
(median survival: 11 months). Data were analyzed using a Log-rank test. C Relative pancreas weights of BKC mice 
at the ages of four and eight weeks and twelve months compared to age-matched KC mice. Data were analyzed 
by 1-way-ANOVA and Tukey’s multiple comparison test. D H&E staining of pancreata of 1-week-old; 4-week-old; 
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8-week-old and mice at the age of 15 months. E Representative immuno-staining of ACTA2 in pancreata of 
8-week-old KC and BKC mice to reveal the amount of activated stellate cells. F Masson’s Trichrome staining of 
pancreata of 8-week-old KC and BKC mice depicting connective tissue in BKC mice. Scale bars: 100 µm. All data 
were generated as means±SEM. *P<0.05, ***P<0.001. 
 
3.3.4.4 BTC ACTIVATES THE ERBB RECEPTORS, ENHANCES RAS ACTIVITY AND INDUCES ADM. 
BTC is able to bind both autonomous receptors, EGFR and ERBB4, and due to receptor 
hetero-dimerization, BTC also activates ERBB2 or ERBB3. We investigated the ERBB 
receptor phosphorylation by Western blot analysis upon BTC overexpression in KC mice at 
the age of one week, an appropriate time point, since pancreatic tissues were still normal and, 
most importantly, had a similar cellular composition. BTC overexpression in KC mice resulted 
in the activation of EGFR, ERBB2 and ERBB4. ERBB3 was not phosphorylated in both groups. 
ERBB expression levels were similar in both groups (Figure 3.5 A,B). To evaluate the receptor 
dimerization behavior upon BTC activation, we performed co-immunoprecipitations. In BKC 
mice EGFR bound ERBB2, but not ERBB3. KC mice had much less EGFR/ERBB2 dimers 
even though, when the reduced amount of pulled-down EGFR protein was considered. Due to 
the high heterogeneity in pancreata of BKC mice at the age of eight weeks, we compared 
tumors of 8-week-old BKC mice with tumors of 12-month- old KC mice presenting a similar 
tumor burden. The amount of EGFR/ERBB2 dimers in KC pancreata was again lower 
compared to BKC mice (Figure 3.5 C). ERBB3 did not bind to EGFR in any condition. There 
are several ways for BTC to accelerate PDAC development. KRASG12D is the initiating mutation 
in PDAC but the latency for tumor development is very long and often, other stimuli are 
necessary to induce RAS dependent transformation of normal tissue292-294. We assumed that 
BTC could be a driver of RAS activity to accelerate tumor development. A RAS activity assay 
of pancreata of 8-week-old KC mice and BKC mice revealed that BKC mice harbor a 
significantly higher amount (3-fold) of active RAS compared to KC mice (Figure 3.5 D,E). To 
investigate which receptors transmit BTC induced RAS activation, we studied RAS activity in 
the pancreata of BKC mice with either EGFR (E1 KO;BKC), ERBB2 (E2 KO;BKC) or ERBB4 
(E4 KO;BKC) depleted. We revealed that BTC-mediated RAS activity was exclusively 
transmitted by EGFR (Figure 3.5 F). Also crucial for PDAC is ADM development. Since it is 
known that BTC regulates (trans-) differentiation106-110, we assumed that BTC might be 
involved in trans-differentiating acinar to duct cells, thereby accelerating the onset of PDAC. 
We isolated wildtype murine acinar cells, embedded them into a 3-D collagen matrix and 
stimulated with BTC or TGFA, for 5 days (Figure 3.5 G). While wildtype cell clusters did not 
show signs of transformation, the majority of BTC stimulated cells transformed into a duct-like 
shape, as observed in TGFA treated cells (data not shown). Through specific signaling 
cascades or in a tissue-dependent manner, ERBB4 is able to synthesize four different splice 
isoforms. We hypothesized that BTC might be able to induce alternative splicing in the Erbb4 
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gene causing splice-form-dependent signaling in the KC pancreas. However, we revealed by 
real-time PCR that BTC had no significant influence on Erbb4 splicing in pancreata of KC mice 
(Figure 3.5 H).  
Figure 3.5: BTC activates the ERBB receptors, enhances RAS activity and induces ADM 
A Western blot and B corresponding densitometrical analysis showing the phosphorylation of EGFR, ERBB2, 
ERBB3 and ERBB4 in pancreata of 1-week-old BKC mice compared to age-matched KC mice. GAPDH served as 
reference protein. Data were analyzed by 2-way-ANOVA with Bonferroni post-test. C Co-immunoprecipitation of 
EGFR and indicated receptors in lysates of pancreata of mice with different genotypes (indicated with a + or – 
above the IBs) at the age of 8 weeks (w) and of KC mice at the age of 12 months (m). D RAS activity assay with E 
corresponding densitometrical analysis illustrating the abundance of active RAS protein in pancreata of KC mice 
upon BTC overexpression. Total protein (TP) served as reference. Data were analyzed with a Student‘s t-test. F 
RAS activity assay comparing pancreata of BKC mice with pancreata of BKC mice lacking either EGFR 
(E1KO;BKC), ERBB2 (E2KO;BKC) or ERBB4 (E4KO;BKC). G 3-D primary tissue culture of acinar cells of 3-week-
old wildtype mice, treated with BTC compared to untreated cells (Co). Scale bars: 100 µm. H Real-time PCR 
targeting ERBB4 splice forms in 1-week-old BKC and KC mice. PD, pull down, IB, immunoblot, GST-RAF-RAS-BD, 
glutathione-S-transferase-RAF-RAS-binding domain, arrows indicate ductal structures. All data were generated as 
means±-SEM. *P<0.05, **P<0.01, ***P<0.001. 
3.3.4.5 ERBB2 AND ERBB4 AFFECT THE TUMOR BURDEN IN BKC MICE.  
BTC signaling is mediated by EGFR enhancing RAS activity, but in order to reveal, whether 
ERBB2 and ERBB4 are involved in BTC-mediated PDAC, we knocked out ERBB2 or ERBB4 
individually. The lack of ERBB2 or ERBB4 in the BKC mouse (E2 KO;BKC and E4 KO;BKC, 
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respectively) showed different effects. While all groups grew similar until week six after birth, 
E2 KO;BKC mice had significantly reduced body weight compared to BKC mice and 
E4 KO;BKC mice showed a significantly increased body weight compared to BKC littermates 
(Figure 3.6 A), predicting a better outcome for mice with an ERBB4 depletion. Indeed, the 
Kaplan-Meier curve depicts, with a median survival of 15 months the longest survival in 
E4 KO;BKC mice, but also, E2 KO;BKC mice present with a median survival of 12,5 months a 
significantly prolonged survival compared to BKC mice (median survival: 2.75 months) (Figure 
3.6 B), indicating oncogenic functions for both receptors. The relative pancreatic weight of 
E2 KO;BKC mice was decreased compared to that of BKC mice at the age of eight weeks 
(P=0,059) (Figure 3.6 C, left panel) and was similarly lower in moribund mice (Figure 3.6 C, 
right panel). The H&E (Figure 3.6 D, left panel) and Masson’s trichrome (Figure 3.6 D, right 
panel) staining of E4 KO;BKC pancreata revealed a penetration of cancer cells similar to BKC 
mice, presenting with fibrosis, PanIN and carcinoma, while the lack of ERBB2 rather resembled 
a picture of atypical flat lesions mixed with ADM and low grade PanIN, with the same amount 
of fibrosis compared to BKC pancreata, but with a decreased penetration of (pre-)neoplastic 
tissue, since acinar tissue was frequently observed. Western blot analysis revealed that the 
loss of ERBB4 induced changes in the ERBB signaling network (Figure 3.6 E,F). The lack of 
ERBB4 resulted in a significantly decreased EGFR and ERBB2 phosphorylation, and it 
induced enhanced ERBB3 activation. Further, the lack of ERBB4, resulted in a significant 
downregulation of MAPK and SAPK signaling. In 1-week-old mice, EGFR activation was 
significantly enhanced in E4 KO;BKC pancreata, also MAPK activation was increased (Suppl. 
Fig. S 3.3 A,B). Compared to the knockout of ERBB4, the lack of ERBB2 only resulted in 
significantly decreased SAPK signaling and in decreased EGFR phosphorylation (P=0.055). 
But no compensation of other ERBB receptors was observed (Suppl. Fig. S 3.4 A,B). Despite 
decreased SAPK signaling acinar cells of ERBB2 KO;BKC mice demonstrated cleaved 
caspase-3 positivity in immunostainings (Suppl. Fig. S 3.4 C).  
3.3.4.6 THE LOSS OF EGFR ALMOST RESCUES THE BTC-MEDIATED PHENOTYPE IN 8-WEEK-OLD 
KC MICE COMPLETELY. 
We deleted EGFR pancreas-specifically and revealed that EGFR depleted BKC mice (EGFR 
KO;BKC) had increased body weights indicating a better physical condition at the age of two 
and twelve months (Figure 3.7 A, left panel). 100% of EGFR KO;BKC mice were still vital at 
the time of dissection (12 months) indicating a drastically prolonged survival compared to BKC 
mice (data not shown). Their pancreas weights were significantly decreased in 8-week-old and 
increased in 12-month-old mice compared to BKC mice (Figure 3.7 A, right panel) implying a 
better condition. Histology analysis revealed a predominantly normal pancreas in 
EGFR KO;BKC mice, albeit with multiple foci presenting ADM (H&E, Figure 3.7 B), but with a 
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complete lack of fibrosis, shown by Masson’s trichrome staining to pancreata of BKC mice 
(Figure 3.7 B). ADM in 8-week-old mice did not occur due to incomplete homologous 
recombination of the EGFR locus, as observed in Ardito et al. and Navas et al156,273, as verified 
in the negative immunostaining targeting EGFR (Figure 3.7 E). However, ADM were positive 
for ERBB2, ERBB3 and ERBB4 (Figure 3.7 E). Interestingly, Western blot analysis revealed 
that the lack of EGFR comes along with a decrease in phosphorylation and expression of 
ERBB2, ERBB3 and full length ERBB4 (Figure 3.7 C,D). However, we revealed that the ICD 
of ERBB4 was highly phosphorylated in the pancreata of EGFR KO;BKC mice compared to 
BKC mice indicating compensational ERBB4 signaling for ADM development upon the loss of 
EGFR (Figure 3.7 C,D).  
 
Figure 3.6: ERBB2 and ERBB4 affect the tumor burden in BKC mice 
A Body weight curves all groups. Data were analyzed by 2-way-ANOVA. B Kaplan-Meier-Curve depicting the 
survival of E2 KO;BKC mice (median survival: 12.5 months) and E4 KO;BKC mice (median survival: 15 months) 
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compared to BKC mice (median survival: 2,75 months).  Data were analyzed using a Log-rank test. C Relative 
pancreatic weight of all groups of 8-week-old mice (left panel) and of 12-months-old mice (right panel) compared to 
E2 KO;BKC, E4 KO;BKC and KC mice. Data were analyzed by ANOVA and Tukey’s multiple comparison tests. D 
Histology of BKC mice compared to E2KO;BKC and E4KO;BKC mice at 8 weeks represented by H&E (left panel) 
and Masson’s trichrome staining (right panel). E Western blot analysis with F corresponding densitometrical 
analysis comparing pancreata of 8-week-old BKC mice to E4KO;BKC littermates. Data were analyzed by ANOVA 
and Tukey’s multiple comparison tests. *P<0.05, **P<0.01, ***P<0.001. Scale bars: 100 µm. 
 
Figure 3.7: The lack of EGFR in BKC mice revealed major changes in body weight, histology and in ERBB 
signaling 
A Body and relative pancreas weights of EGFR KO;BKC mice compared to BKC mice. Data were analyzed by 
ANOVA and Tukey’s multiple comparison test. B Representative H&E (left panel) and Masson`s trichrome (right 
panel) stainings of pancreata of BKC mice and EGFR KO;BKC mice. C Western blot analysis and D corresponding 
densitometrical analysis showing the phosphorylation and expression of ERBB2, ERBB3 and full length ERBB4, 
and the phosphorylation of the ICD of ERBB4. CDH1 served as reference protein. Data were analyzed by ANOVA 
and Tukey’s multiple comparison test. E Immunohistochemistry stainings against EGFR, ERBB2, ERBB3 and 
ERBB4 of pancreas samples of 8-week-old EGFR KO;BKC mice. Scale bars: 100 µm. ***P<0.001. 
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3.3.5 DISCUSSION 
PDAC belongs to the deadliest malignancies, worldwide198. EGFR is crucial for the 
development of oncogenic KRAS-induced PDAC development156,273. However, targeting 
EGFR is only marginally beneficial with a small subset of patients responding to 
EGFR-targeted therapy252. Since EGFR is only one family member of four RTKs, either working 
autonomously or as partner of ERBB2, ERBB3 or ERBB4, we assumed that the remaining 
ERBB receptors had been underestimated in recent years and could also play an important 
role in PDAC. In particular, because ERBB ligands, specific for ERBB4, have been implicated 
in PDAC development or progression. To estimate the power of ERBB ligands in PDAC, we 
deleted BTC (specific for EGFR and ERBB4) in the KC mouse model (B-/-KC) and revealed 
that the initiation and progression of PDAC was decelerated. A 100% rate of viable B-/-KC mice 
at the age of 12 months also suggests increased survival rates. The benefits of BTC deletion 
might stem from decreased EGFR expression and phosphorylation levels, which we observed 
in B-/-KC pancreata during all investigated ages. To our knowledge, we are the first group, 
which deleted an ERBB ligand in PDAC. It is intriguing to observe that the deletion of only one 
ERBB ligand can be powerful enough to modulate EGFR regulation and PDAC progression, 
in particular, because in human and in murine PDAC, almost all seven EGFR ligands are 
expressed abundantly and could, compensate the loss of one single ligand. We provide 
evidence that BTC is functionally involved in murine PDAC, since its loss affects the KC mouse 
so powerful and since it is also expressed in human PDAC, hPaCaCells and in PanIN of all 
our investigated KC mice. In hPaCaCells, it activates all receptors of the family. At the age of 
eight weeks, BKC pancreata presented PDAC and desmoplasia and BKC mice displayed a 
decrease in the median survival of almost nine months compared to KC mice. This is a drastic 
phenotype, when compared to the overexpression of the EGFR ligand TGFA presenting 
IPMN-like lesions, and showing only low-grade lesions at eight weeks with a higher median 
survival295 as BKC mice. HBEGF overexpression in KC pancreata revealed a complete 
replacement of the normal pancreatic tissue by low-grade lesions PanIN3 and PDAC, already 
at the age of two weeks265. In the latter study the soluble form of HBEGF was overexpressed, 
which might lead to a more drastic outcome than by using full-length. However, there is enough 
evidence to state that BTC is implicated in PDAC as a tumor promoting factor. BTC activates 
EGFR and ERBB4 and it activates ERBB2, at least by hetero-dimerization with EGFR, implying 
that ERBB2 and ERBB4 also play a role in BTC-mediated PDAC. KC mice have a long latency 
to develop tumors and although all pancreatic cells are equipped with mutated KRAS, only a 
subset of cells develops lesions and, at low frequency, invasive PDAC292. Studies suggest that 
the additional loss of tumor suppressors296 or that other secondary events, i.e. pancreatitis293 
or incidences increasing KRASG12D activity above a certain threshold294, are required to initiate 
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tumorigenesis. BTC could be such a factor enhancing RAS activation, mediated by EGFR and 
thereby possibly accelerating the onset and progression of PDAC. ERBB2 and ERBB4 are not 
involved in RAS activation, indicating that only EGFR homo-dimers. It is not surprising that 
EGFR is a crucial player in KRAS-mediated oncogenesis, since it was shown that mice do not 
developed PDAC in an EGFR depleted background156,273. EGFR is crucial for acinar cells to 
trans-differentiate into duct cells. The EGFR ligands TGFA and HBEGF have been implicated 
in this process, previously147,265. BTC has a differentiation potential in many other cell types106-
110 and we found that BTC is also able to transdifferentiate wildtype acinar cells into duct cells. 
However, BTC transgenic mice never developed ADM at any age. BTC is not an oncoprotein 
per se, it effects only as trigger for tumorigenesis.  
While the importance of EGFR in PDAC is established in the field, the role for ERBB2 and 
ERBB4 are discussed controversially. ERBB2 mRNA was reported to be expressed in 100% 
of PDAC samples with increased protein expression compared to normal pancreas266. A 
different study published overexpression of ERBB2 in PDAC only at low frequencies276. 
Although ERBB2 amplification was not associated with the outcome of PDAC in a 
meta-analysis297, another study correlated the overexpression of ERBB2 with an aggressive 
phenotype278. However, to our knowledge, no functional studies regarding ERBB2 in PDAC 
exist, and attempts to targeting ERBB2 were rather disappointing253. The deletion of Erbb2 in 
BKC mice resulted in a significantly prolonged survival, which can be explained by decelerated 
PDAC development, observed in the histopathology sections of the pancreata. Since ERBB2 
hetero-dimerizes with EGFR, and therefore might have a function in PDAC, it is not surprising 
that ERBB2 depletion has a beneficial effect in BKC mice. The delay in PDAC progression 
might be explained by a decrease in EGFR and SAPK signaling. SAPK activity was decreased 
in ERBB2 depleted BKC mice, but it cannot be associated with decreased apoptosis, since 
cleaved caspase-3 positivity rather indicated enhanced apoptosis compared to BKC mice. 
Possibly, decreased SAPK signaling results in transcriptional regulation rather than in the 
regulation of apoptosis. The ambivalence of ERBB4 in PDAC, as in many other cancers, has 
emerged from studies stating tumor suppressive functions for the receptor, in that ERBB4 
expression was low in PDAC tissues and hPaCaCells266 and decreased in non-metastatic 
tumors282. Other studies showed that a constitutively active ERBB4 homo-dimer mutant 
inhibited colony formation in a pancreatic cancer cell line283. Other investigations rather 
classified ERBB4 as an oncogene, after revealing enhanced anchorage-independent growth 
of hPaCaCells by the stimulation of ectopic ERBB4 expression283. We also attribute ERBB4 
an oncogenic function, since its knockout prolonged the survival of BKC mice enormously. 
The majority of pancreata of BKC mice lacking ERBB4 showed a similar histopathology as 
BKC mice, displaying with high-grade PanIN and carcinoma, which is not in line with the 
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survival outcome. ERBB4 depleted BKC mice revealed decreased EGFR activity, MAPK and 
SAPK signalling. Decreased MAPK activation is not simply explained by decreased EGFR 
signaling, since this pathway was not affected by the loss of ERBB2 (also displaying 
decreased EGFR activity, P=0.055). Thus, these changes must be specific to ERBB4 
depletion. Considering that ERBB4 KO;BKC mice did not show a reduction in RAS activity, it 
is surprising that they show reduced MAPK signaling, which acts downstream of RAS. Without 
ERBB4 signaling, RAS might change the selection of downstream targets. The reduction in 
MAPK signaling might result in a reduced transcription activity of its target genes, thereby 
acting in an anti-tumorigenic way. In Western blots of 1-week-old mice, we detected enhanced 
EGFR and MAPK activity in ERBB4-depleted BKC mice indicating that EGFR/MAPK are 
involved in PDAC induction, but may EGFR/MAPK are not as important for PDAC 
progression. This supports the thesis of EGFR dependency in KC mice, but the compensatory 
mechanism also indicates a role for ERBB4 in PDAC initiation, too. It also suggests the 
causality of EGFR and MAPK activity in an ERBB4-dependent manner. Possibly, MAPK 
signaling is preferably regulated by EGFR/ERBB4 hetero-dimers, independently of ERBB2. 
Although EGFR signaling was decreased, no histopathologic changes were detected. 
Increased ERBB3 activation possibly compensates, in part, the loss of EGFR signaling. 
ERBB4 individuality results on the one hand from its capability to produce splice forms that 
affect ERBB4 signaling, on the other hand, ERBB4 can act through its cytosolic domain286 
(ICD). Both events were not observed in BKC mice.  
The deletion of Egfr resulted in the almost complete reversion of the BKC phenotype. 
Pancreatic and body weights recovered and the histological landscape appeared almost 
normally. However, in 8-week-old BKC mice lacking EGFR, ADM lesions were observed 
multi-focally, which were verified to be EGFR negative, but ERBB2, ERBB3 and ERBB4 
positive, indicating that, when the family is challenged, other receptors possibly take over to 
induce ADM. Interestingly, the lack of EGFR was accompanied by the downregulation of 
ERBB2, ERBB3 and full length ERBB4, but it induced ERBB4 ICD signaling indicating a 
compensatory mechanism upon the loss of EGFR. The ERBB4 ICD is possibly responsible for 
ADM development in EGFR depleted BKC mice, since all remaining receptors, which were 
expressed in ADM lesions were less phosphorylated. These findings are in line with a study 
that associated BTC with resistance to EGFR treatment in breast cancer cell lines115. The 
treatment with tyrosine kinase inhibitors led to acute BTC expression, induction of 
ERBB2/ERBB4 dimers and ERBB4 cleavage, thereby evading EGFR inhibition and 
reactivating of EGFR mediated signaling cascades. This is partially in line with our results 
regarding ERBB4 activation and ERBB4 RIP upon BTC activation in an EGFR depleted PDAC 
mouse model. This compensational mechanism of the ERBB family could possibly play a role 
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in the resistance of an EGFR inhibitor therapy in PDAC patients, and in attenuated PDAC 
development in EGFR/TP53-depleted KC mice156,273. 
We have shown that the depletion of BTC ameliorates the outcome of PDAC and, 
appropriately, that BTC overexpression deteriorates PDAC prognosis in KC mice. BTC 
involves not only EGFR activation, it also uses their partners in crime to induce accelerated 
PDAC development and progression. BTC enhances RAS activity, thereby potentially 
transforming acinar to duct cells. The beneficial loss of ERBB2 and ERBB4 implies that both 
receptors are potent oncogenes in PDAC. Especially, enhanced ERBB4 ICD activation upon 
EGFR depletion points to a compensatory behavior of the ERBB family emphasizing their role 
as co-targets in combinatorial EGFR-targeted therapies. Our data promotes the results of 
Momeny et al. who revealed the pan-ERBB inhibitor dacomitinib to exhibit stronger anti-tumor 
effects than conventional single-receptor targeting of PDAC cells298. We suggest, that targeting 
the whole ERBB family, rather than a single receptor, might be promising for future custom 
PDAC therapy development.  
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3.3.6 SUPPLEMENTARY FIGURES 
 
Suppl. Fig. S 3.1: Generation and verification of the BTC knockout mouse 
A Partial DNA sequence of Btc exon 2. The sgRNA binding site is indicated in blue, the protospacer adjacent motif 
(PAM) in red. Insertions (orange) of 1 bp lead a shift of reading frame. Partial amino acid (aa) sequences encoded 
by the WT and mutant Btc alleles. WT BTC aa sequence in black (aa coded by adjacent non-symmetrical exons in 
blue), missense aa sequence in red, and the premature termination codon as asterisk. WT=wildtype. KO=knockout. 
B Verification of the frame shift by reverse-transcriptase PCR of Li (liver), Ki (kidney), He (heart), UT (uterus), SG 
(salivary gland), Br (brain) after the restriction of the 500 bp amplicon with PflMI into fragments of 290 and 210 bp, 
respectively. The successful cleavage by PflMI indicates wildtype Btc (Btc+/+), while the lack of cleavage indicates 
the successful frame shift introduced by CRISPR/Cas9 and hence the BTC knockout (Btc-/-). H20 served as negative 
control, Gapdh as control PCR. C The crossing of BTC-/- mice into the KC background showed no change of body 
or pancreatic weights at the ages of 8 weeks or 12 months, respectively. D Immunohistochemistry targeting BTC in 
the pancreas of wildtype mice (BTC+/+) marking the islets of Langerhans and the cell membrane of acinar cells, 
BTC knockout mice (BTC-/-) presenting no signal for BTC staining. KC mice express BTC in premalignant lesions 
and BTC-/-;KC mice are immuno-negative for BTC. Scale bars: 100 µm. 
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Suppl. Fig. S 3.2: ERBB receptors in normal pancreas (NP) and in human PDAC (hPDAC) 
 Immunohistochemistry in NP and PDAC reveals the expression of all ERBB receptors in PanIN of human PDAC. 
Scale bars: 50 µm. 
 
Suppl. Fig. S 3.3: Activation of EGFR in pancreata of 1-week-old mice 
A Western blot and B corresponding densitometrical analyses of pancreata of 1-week-old ERBB4 KO;BKC mice 
depict enhanced EGFR activation and decreased EGFR expression compared to age-matched BKC mice. GAPDH 
served as reference protein. Data were analyzed by Student‘s t-test, *P<0.05. 
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Suppl. Fig. S 3.4: Change of BKC pancreata upon ERBB2 depletion in 8-week-old mice 
A Western blots and B corresponding densitometrical analyses of BKC pancreata compared to E2 KO;BKC 
pancreata revealed significantly decreased SAPK activation. Data were analyzed by Student‘s t-test, *P<0.05. C 
IHC detecting cleaved caspase 3 in pancreata of BKC mice lacking ERBB2 compared to BKC mice, demonstrates 
the activation of apoptosis in acinar clusters upon the loss of ERBB2. Scale bars: 100 µm. 
3.3.7 SUPPLEMENTARY TABLES 
Suppl. Table S 3.1: Antibodies employed for IHC 
Antigen Antibody Host Dilution 
mBTC R&D Systems, Minneapolis, MN, USA 
#AF1025 
Goat 1:500 
hBTC R&D Systems, AF261NA Goat 1:300 
TGFA Merck, Darmstadt, Germany, GF10 Mouse 5 µg/ml 
AREG R&D Systems, MAB989 Mouse 5 µg/ml 
EREG R&D Systems, AF1068 Goat 5 µg/ml 
ACTA2 Proteintech, Manchester, UK, #14395-1-
AP 
Rabbit 1:200 
mEGFR R&D Systems, AG1280 Goat 5 µg/ml 
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hEGFR R&D Sytems #AF231 Goat 1:800 
hERBB2 Cell Signaling #4250 Rabbit 1:800 
hERBB3 Cell Signaling #12708 Rabbit 1:500 
hERBB4 Proteintech #19941-1-AP Rabbit 1:400 
Cleaved Caspase 3 Cell Signaling #9661 Rabbit 1:200 
Donkey α Goat R&D Systems, #HAF109 Donkey 1:200 
SignalStain® Boost IHC 
Detection Reagent 
Cell Signaling #8114  Ready to 
use 
 
Suppl. Table S 3.2: Antibodies employed for Western blot 
All antibodies from Cell Signaling and mBTC (R&D) were diluted in 5% BSA in TBS-T, while all Santa Cruz 
antibodies were diluted in 5% milk in TBS-T. 
Antigen Antibody Host Dilution 
p-EGFR (Tyr1068) Cell Signaling, Boston, USA #3777 Rabbit 1:1000 
p-ERBB2 (Tyr877) Cell Signaling #2241 Rabbit 1:1000 
p-ERBB3 (Tyr1289) Cell Signaling #4791 Rabbit 1:1000 
p-ERBB4 (Tyr 1258) Abcam, Camebridge, UK ab76132 Rabbit 1:1000 
EGFR Santa Cruz, Heidelberg, Germany #03 Rabbit 1:500 
ERBB2 Santa Cruz #284 Rabbit 1:500 
ERBB3 Santa Cruz #285 Rabbit 1:500 
ERBB4 Santa Cruz #283 Rabbit 1:500 
p-SAPK Cell Signaling #9251 Rabbit 1:1000 
SAPK Cell Signaling #9252 Rabbit 1:1000 
p-p44/42 MAPK 
(Thr202/Tyr204) 
Cell Signaling #4370 Rabbit 1:1000 
p44/42 MAPK Cell Signaling #9102 Rabbit 1:1000 
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CDH1 Cell Signaling #14472 Mouse 1:1000 
mRAS Cell Signaling #8832 Mouse 1:200 
mBTC R&D Systems #AF1025 Goat 1:2000 
TUBA1A Cell Signaling, # 2125 Rabbit 1:5000 
GAPDH Cell Signaling, #2118 Rabbit 1:5000 
Goat α Rabbit Cell Signaling, #7074 Goat 1:2500 
Rabbit α Mouse Cell Signaling, #7076 Rabbit 1:2000 
 
Suppl. Table S 3.3: Primers employed for real time-PCR 
Gene Primer type Primer sequence 
ERBB4 JM-a Forward Primer 
Reverse Primer 
5’- GTGTAACGGTCCCACTAGTC -3’ 
5’- GCCATGATCACCAGGATGAAG -3’ 
ERBB4 JM-b Forward Primer 
Reverse Primer 
5’- CATTGAAGACTGCATCGGCCT -3’ 
5’- GCCATGATCACCAGGATGAAG -3’ 
ERBB4 CYT-1 Forward Primer 
Reverse Primer 
5’- GTGAAATTGGACACAGCCCTCC -3’ 
5’- GGAGTCATCAAACATCTCAGCC -3’ 
ERBB4 CYT-2 Forward Primer 
Reverse Primer 
5’- GACTCCAATAGGAATCAGTTTGTG -3’ 
5’- GGAGTCATCAAACATCTCAGCC -3’ 
GAPDH Forward Primer 
Reverse Primer 
5’- GTGGAAGGGCTCATGACCAC -3’ 
5’- GCCCACAGCCTTGGCAGCA -3’ 
RPL30 Forward Primer 
Reverse Primer 
5’- AACAACTGTCCAGCTTTGAGG -3’ 
5’- GCATACTCTGTAGTATTTTCCACACG -3’ 
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3.4 CONCLUSIONS & OUTLOOK 
PDAC is expected to become the 3rd leading cause of cancer deaths in the near future. 
Although striking findings have been made during the past 20 years, treatment has improved 
only marginally during that period. The initializing events of PDAC development were 
elucidated, the mutations resulting in PanIN development and aberrant signaling were 
revealed. This yielded in promising targets for treatment options and in numerous clinical trials. 
However, so far, none of these options provided significant benefit in the clinic. Due to the 
onset of symptoms only in late stages of the disease und the lack of early markers, PDAC is a 
disease with a high mortality, barely giving clinicians the chance to attempt treatment. In the 
majority of cases, at the time of clinical presentation, patients are in an advanced and 
metastatic disease stage and frequently, only palliative treatment can be provided. With only 
8%, the 5-year survival rate is the worst of all cancers. And rates are even worse for locally 
advanced or overall advanced stage patients. The only attempt for a cure described so far is 
resection of the pancreas, which can only be applied to 15-20% of the affected patients, 
thereby increasing their 5-year-survival up to 19%. Besides resection, the-standard-of-care 
therapy is systemic chemotherapy. For targeted therapy, EGFR has been the most promising 
target, since it is frequently overexpressed in PDAC and associated with a poor outcome for 
the patient. Also, the depletion of EGFR prevented the development of pancreatic cancer in 
PDAC mouse models, highlighting the disease’s dependency on EGFR. The inhibition of 
EGFR by the small molecule erlotinib in combination with gemcitabine therapy significantly 
increased the survival of PDAC patients compared to gemcitabine mono-therapy, albeit with 
only marginal relevance in the clinic. In pre-clinical and clinical trials, PDAC cancer cells 
commonly evade EGFR dependency but the underlying mechanisms are still not understood. 
Publications on the involvement of the remaining ERBB receptors of the family are 
controversial. The PDAC research community currently does not agree on the prognostic value 
of ERBB2 expression, while ERBB3 is consistently associated with poor outcome for the 
patient and ERBB4 is mostly expressed at low levels in human PDAC. However, functional 
studies of ERBB4 attribute an ambivalent role to this receptor. ERBB ligands present a different 
case, since the majority of them is frequently expressed or overexpressed in pancreatic cancer 
and, especially TGFA and HBEGF seem to be deeply involved in PDAC development. 
However, many gaps remain about the participation of each receptor in these processes. The 
approach of this work aimed to investigate the receptor system more closely in a PDAC mouse 
model. The approach should reveal the involvement of family members, other than EGFR, 
which were possibly underestimated due to low expression levels or contradictory findings.  
We revealed a major role of BTC on PDAC development by the depletion of the ligand by 
CRISPR/Cas9 technology in a PDAC mouse model (Ptf1acre/+;KRASG12D/+, herein referred to 
 
77 
 
as KC mice). KC mice harbor a constitutive activation of KRAS via mutation, specifically in the 
pancreas due to Cre-loxP technology using the pancreas-specific promoter Ptf1a. KC mice 
lacking BTC presented attenuated PDAC development. This event might be associated with 
the decreased EGFR phosphorylation and expression upon BTC depletion in KC mice, 
observed in early and late stages of PDAC development. To analyze BTC function in PDAC 
and which receptors are involved, we crossed Btc tg mice with KC mice. KC mice generally 
display a long latency and an incomplete penetrance to develop pancreatic adenocarcinoma. 
Btctg/+;Ptf1acre/+;KrasG12D/+ mice (herein referred to as BKC mice) express BTC ubiquitously. 
Although being only specific for EGFR and ERBB4, BTC induced a complex activation of the 
ERBB system and resulted in the hetero-dimerization of ERBB2, at least with EGFR. While 
ERBB3 activation was not observed in BKC mice, it could be stimulated by BTC in human 
cells. EGFR, ERBB2 and ERBB4 activation was discovered in both models. The majority of 
BKC mice died at eight weeks with a median survival of 2.75 months, which is approximately 
nine months less compared to the median survival of KC mice. Pancreata of BKC mice were 
completely replaced by desmoplasmic tissue and PDAC, which started as early as after one 
week of age. We revealed BTC to be able to induce ADM in 3-D primary cell culture of wildtype 
acinar cells. ADM is a crucial step in pancreatic carcinogenesis, which is initiated by oncogenic 
KRAS. However, in the PDAC community, it is generally suggested that an additional trigger 
is required for comprehensive oncogenic KRAS activation in the pancreas. Our investigations 
revealed that BTC enhanced RAS activation, thereby possibly shifting RAS activity above a 
certain threshold, in order to induce ADM. In pancreata of BKC mice with a pancreas-specific 
deletion of the EGFR receptor (using the Cre-loxP system), we observed that the enhanced 
RAS activation was exclusively mediated by EGFR. BKC mice lacking ERBB2 or ERBB4 
(ERBB2 KO;BKC and ERBB4 KO;BKC, respectively) did not show any changes in RAS 
activation compared to BKC mice. However, RAS activity does not seem to be the only crucial 
function by which BTC accelerated PDAC development. The pancreas-specific KO of ERBB2 
and ERBB4 in BKC mice significantly prolonged the survival (ERBB2 KO;BKC median 
survival: 12.5 months, ERBB4 KO;BKC median survival: 15 months), which could be 
explained, in part in ERBB2 KO;BKC mice, by attenuated PDAC progression. The grade of 
PDAC and the degree of replacement of acinar tissue in ERBB4 KO;BKC mice was similar to 
BKC mice. The lack of each receptor resulted in reduced EGFR activation, and the lack of 
ERBB4 in BKC mice also led to reduced MAPK and SAPK signaling, which has to be specific 
to EGFR/ERBB4 hetero-dimers, since it was not observed in ERBB2 KO;BKC animals. 
Additionally, ERBB2 activation was decreased in ERBB4 KO;BKC mice. The depletion of 
EGFR revealed the most prominent alteration of the BKC phenotype. The pancreata of these 
mice presented predominantly normal, but they displayed ADM multi-focally, which were 
positive for ERBB2, ERBB3 and ERBB4 immuno-stainings. In these mice, Western blot 
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analyses revealed that the lack of EGFR was accompanied by the decreased phosphorylation 
and expression of ERBB2, ERBB3 and full-length ERBB4. However, the ICD of ERBB4 was 
highly phosphorylated, indicating a compensatory mechanism of ERBB4 signaling upon EGFR 
depletion.  
Manipulating the activity of the ERBB family in a PDAC mouse model points to an oncogenic 
role for ERBB2 and ERBB4, which might not be obvious at first. In particular, ERBB2 and 
ERBB4 affect the survival either by influencing PDAC progression or intracellular signaling. 
Though EGFR has the most dominant pathogenic effect, it is not exclusively responsible for 
the phenotype. ADM development possibly by ICD signaling of ERBB4, despite EGFR 
depletion, highlights the importance of the remaining ERBB family members, in particular, 
considering EGFR targeted therapies or the development of resistance to EGFR treatment. A 
recent study about the pan-inhibition of the ERBB family, rather than one single receptor in 
human PDAC cells revealed promising results. This and our data suggest that PDAC treatment 
should involve all ERBB receptors and not be focused on EGFR alone. The broader inhibition 
spectrum might have the advantage of decreased medication doses and thereby possibly of a 
reduction of side effects in the clinic. Many clinical trials are underway, mostly targeting 
intracellular signaling molecules. However, based on the redundancy and complexity of these 
signaling pathways, the inhibition of single molecules is ineffective in intermitting these 
pathways and extracellular signals are still successfully transmitted into a cellular response. 
This is also true for targeting of EGFR. Hence, the combinatorial inhibition of a certain signaling 
molecule and its up- or downstream target is favored by researchers, today. Using this 
approach, promising results have recently been presented including EGFR combinatorial 
therapies. Yet, the influence of the remaining receptors ERBB2, ERBB3 and ERBB4 should 
not be underestimated. Still, they might be part of a redundant signaling cascade and possibly 
provide an alternative signaling route within the EGFR axis.   
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4 SUPPLEMENTARY PROJECT 
During the studies of my PhD, I was involved in an additional project, which resulted in a 
manuscript, which was re-submitted to the journal ‘International Journal of Obesity’ in July 
2019. Addendum: This manuscript was accepted for publication in a revised version in October 
2019 at ‘International Journal of Obesity’. 
 
 
I presented this project in form of a podium talk at the ‘European Association for the studies 
of diabetes’ with the title ‘Maternal and paternal pre-conceptional overweight results in 
different sex-specific transcriptome changes of blastocysts and spermatozoa sncRNAs’ in 
Munich in September, 2016, and in form of a podium talk at the ‘50. Jahrestagung 
Physiologie und Pathologie der Fortpflanzung’ with the title ‘Peri-conceptional overweight in 
male and female mice causes sex-specific transcriptome changes in blastocysts which could 
result from differentially expressed sncRNA in spermatozoa of obese males’ in Munich in 
February, 2017.  
 
 
 
 
4.1 CONCLUSIONS 
Adverse environmental effects before and during pregnancy, e.g. stress, under- or 
overnutrition or diabetes mellitus can cause epigenetic changes in the developing embryo, 
which can, in turn, lead to a permanent dysregulation of tissues or organs and manifest as 
diseases in the adult offspring. With an increase of obesity by 150 million adults within the last 
decade to over 650 million obese adults and 125 million obese children, obesity is a globally 
rising problem. The rates for overweight are even higher. Reasons for this may not exclusively 
be attributed to lifestyle changes. Evidence is rising that the susceptibility of becoming obese 
is inherited epigenetically. Prior to this study, our lab investigated the offspring of 
peri-conceptionally obese female mice and found differences in the phenotypes of the adult 
male and female offspring compared to the offspring of lean mothers. This indicated that 
maternal epigenetic programming of the offspring is sex-specific. However, there was 
increasing evidence that the father’s nutrition and disease history also had an influence on the 
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health of the offspring, but no sex-specific differences were reported, yet. Also unknown was, 
how and at which time point of embryonic development these epigenetic changes, provided by 
both parents, act on the embryo. In the early blastocyst of mice (3.5 days post coitum), both 
strands of parental DNA of the embryo are being de-methylated and embryonic gene activation 
begins, starting with de novo methylation. We assumed this period to be an ideal time window 
for epigenetic changes to occur.  
In this study, we investigated the transcriptome of blastocysts derived from either 
peri-conceptionally obese mothers or fathers using microarray analyses and sorted the 
blastocysts sex-specifically by real-time PCR. The blastocyst transcriptome was compared to 
the transcriptome of blastocysts which derived from lean parents. We observed that obesity of 
the mother led to changes in the blastocyst transcriptome, which were predominantly affecting 
male blastocysts (92 differently abundant transcripts (DAT)) and of which the major change 
was an increase of DATs. Only four DATs were down-regulated in female blastocysts. Obesity 
of the father, however, resulted in exclusively increased DATs in male blastocysts and in 
predominantly decreased DATs in female blastocysts. The datasets of DATs of obese mothers 
and obese fathers showed a considerable overlap. These data revealed that an obesogenic 
exposure to both parents leads to transcriptome changes in the early embryo, which were 
more pronounced in male than in female blastocysts. And while in male blastocysts, DATs 
were predominantly upregulated, in female embryos, DATs were predominantly 
downregulated. The presence of RNA in sperm is reported controversially, but there is 
evidence rising that small non-coding RNA (sncRNA) might be carried in the sperm and 
inherited to the next generation, or even trans-generationally. We performed Next Generation 
Sequencing (NGS) on small RNAs of the sperm of obese mice and we revealed nine 
microRNAs (miRNAs) to be more abundant than in the sperm of lean mice. By NGS we 
detected targets of these miRNAs in oocytes of lean mice, and revealed that 75% of the 
decreased DATs could possibly have been targeted by these nine miRNAs of obese fathers. 
During the course of our study, an increasing number of studies was published, all with 
evidence on different kinds of RNA in the sperm of mice, which act on the epigenome of the 
embryo but their mechanisms still need to be determined. Our findings demonstrate that 
epigenetic changes affecting the transcriptome the embryo are sex-specific and that they occur 
before embryo implantation in utero. Sperm small RNA are possibly inducing these changes. 
These data shed light on the importance of the contribution of both parents, that obesity can 
alter the embryo significantly in a sex-dependent manner, thereby laying the basis for future 
diseases of the offspring. 
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4.2 SEX-SPECIFIC PROGRAMMING EFFECTS OF PARENTAL OBESITY IN PRE-
IMPLANTATION EMBRYONIC DEVELOPMENT 
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4.2.1 ABSTRACT 
Obesity is a global rising problem with epidemiological dimension. Obese parents can have 
programming effects on their offspring leading to obesity and associated diseases in later life. 
This constitutes a vicious circle. Epidemiological data and studies in rodents demonstrated 
differential programming effects in male and female offspring, but the timing of their 
developmental origin is not known. This study investigated if sex-specific programming effects 
of parental obesity can already be detected in the pre-implantation period. Diet induced obese 
male or female mice were mated with normal-weight partners and blastocysts were recovered. 
Gene expression profiling revealed sex-specific responses of the blastocyst transcriptome to 
maternal and paternal obesity. The changes in the transcriptome of male blastocysts were 
more pronounced than those of female blastocysts, with a stronger impact of paternal than of 
maternal obesity. The sperm of obese mice revealed an increased abundance of several 
miRNAs compared to lean mice. Our study indicates that sex-specific programming effects of 
parental obesity already start in the pre-implantation period and reveals specific alterations of 
the sperm miRNA profile as mechanistic link to programming effects of paternal obesity.  
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4.2.2 INTRODUCTION 
Epidemiological studies revealed that, during pregnancy, maternal environmental factors, like 
diseases, stress, body composition and lifestyle can have developmental programming effects 
and cause diseases in later life of the offspring, e.g. obesity, type 2 diabetes and cardiovascular 
diseases299,300. Developmental programming results in altered gene expression caused by 
epigenetic changes, such as histone modifications301, methylation of CpG islands302 or small 
non-coding RNAs (sncRNA)303 in utero. A sensitive time window for programming is the de 
novo methylation of the genome at the early blastocyst stage304. We and other groups 
demonstrated that peri-conceptional overnutrition in female mice induces sex-specific 
programming of long-term health risks in the offspring305-310. Male offspring showed increased 
weight gain, while female offspring gained less body fat compared to sex-matched offspring 
from normal-weight mothers310. In addition, paternal programming effects have been 
demonstrated as a consequence of an altered small RNA profile in their sperm303, which - after 
fertilization of oocytes - can influence gene expression of the early embryo. In our current 
study, we investigated whether pre-conceptional maternal or paternal obesity affects the 
embryonic transcriptome already at the blastocyst stage and if such changes are different 
between male and female embryos. Our previously established diet induced obesity (DIO) 
mouse model310 and lean control mice were used to recover blastocysts as well as oocytes 
and sperm. Since we observed that maternal obesity has a sex-specific programming effect in 
the offspring310, we sexed the blastocysts before analyzing their transcriptomes. As a potential 
mechanism of paternal programming effects, we investigated sncRNAs of sperm of obese vs. 
lean mice and matched them to their predicted target mRNAs in oocytes of lean and obese 
female mice. 
4.2.3 MATERIALS AND METHODS 
See details in Supplementary Materials and Methods (4.2.4).  
4.2.3.1 ANIMALS  
All procedures were performed in accordance with the Committee on Animal Health and Care 
of the state of Upper Bavaria (Regierung von Oberbayern, Germany; permission Az. 55.2.1.54-
2532-51-12) and according to the German Animal Welfare Act and Directive 2010/63/EU on 
the protection of animals used for scientific purposes. NMRI mice (RjHan:NMRI) were 
purchased from Janvier (Le Genest St Isle, France). For a period of nine weeks, cohorts of 
three-week-old mice were fed a modified D12492 high-fat, high-calorie diet (HFD) (E15741-
34; ssniff, Soest, Germany), or received a control diet to D12492 (CD) (ssniff) (Suppl. Table S 
4.5). At the age of twelve weeks, mice were killed to recover sperm or oocytes, or mated. Three 
types of mating were set up (n = 7 per mating type): i) obese male × lean female (MOb×FCo); 
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ii) lean male × obese female (MCo×FOb); and lean male × lean female (MCo×FCo) (Suppl. Fig. S 
4.1 A-E). At day 3.5 post coitum, female mice were sacrificed and blastocysts were isolated in 
M2 medium.  
4.2.3.2 SEXING OF BLASTOCYSTS AND MICROARRAY ANALYSIS 
Blastocysts were sexed by quantitative RT-PCR analysis of Slc25a5 (X-chromosome specific) 
and Ddx3y (Y-chromosome specific) expression (Suppl. Fig. S 4.1 F,G). For holistic gene 
expression analysis the lysate of three sex matched blastocysts from one mother were pooled 
and analyzed on an Affymetrix GeneChip™ (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Four replicates of blastocyst pools were analyzed for each 
parental group (MObxFCo, MCoxFOb, MCoxFCo); in total: 24 microarrays.   
4.2.3.3 TRANSCRIPTOME ANALYSIS OF SPERM AND OOCYTES  
For transcriptome analysis the sperm of eight obese and eight lean mice, and oocyte pools 
(pools of 4 oocytes per dam) of six obese and six lean mice were investigated. RNA-
sequencing libraries were generated using the tagmentation technology of the NexteraXT Kit 
(Illumina) following the manufacturer’s instructions.  
4.2.3.4 STATISTICAL ANALYSIS  
Data was analyzed by Student’s t-test (unpaired and equal). Data is represented as mean+SD 
(GRAPHPAD PRISM version 5.0). Microarray data sets were analyzed by Local Pooled Error 
(LPE) estimation. P<0.05 was considered significant.  
4.2.4 SUPPLEMENTARY MATERIALS AND METHODS  
4.2.4.1 ANIMALS AND ENVIRONMENTAL ENRICHMENT  
NMRI mice (RjHan:NMRI) were purchased from Janvier (Le Genest St Isle, France). Mice were 
maintained under specific pathogen-free conditions in the closed barrier facility of the Gene 
Center, Munich at 23 °C, 40% humidity, with a 12 h light/dark cycle (lights on at 7 AM) and had 
access to water and their appropriate diet ad libitum. All procedures were performed in 
accordance with the Committee on Animal Health and Care of the state of Upper Bavaria 
(Regierung von Oberbayern, Germany; permission Az. 55.2.1.54-2532-51-12) and according 
to the German Animal Welfare Act and Directive 2010/63/EU on the protection of animals used 
for scientific purposes.  
4.2.4.2 DIET, MATING AND TISSUE REMOVAL  
For blastocyst analysis: For a period of nine weeks a three-week-old cohort of seven male 
(M) and female (F) mice were fed a modified D12492 high-fat, high-calorie diet (HFD) (E15741-
34; ssniff, Soest, Germany), and another cohort of 14 male and female animals received a 
control diet D12492 (CD) (ssniff) (diet composition is shown in (Suppl. Table S 4.5). Body 
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weight was monitored every week and body fat content was measured weekly by magnetic 
resonance imaging (Minispec LF50; Brucker, Stuttgart, Germany). At the age of 12 weeks, 
HFD mice (MOb, FOb) were mated with CD mice (MCo, FCo) and as control group CD fed animals 
were mated with each other. During mating all animals were fed the CD and screened for 
vaginal plugs every morning and evening. At day 3.5 post coitum (dpc), female mice were 
sacrificed by cervical dislocation and blastocysts were isolated in M2 medium. Blastocysts 
were washed three times in PBS, separately snap frozen in PBS, and stored at -80 °C until 
used for further analysis.  
For sperm analysis: 16 three-week-old male mice received either a HFD or a CD for a period 
of nine weeks prior to sperm isolation. Both caudae epididymidis were removed, trimmed free 
from fat and placed in PBS for sperm swim up. The caudae epididymidis were incised at five 
different spots, enabling the sperm to swim up in 200 µl PBS for five minutes. The PBS 
containing sperm was transferred into an Eppendorf tube containing 1 ml PBS for 10 minutes. 
Motile sperm swam to the upper phase of the PBS while somatic cells sedimented to the 
bottom of the tube. The upper 200 µl phase PBS, containing the motile sperm, was transferred 
into a fresh Eppendorf tube containing 700 µl QIAZOL buffer (QIAGEN, Hilden, Germany), 
sonicated with a low amplitude (Bioruptor Plus, Diagenode SA, Seraing, Belgium) for five 
cycles. Each cycle consisted of a pulse of 30 seconds followed by a rest of 90 seconds. 
Afterwards, the samples were shock frozen in liquid nitrogen and stored at -80 °C.  
For oocyte analysis: 18 three-week-old female mice received either a HFD or CD, 
respectively, for a period of nine weeks prior to being mated with vasectomized male mice. 
During mating, all animals were fed a CD and screened for vaginal plugs every morning and 
evening. At day 0.5 p.c. female mice were sacrificed by cervical dislocation and oocytes were 
isolated in M2 medium. Oocytes were washed three times in PBS, separately snap frozen in 
PBS, and stored at -80 °C until used for further analysis.  
4.2.4.3 MICROARRAY ANALYSIS OF SEXED BLASTOCYSTS  
Isolated, single blastocysts were lysed in 10 µl buffer using Direct Lysis Kit (NuGEN, Leek, 
Netherlands) according to the manufacturer’s instructions. For blastocyst sexing 1 µl lysate 
was used in a TaqMan Genexpression Assay using the CellsDirect One-step qRT-PCR Kit 
(Thermo Fisher Scientific, Darmstadt, Germany) according to the manufacturer’s instructions. 
Blastocysts were sexed by quantitative RT-PCR for the following genes: Slc25a5 
(X-chromosome specific) and Ddx3y (Y-chromosome specific). Therefore, the following 
TaqMan gene expression assays were used: Assay-ID: Mm00846873_g1 and Assay-ID: 
Mm00465349_m1 (Thermo Fisher Scientific). The TaqMan Assay was carried out in a 
StepOne machine (Thermo Fisher Scientific) in a final volume of 20 µl. Assay conditions were: 
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Holding Stage: 50°C for 15 min, 95°C for 2 min and for the Cycling Stage (with in total 50 
cycles): 95°C for 15 sec, 60°C for 45 sec. 
For whole-transcriptome gene expression analysis the lysate of three sex-matched blastocysts 
from one mother were pooled. Per parental group (MOb x FCo, MCo x FOb, MCo x FCo) and for 
each male or female blastocyst pool, four replicates were analyzed, respectively; in total: 24 
microarrays. Targets for the microarray analysis were generated using the Ovation One-Direct 
System (NuGEN) according to the manufacturer’s instructions. Briefly, first primer was 
annealed to the lysate followed by first and second strand cDNA synthesis. Purified cDNA was 
amplified using the SPIA technology (NuGEN). Before amplified targets were purified post-
SPIA modification was completed. 4 µg of purified target cDNA was fragmented and Biotin-
labeled using the FL-modul (NuGEN) according to the manufacturer’s instructions. Afterwards 
the quality of the fragmented and labeled samples were controlled by using the Agilent 2100 
Bioanalyzer. 1.5 µg of fragmented and labeled sample was hybridized on an Affymetrix 
GeneChip™ (Thermo Fisher Scientific) using the respective Hybridization, Wash and Stain Kit  
(Thermo Fisher Scientific) according to the manufacturer’s instructions. After 17 (+/- 1) hours 
of hybridization the microarrays were read out on the Affymetrix Fluidics Station. The full 
blastocyst transcriptome data set was uploaded at NCBI Gene Expression Omnibus and has 
the data accession number GSE133767. 
4.2.4.4 QUANTITATIVE RT-PCR  
Total RNA was isolated with TRIZOL reagent (Invitrogen, Darmstadt, Germany) and 1 µg of 
RNA samples were reverse-transcribed in a final volume of 20 µl using RevertAid Reverse 
Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Quantitative RT-PCR was carried out in a LightCycler®480 (Roche, Mannheim, Germany) 
using the primers (0.5 µM) listed in Suppl. Table S 4.4, 1 µl cDNA, 0.2 µM probe (Universal 
ProbeLibrary Set, Roche), and the LightCycler® 480 Probes Master Mix (Roche) in a final 
volume of 10 µl. Cycle conditions were 95°C for 5 min for the first cycle, followed by 45 cycles 
at 95°C for 10 s, 60°C for 15 s, and 72°C for 1 s. Transcript copy numbers were normalized to 
beta-actin (Actb) mRNA copies. The ΔCt value of the sample was determined by subtracting 
the average Ct value of the target gene from the average Ct value of the Actb gene. For each 
primer pair we performed no-template control and no-RT control assays, which produced 
negligible signals that were usually greater than 40 in Ct value. All experiments were performed 
in duplicates. All primers and probes are listed in Suppl. Table S 4.4. 
4.2.4.5 RNA ISOLATION OF MOUSE SPERM  
Total RNA was extracted from purified sperm using the miRNeasy Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. In brief, the in QIAZOL buffer 
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shock-frozen sperm samples were thawed on ice and incubated for 5 min at room temperature 
(RT). Chloroform was added to the homogenate, thoroughly mixed and centrifuged at 4 °C to 
get separate phases. The aqueous phase was extracted and mixed with 100% ethanol and 
applied to a silica-based RNeasy spin column to bind total RNA >18nt. A DNase digest was 
performed for 15 min at RT. The RNA was washed several times and dissolved in RNase-free 
water. The RNA samples were concentrated and purified by an RNA-bead cleanup with 
Agencourt® RNAClean® XP Beads (Beckman Coulter, Krefeld, Germany). Total RNA was 
incubated and bound to magnetic RNAClean® XP Beads in 80% ethanol, washed and eluted 
in RNase-free water. The RNA concentration was measured by Qubit™ fluorimeter (Thermo 
Fisher Scientific). RNA quality was investigated by performing a capillary gel electrophoresis 
using an Agilent RNA 6000 Pico Chip and an Agilent Small RNA Chip on the Agilent 2100 
Bioanalyzer according to the manufacturer’s instructions.  
4.2.4.6 LIBRARY PREPARATION AND SEQUENCING OF SMALL RNAS OF MOUSE SPERM 
A cDNA library was prepared using the NEXTflex™ Small RNA Sequencing Kit v2 (HISS 
Diagnostics GmbH, Freiburg, Germany) according to the manufacturer’s instructions starting 
with less than 2 µg of total RNA. In brief, the NEXTflex™ 4N adenylated adapter was ligated 
to the 3’-end of the small RNA prior to the ligation of the adapter to the 5’-end. After reverse 
transcription of the first strand using universal primers, the product was purified by Agencourt 
AMPure XP bead clean up (Beckman Coulter) and the second strand was synthesized by PCR 
amplification using NEXTflexTM Small RNA Barcode Primers – Set A. The PCR products were 
fragmented on a TBE-PAGE, the gel was stained with SYBR Gold (Invitrogen) and fragments 
of the size of 150 nucleotides were excised, eluted and purified. The quality of the cDNA was 
investigated using an Agilent DNA 1000 Chip on the Agilent 2100 Bioanalyzer according to the 
manufacturer’s instructions and sequenced on an Illumina HiSeq1500 machine (single end 
read, 50 nt). Deep sequencing reads were preprocessed on a Galaxy server311 hosted by 
LAFUGA, Gene Center, Munich. The data was demultiplexed using Ilumina Demultiplex 
v1.0.0, adapter sequences were removed from the 3’ end using Clip Adaptor Sequence v1.0.0 
(tggaattc, seed 8, mismatch 0, minimum length after clipping 1), random nucleotides at the 5’ 
and 3’ end of the reads were trimmed using FastqFilter v1.0 (enable trimming T, absolute, 4nt 
each end) and length selection of the reads was performed using Filter FASTQ v1.0.0. Length 
selected reads were mapped to the mouse genome, to mature miRNAs, hairpins, rRNAs, 
tRNAs and piRNA cluster (mm9) using Bowtie312, (-v0). The abundance of reads mapping to 
specific features was analyzed using Perl scripts and R v3.2.3. Statistical significance was 
calculated using the two-sided Mann-Whitney U test and plotted in R. Data is represented as 
mean ± SD (GRAPHPAD PRISM version 5.0 for Windows, GraphPad Software, San Diego, 
CA, USA). 
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4.2.4.7 TRANSCRIPTOME ANALYSIS OF ISOLATED MOUSE SPERM  
For transcriptome analysis 2 ng of isolated RNA were treated with DNaseI (Thermo Scientific). 
Afterwards, the RNA was used to generate double-stranded cDNA using the Ovation RNA Seq 
V2 Kit (NuGEN) according to the manufacturer’s instructions. The purified cDNA was 
quantified using the HS DNA Kit (Thermo Fisher Scientific). Samples were measured on 
Qubit™ fluorimeter (Thermo Fisher Scientific). Sequencing libraries were generated using the 
Ovation Rapid DR Multiplex System (NuGEN) according to the manufacturer’s instructions. 
Briefly, between 1.4 and 1.8 µg of double-stranded cDNA were fragmented with the M220 
Focused ultrasonicator (Covaris, Brighton, UK). On this system the fragment size was 
programmed to peak at 250 bp. After purification, the concentration of the fragmented cDNA 
was determined using the HS DNA Kit (Thermo Fisher Scientific). Samples were measured on 
Qubit™ fluorimeter (Thermo Fisher Scientific). In the following end repair, 250 ng of 
fragmented and purified cDNA were used. After adapter ligation and final repair, the DNA was 
purified and amplified. After amplification, the sequencing libraries were purified and quantified 
using a DNA 1000 Chip on the Agilent 2100 Bioanalyzer according to the manufacturer’s 
instructions and finally sequenced on an Illumina HiSeq1500 machine (single-end read, 100 
nt). The sequencing reads were preprocessed on a Galaxy server311 (hosted by LAFUGA, 
Gene Center, Munich). The data was demultiplexed using Illumina Demultiplex v1.0.0 and 
adapter sequences were removed from the 3’ end using Clip Adaptor Sequence v1.0.0 (seed 
10, mismatch 0, minimum length after clipping 20). The output was mapped to the mouse 
genome (mm10). The abundance of reads mapping to the specific feature type (here: exon, 
minimum alignment quality 0, mode union, paired-end no, strand specificity yes) were analyzed 
using HTSeq-count v1.0.0 and a differential gene expression analysis (CD vs. HFD) based on 
the negative binominal distribution was performed using DESeq2313 v1.0.19 setting the FDR < 
0.05. The full sperm transcriptome data set was uploaded at NCBI Gene Expression Omnibus 
and has the data accession number GSE133915, and the miRNA data set was uploaded at 
European Nucleotide Archive and has the data accession number PRJEB33337.  
4.2.4.8 TRANSCRIPTOME ANALYSIS OF OOCYTES  
Full-length cDNA of four pooled oocytes was generated using the SMART Seq v4 Ultra Low 
Input RNA kit for Sequencing (Takara Bio, Mountain View, CA, USA) according to the 
manufacturer’s instructions. The template switching activity of reverse transcriptase to enrich 
full-length cDNA as well as the addition of defined PCR adapters directly to the ends of the 
first strand cDNA define the SMART technology. In brief, after lysis, full-length first strand 
cDNA was generated followed by reverse transcription and long-distance PCR. Finally, the 
amplified cDNA was purified using Agencourt AMPure XP Beads (Beckman Coulter). The 
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obtained full-length cDNA was validated using the Qubit™ fluorimeter (Thermo Fisher 
Scientific). 
The RNA-Sequencing libraries were generated using the tagmentation technology of the 
NexteraXT Kit (Illumina) following the manufacturer’s instructions. This technology relies on an 
engineered transposome to tagment double stranded DNA and tagging it with a universal 
overhang. In brief, double stranded template DNA is combined with Nextera XT transposome 
with adapters. After tagmentation to fragments and the addition of adapters, a limited-cycle 
PCR was performed to add index adapter sequences. Finally, libraries were purified using 
Agencourt AMPure XP Beads (Beckman Coulter). Libraries were quantified on the Bioanalyzer 
and finally sequenced on an Illumina HiSeq1500 machine (single end read, 100 nt). The 
sequencing reads were preprocessed on a Galaxy server311 (hosted by LAFUGA, Gene 
Center, Munich). The data was demultiplexed using Illumina Demultiplex v1.0.0 and adapter 
sequences were removed from the 3’ end using Clip Adaptor Sequence v1.0.0 (seed 10, 
mismatch 0, minimum length after clipping 20).  The output was mapped to the mouse genome 
(mm10). The abundance of reads mapping to the specific feature type (here: exon, minimum 
alignment quality 0, mode union, paired-end no, strand specificity yes) were analyzed using 
HTSeq-count v1.0.0 and a differential gene expression analysis (CD vs. HFD) based on the 
negative binominal distribution was performed using DESeq313 v1.0.19 setting the FDR < 0.05. 
The full oocyte transcriptome data set was uploaded at NCBI Gene Expression Omnibus and 
has the data accession number GSE133914. 
4.2.4.9 STATISTICAL ANALYSIS  
Body weight and body fat content were statistically analyzed using PROC MIXED (linear mixed 
models; SAS release 8.2, SAS Institute, Cary, NC, USA) considering the fixed effects of diet, 
age, their interaction, and the random effect of animal310. qRT-PCR was analyzed by Student’s 
t-test (unpaired and equal). Data is represented as mean+SD (GRAPHPAD PRISM version 
5.0). Microarray data sets were analyzed by Local Pooled Error (LPE) estimation. P<0.05 was 
considered significant.  
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4.2.5 RESULTS 
4.2.5.1 PARENTAL OBESITY INFLUENCES GENE EXPRESSION AT THE BLASTOCYST STAGE IN A 
SEX-SPECIFIC MANNER  
Microarrays revealed that in blastocysts of obese fathers (MOb) the transcript abundance of 98 
genes was altered compared to control blastocysts. Interestingly, this effect was strongly 
dependent on the sex of the embryos. In male blastocysts, all differentially abundant transcripts 
(DATs; n = 49) were increased, whereas in female blastocysts the majority of DATs was 
decreased in abundance (47 down, 2 up), resulting in 217 DATs between male and female 
blastocysts from obese fathers. In contrast, maternal obesity (FOb) mainly affected the 
transcriptome of male blastocysts (92 DATs; 79 up, 13 down compared with male control 
blastocysts), while the transcriptome of female blastocysts was only moderately altered (4 
DATs down compared with female control blastocysts) and only 7 DATs were found between 
male and female blastocysts (Figure 4.1 B; Suppl. Table S 6.1). These results demonstrate, 
that male and female blastocysts are differently affected by parental obesity. Furthermore, the 
transcriptome changes induced by paternal or maternal obesity in male blastocysts showed a 
considerable overlap, while no overlap in DATs was found between male and female 
blastocysts derived from either obese fathers or mothers (Figure 4.1 C). Microarray results 
were confirmed for eight genes by quantitative RT-PCR (Suppl. Fig. S 4.2). 
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Figure 4.1: Microarray analysis of male and female blastocysts from different male (MOb) and female (FOb) 
obese parents 
A Study design and number of altered transcripts compared to the control group in female blastocysts (pink) and 
male blastocysts (blue) of FOb (right) and MOb (left) compared to controls (center). B Microarray analysis showing 
differentially expressed transcripts of blastocysts from MOb or FOb compared with controls, and male blastocysts 
compared with female blastocysts within each group. C Venn diagram depicting the number of uniquely or identically 
regulated transcripts in all groups, orange bubble: transcripts of female blastocysts of MOb; pink bubble: differentially 
expressed transcripts of female blastocysts of FOb; blue bubble: transcripts of male blastocysts of FOb; green bubble: 
transcripts of male blastocysts of MOb. Arrows indicate an up-(↑) or down-(↓) regulation of genes in the respective 
group compared to FCox MCo. 
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4.2.5.2  DIFFERENT MIRNAS AND PIRNAS WERE UP-REGULATED IN THE SPERM OF HFD MICE  
Since there is evidence rising that sncRNAs can be inherited by sperm and that they provide 
an explanation for specific disease susceptibilities in the offspring300,303,314, we investigated the 
small RNA pattern in sperm of obese males vs. lean controls (Suppl. Fig. S 4.3 A). Next 
generation sequencing (NGS) revealed 11 small RNAs with significant abundance differences 
between sperm of MOb mice and MCo sperm (Figure 4.2 A). Since miRNAs silence mRNAs, we 
evaluated if lower expressed transcripts in blastocysts derived from MOb are predicted or 
validated targets of miRNAs that were up-regulated in their sperm. Indeed, 34 out of 47 down-
regulated transcripts in female blastocysts are targets of the identified miRNAs (Suppl. Table 
S 4.1). On the other hand, we identified 18 target mRNAs of the two significantly down-
regulated miRNAs (miR-30a/b) upregulated in male blastocysts derived from obese fathers 
(Suppl. Table S 4.2). Besides the altered miRNA pattern, we found the products of five piwi-
interacting RNAs (piRNAs) of the pachytene loci315 to be significantly up-regulated and one of 
the prepachytene gene loci315 to be down-regulated in the sperm of MOb mice compared with 
MCo sperm (Figure 4.2 B).  
4.2.5.3 NGS ANALYSIS REVEALED NUMEROUS SIGNIFICANT CHANGES IN THE TRANSCRIPTOME OF 
OOCYTES FROM OBESE FEMALES  
We evaluated the transcriptome of oocytes from obese and lean female mice by NGS (Suppl. 
Fig. S 4.3 B). We identified 442 transcripts with significantly increased and 221 transcripts with 
significantly decreased abundance in oocytes of FOb compared with FCo oocytes (Suppl. Table 
S 4.3 (with top 20 genes) and Suppl. Table S 6.2 for the complete list). We investigated whether 
the down-regulated mRNAs of female blastocysts from MOb, potentially serving as targets of 
the up-regulated miRNAs in the sperm of MOb, were already expressed in the transcriptome of 
FCo-oocytes. We identified 27 mRNAs in the oocyte transcriptome, which match potential 
targets of the four most up-regulated miRNAs in the sperm of MOb mice (Figure 4.2 C). This 
analysis confirmed that the mRNA targets of our identified miRNAs in the MOb sperm are 
expressed in oocytes and were down-regulated in female blastocysts generated by fertilization 
with MOb sperm.  
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Figure 4.2: Differential abundance of small RNAs in the sperm of obese (MOb) compared with lean control 
males (MCo) 
A Significantly regulated miRNAs in the sperm of MOb vs. MCo mice. B Significantly regulated piRNAs in the sperm 
of MOb vs. MCo mice. Significance was calculated using the two-sided Mann-Whitney U-test; *P<0.05. C Heatmap 
and matches of the most prominently up-regulated miRNAs in sperm of MOb mice and their target mRNAs, which 
were significantly down-regulated in the transcriptome of blastocysts of MOb mice. 
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4.2.6 DISCUSSION 
Studies verified that the sex plays a fundamental role during the initiation phase of diseases, 
in particular on the molecular level of mental disorders and metabolic diseases316. In our 
current work, we revealed that male blastocysts of obese females (FOb) have a higher number 
of transcriptome changes than female blastocysts. This is in line with our previous observation 
of more marked phenotypic changes (e.g. increased body weight) in male than in female 
offspring of obese mothers310, which was also observed by other studies305-308,317. Taken 
together, these observations suggest that during pre-implantation development male embryos 
are more susceptible than female embryos to an obesogenic maternal environment and the 
resulting programming effects may – at least in part – persist into postnatal life.  
Interestingly, paternal obesity also resulted in significant transcriptome changes of blastocysts, 
which were clearly sex-specific. The 49 DATs found in male blastocysts were increased in 
abundance and overlapped completely with the set of up-regulated DATs in male blastocysts 
of obese mothers, demonstrating concordant effects of parental obesity on the transcriptome 
of male blastocysts. In contrast, 47 of 49 DATs in female blastocysts of obese fathers were 
down-regulated transcripts, demonstrating sex-specific programming of paternal obesity. 
Recently, several studies showed correlations of paternal obesity with the development of non-
communicable diseases in the offspring, suggesting that paternal obesity at conception may 
impact on the offspring’s metabolic health later in life318,319. In vitro fertilization studies showed 
that spermatozoa of DIO mice induced the development of increased body weight in the 
offspring, indicating a function for spermatozoa in epigenetic programming of the 
offspring300,319,320. We showed that obesity causes significant alterations in the RNA profile of 
mouse sperm, such as increased abundances of nine miRNAs. Interestingly, almost 75% of 
the down-regulated transcripts in female blastocysts of obese fathers were predicted targets 
of these nine miRNAs. Differentially regulated piRNAs in mouse sperm could possibly be 
inherited to the next generation and have an impact on the F2 generation as described 
previously321. Future studies, e.g. with sex-sorted sperm, are required to provide further 
insights into sex-specific paternal programming effects in pre-implantation embryos. 
Mechanisms how the sperm RNA code can influence metabolic health of offspring have been 
reviewed recently322. 
In conclusion, our study revealed differential transcriptome changes in male and female 
blastocysts associated with maternal or paternal obesity, suggesting the preimplantation 
period as a critical window for sex-specific developmental programming effects.    
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4.2.7 SUPPLEMENTARY FIGURES 
 
Suppl. Fig. S 4.1: Experimental design and sexing of blastocysts 
A Study design. B,C Body weight curve of male B and female C mice during exposure to HFD and CD. n=7 HFD/7 
CD. D,E Body fat of D male and E female mice was measured by magnetic resonance imaging. Data is represented 
as mean±SEM, was analyzed by 2-way ANOVA, and differences between groups were analyzed by Student’s t-
test (unpaired and unequal). *P<0.05, **P<0.01. F,G Quantification plots of RT-PCR analysis for sex-sorting show 
X-chromosome linked gene Slc25a5 (purple) and Y-chromosome linked gene Ddx3y (blue) of male f and female g 
blastocysts. 
 
 
Suppl. Fig. S 4.2: Microarrays were confirmed by quantitative RT-PCR of 8 selected genes 
A Male blastocysts (XY) of HFD mothers, B male blastocysts (XY) of HFD fathers, C female blastocysts (XX) of 
HFD mothers, D female blastocysts (XX) of HFD fathers were compared with the CD group. Expression levels are 
relative to Actb expression. Data is represented as mean±SEM, and significance was calculated by Student’s t-test. 
*P<0.05, **P<0.01 
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Suppl. Fig. S 4.3: Body weights of donor mice 
A Body weight of sperm donors fed a HFD or CD. n=8 HFD/8 CD. B Body weight of oocytes donors fed a HFD or 
CD. n=9 HFD/9 CD. Data is represented as mean±SEM, and were analyzed by 2-way ANOVA, and statistical 
differences between groups were calculated by Student’s t-test. *P<0.05. , **P<0.01 , ***P<0.001. 
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4.2.8 SUPPLEMENTARY TABLES 
Suppl. Table S 4.1: Correlation of the down-regulation of transcripts in female blastocysts of MOb with 
miRNA abundance in sperm of obese mice  
Down-regulated transcripts of female blastocysts derived from obese fathers MOb, which are predicted or validated 
targets of significantly up-regulated miRNAs in the sperm of obese fathers MOb. 
 
miR-
1839 
miR-
136 
miR-
142 
miR-
140 
miR- 
495 
miR- 
16 
miR-
22 
miR-
192 
Otud6b        
Atp13a3 
 
 
 
   
Ak4 
 
    
 
Ppp6c 
 
 
 
   
Cmpk1 
 
    
 

Lsm6 
  
  
 
 
Tmed2 
 

 
 
 
 
Zranb1 
 
    
  
Dnajb6 
 

 
 
  

Slc44a1 
 

 

 

 
Srsf3 
 
 
 

  

Xlr3b 
   
  
 
Xlr3c 
   
  
 
Cnot1 
  
   
  
Dnajc13 
  
  
   
Nabp1 
   

 

 
Rap1a 
  

 
  
 
Wtap  
 

  

 
Xlr3a 
    
 
 
Atp6v1c1 
   

   
Dpy30 
    

 

 
Gm2016 
 

     

Ltn1 
    

 

 
Mrps18c 
  

   

 
Paip2 
    
  
 
Sms 
    
  
 
Zc3h15 
  

   

 
Nop56 
    

  
Sucla2 
  
 
 

  
Psma1 
 

  

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Psma6 
 

    

 
Uxt 
   

    
Pfdn2 
    
 
   
Fth1 
      

 
 
Suppl. Table S 4.2: Correlation of the up-regulation of transcripts in male blastocysts of MOb with miRNA 
abundance in sperm of obese mice 
Upregulated transcripts in male blastocysts derived from obese fathers and their matches as predicted or validated 
targets of significantly underrepresented miRNAs found in the sperm of obese mice MOb. 
 
miR-30a miR-30b 
Ube2v2  
Dnajc13  
Ltn1  
Celf1  
Tra2b  
Xpo1  
Purb  
Eif2s1  
Lsm6  
Ttc1  
Prdx2  
Ppp4r2  
Arih2 
 
Rbbp6 
 
Lamtor3 
 
Sumo1 
 

Myef2 
 

Calcoco2  
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Suppl. Table S 4.3: Differentially regulated genes in oocytes of FOb vs. FCo mice 
Listed are the top 20 genes, sorted by p-value. For the complete list, please find Suppl. Table S 6.2. 
Down-regulated Transcripts Upregulated transcripts 
Gene log2-
fold 
Change 
p-value p-adj Gene log2-
fold 
Change 
p-value p-adj 
Plcl1 -4,36 9,16E-09 8,96E-05 Rpl41 3,44 1,63E-07 3,98E-04 
Ung -1,85 6,19E-08 3,03E-04 Anapc13 3,55 1,51E-07 3,98E-04 
Prps2 -3,31 1,63E-06 9,40E-04 2210417A02Rik 2,54 4,14E-07 6,80E-04 
4930512B01Rik -2,31 2,93E-06 1,40E-03 Ndufa11 3,22 4,17E-07 6,80E-04 
Sh2d3c -1,95 3,16E-06 1,40E-03 Timm8b 1,51 1,00E-06 8,65E-04 
E2f4 -1,44 7,56E-06 2,39E-03 Sergef 1,71 1,00E-06 8,65E-04 
Trim75 -1,72 1,37E-05 3,08E-03 Ndufb8 1,82 1,02E-06 8,65E-04 
Ube2s -1,10 1,42E-05 3,08E-03 Lsm7 1,83 1,06E-06 8,65E-04 
Naa40 -1,36 1,91E-05 3,60E-03 Cox6a1 2,93 6,65E-07 8,65E-04 
Pla2g15 -1,32 2,21E-05 3,73E-03 Acot13 3,45 7,72E-07 8,65E-04 
Myt1 -1,11 2,64E-05 4,10E-03 Uba52 3,04 1,22E-06 9,20E-04 
Gm15787 -1,66 2,93E-05 4,21E-03 Rplp2 1,58 1,46E-06 9,40E-04 
Pkmyt1 -0,94 3,14E-05 4,39E-03 Znrd1as 2,02 1,62E-06 9,40E-04 
Tbc1d10a -1,02 3,26E-05 4,49E-03 Zfp935 2,25 1,42E-06 9,40E-04 
Wasf1 -1,19 4,08E-05 5,09E-03 Ccdc122 1,41 1,87E-06 1,01E-03 
Snx9 -1,38 5,42E-05 5,76E-03 Nop10 1,66 2,64E-06 1,36E-03 
Srebf2 -2,04 5,84E-05 5,89E-03 Myl6 1,53 3,01E-06 1,40E-03 
Ncoa4 -1,55 7,38E-05 6,81E-03 Acbd7 1,72 3,89E-06 1,65E-03 
Sh3bgrl2 -1,54 7,64E-05 6,83E-03 Lsm4 2,95 4,08E-06 1,66E-03 
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Patz1 -1,49 7,75E-05 6,83E-03 Ndufa1 2,95 4,86E-06 1,90E-03 
 
Suppl. Table S 4.4: Primers and probes employed for quantitative RT-PCR analysis   
Gene Forward Primer 
5’-3’ 
Reverse Primer 
5’-3’ 
Probe 
5’-3’ 
Celf1 CCAAGTGGTACCAATGCTCTC TCGGTGAAGACCCTGCTG CATCCAGC 
Lamtor3 CTGAACTGCGGGAACACC GCAGAATCGATCTCCACTCC GGCTGGAG 
Tmed2 TGGACATCGACGTGGAGA GGACTCCCGGTCTCCTTTA GGACCAGA 
Otud6b AGAAGGCATCGGAAGGAGA AGCGTTCTTCATTCCCTGAA AGGAGCTG 
Xpo1 GGAAGTCAACACTTTGATATTCCTC CCATCAATAAACGGACCTTTG GGAGACAG 
Sumo1 TGCTGATAATCATACTCCGAAAGA CCCCGTTTGTTCCTGATAAA GGAGGAAG 
Ube2v2 TACAAGGTGGACAGGCATGA GATGGAGGAGCTTCTGGGTA GGCCACCA 
Psma3 GAAGCAGAGAAATATGCCAAGG GCAACTGTTACAGAAATGTAA
ACCA 
CCATCCGC 
Actb CGTGAAAAGATGACCCAGATCA CACAGCCTGGATGGCTACGT TTTGAGACC
TTCAACACC
CCAGCCA 
 
Suppl. Table S 4.5: Composition of provided diets. 
Crude Nutrients High Fat Diet (HFD) 
% 
Control Diet (CD) 
% 
Dry matter 97.1 96.7 
Crude protein (N x 6.25) 24.1 24.1 
Crude fat 34.0 5.1 
Crude fibre 6.0 6.4 
Crude ash 6.1 6.2 
N free extracts 27.0 54.7 
Starch 2.2 26.0 
Sugar/Dextrines 22.4 26.1 
Energy 24.4 MJ/Kg          15.1 MJ/Kg  
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6 APPENDIX 
Suppl. Table S 6.1: Differentially regulated transcripts of male (♂) and female (♀) blastocysts of obese 
females (FOb) or obese males (MOb), respectively, compared to blastocysts of lean mice (FCo x MCo). 
upregulated transcripts (in bold) 
   
downregulated transcripts 
   
    
♂ blastocysts 
   
FOb x MCo  
   
1110012L19Rik 
   
1810035L17Rik 
   
4930522L14Rik 
   
Acadm 
   
Ankrd33b 
   
Arih2 
   
Atp13a3 
   
C430048L16Rik 
   
Ccdc90b 
   
Celf1 
   
Cspp1 
   
Ddx6 
   
Dhx9 
   
Dnajc13 
   
Eif2s1 
   
Erh 
   
Etf1 
   
Etohi1 
   
Fabp3 
   
Fam36a /// AI503316 
   
Gas5 
   
Gins1 
   
Gkap1 
   
Gm12191 /// Rpl30 
   
Gm12952 /// Gm14535 /// Llph 
   
Gm14391 /// Gm14326 
   
Gm14410 /// Gm14430 /// Gm2007 /// Gm14434 /// Gm14308 /// Gm4724 /// 0610010B08Rik 
   
Gm14420 
   
Gm14680 /// Sms 
   
Gm3258 /// Supt4h1 
   
Gm6517 
   
Gm6710 /// LOC627901 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
   
Gm9392 /// Rap1a 
   
Gm9769 /// LOC100048119 /// Ptges3 
   
Gnai3 
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Gtf3c6 
   
H3f3a 
   
Hmgn5 
   
Hspd1 
   
Ik 
   
Lamtor3 
   
Lcp1 
   
Lsm6 
   
Ltn1 
   
Med10 
   
Mir669b 
   
Mir680-1 
   
Mir680-3 
   
Mir9-1 
   
Myef2   
  
Nmt2 
   
OTTMUSG00000016609 /// 100043387 /// Gm14430 /// Gm14434 /// Gm2007 /// Gm14308 
/// Gm4724 /// 0610010B08Rik 
   
Park7 
   
Pbrm1 
   
Ppp4r2 
   
Psma3 
   
Rab18 
   
Rap1b 
   
Rnu3a 
   
Rpp30 
   
Shcbp1 
   
Smek2 
   
Snora31 
   
Snord47 
   
Snrpd3 
   
St13 
   
Strn3 
   
Sumo1 
   
Terf1 
   
Tmem62 
   
Tra2b 
   
Ttc1 
   
Ube2v2 
   
Vma21 
   
Xlr5b /// Xlr5c /// Xlr5a 
   
Xpo1 
   
Ywhaz 
   
Zdhhc17 
   
2810422O20Rik 
   
BC051665 
   
 
118 
 
Mir5117 
   
Gm10324 
   
Gm10792 /// Slc12a6 
   
Luc7l3 
   
Prdx2 
   
Purb 
   
Rbbp6 
   
Snord104 
   
Taf1d 
   
Uba3 
   
Wbp5 
   
♂ blastocysts 
   
FCo x MOb 
   
1810035L17Rik 
   
2810422O20Rik 
   
4930522L14Rik 
   
Arih2 
   
C430048L16Rik 
   
Celf1 
   
Cspp1 
   
Dnajc13 
   
Eif2s1 
   
Etohi1 
   
Gas5 
   
Mir5117 
   
Gins1 
   
Gm10324 
   
Gm12191 /// Rpl30 
   
Gm12952 /// Gm14535 /// Llph 
   
Gm14391 /// Gm14326 
   
Gm14410 /// Gm14430 /// Gm2007 /// Gm14434 /// Gm14308 /// Gm4724 /// 0610010B08Rik 
   
Gm14680 /// Sms 
   
Gm3258 /// Supt4h1 
   
Gm6517 
   
Gm6710 /// LOC627901 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
   
Gm9769 /// LOC100048119 /// Ptges3 
   
Gtf3c6 
   
Hmgn5 
   
Lamtor3 
   
Lsm6 
   
Ltn1 
   
Mir669b 
   
Mir680-1 
   
Mir680-3 
   
 
119 
 
Myef2 
   
OTTMUSG00000016609 /// 100043387 /// Gm14430 /// Gm14434 /// Gm2007 /// Gm14308 
/// Gm4724 /// 0610010B08Rik 
   
Park7 
   
Prdx2 
   
Psma3 
   
Purb 
   
Rbbp6 
   
Rnu3a 
   
Snora31 
   
Snord104 
   
Snord47 
   
Sumo1 
   
Tra2b 
   
Ttc1 
   
Ube2v2 
   
Wbp5 
   
Xlr5b /// Xlr5c /// Xlr5a 
   
Xpo1  
   
♀ blastocysts 
   
FOb x MCo  
   
Otud6b 
   
Snord57 /// Nop56 
   
Tmed2 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
  
   
♀ blastocysts 
   
FCo x MOb 
   
Rny3 
   
Ppp4r2 
   
1700021F05Rik 
   
1810037I17Rik 
   
Ak4 
   
Atp13a3 
   
Atp6v1c1 
   
Calcoco2 
   
Cmpk1 
   
Dnajb6 
   
Dnajc13 
   
Dpy30 
   
Fth1 
   
Gas5 
   
Gm12952 /// Gm14535 /// Llph 
   
Gm14680 /// Sms 
   
Gm3258 /// Supt4h1 
   
Gm6158 /// Cnot1 
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Gm6851 /// LOC635999 /// Pin4 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
   
Gm9392 /// Rap1a 
   
Gpr137b-ps 
   
Hprt 
   
LOC100046079 /// Cox5b 
   
Lsm6 
   
Ltn1 
   
Malat1 
   
Mrps18c 
   
Obfc2a 
   
Otud6b 
   
Paip2 
   
Park7 
   
Pfdn2 
   
Ppp6c 
   
Psma1 
   
Psma6 
   
Scarna17 
   
Slc44a1 
   
Snord57 /// Nop56 
   
Snrpd3 
   
Srsf3 
   
Sucla2 
   
Tceb1 
   
Tmed2 
   
Uxt 
   
Wtap 
   
Xlr3c /// Xlr3b /// Xlr3a 
   
Zc3h15 
   
Zranb1 
   
  
   
FCo x MCo 
   
♂ vs. ♀ 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
   
Scarna17 
   
Sumo1 
   
Gm14680 /// Sms 
   
Gm3258 /// Supt4h1 
   
Hmgn5 
   
Gm9769 /// LOC100048119 /// Ptges3 
   
Rbbp7   
  
Gm9392 /// Rap1a   
  
Ube2v2   
  
Gas5   
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Gtf3c6   
  
Snord57 /// Nop56   
  
Lsm6   
  
Vma21   
  
Dnajc13   
  
Rnu2-10   
  
Nutf2-ps1 
  
  
  
FOb x MCo  
   
♂ vs. ♀ 
   
Gas5 
   
Rab24 
   
A630089N07Rik 
   
Otud6b 
   
Ssbp1 
   
Wbp5 
   
Xist 
   
 
 
FCo x MOb 
   
♂ vs. ♀ 
   
Cspp1 
   
Terf1 
   
Pdcl3 
   
Bzw1 
   
Arpc2 
   
0610007P22Rik 
   
0610009B22Rik 
   
1600012F09Rik 
   
1700021F05Rik 
   
1810035L17Rik 
   
1810037I17Rik 
   
4930522L14Rik 
   
4932438A13Rik 
   
6720456B07Rik 
   
A630089N07Rik 
   
A730098P11Rik /// Gm6747 /// Morf4l1 
   
Actr3 
   
Ak4 
   
Anapc13 
   
Ankrd33b 
   
Arcn1 
   
Arl6ip1 
   
Arl6ip4 
   
Atp13a3 
   
Atp6v0c 
   
 
122 
 
BC051665 
   
C1qbp 
   
C430048L16Rik 
   
Calcoco2 
   
Calm1 /// Calm3 /// Calm2 
   
Cct7 
   
Cdc42 
   
Cdv3 
   
Celf1 
   
Cmpk1 
   
Cops2 
   
Cops6 
   
Cox4i1 
   
Csde1 
   
Csnk2a1 
   
Cstb 
   
Cycs 
   
Ddx5 
   
Ddx6 
   
Dhx9 
   
Dnajb6 
   
Dnajc13 
   
Dppa4 
   
Dpy30 
   
Eef1a1 
   
Eif1ax 
   
Eif2s1 
   
Eif2s2 
   
Eif3e 
   
Etfb 
   
Etohi1 
   
Fabp3 
   
Foxo3 
   
Fth1 
   
Gapdh 
   
Gas5 
   
Ghitm 
   
Gins1 
   
Gm10177 /// Gm11575 /// Gm4184 /// Sec61g 
   
Gm10324 
   
Gm10639 /// Gsta2 /// Gsta1 /// Gm3776 
   
Gm10792 /// Slc12a6 
   
Gm12657 /// H3f3a 
   
Gm12952 /// Gm14535 /// Llph 
   
Gm13139 /// Gm13251 /// 1700029I01Rik 
   
Gm13363 /// LOC100044742 /// Ptp4a1 
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Gm14326 /// Gm6710 
   
Gm14391 /// Gm14326 
   
Gm14410 /// Gm14430 /// Gm2007  
   
Gm14420 
   
Gm15455 
   
Gm19750 /// Ywhah 
   
Gm3258 /// Supt4h1 
   
Gm5093 /// Gm7589 /// Rpl11 
   
Gm5593 /// Ccnb1 
   
Gm6158 /// Cnot1 
   
Gm6594 /// Gm6750 /// Gm9525 /// Hmgn2 
   
Gm6710 /// LOC627901 
   
Gm8300 /// Gm2022 /// Gm5662 /// Gm2016 
   
Gm9769 /// LOC100048119 /// Ptges3 
   
Gnb1 
   
H2afz 
   
H3f3a 
   
Hdac2 
   
Hmgb1 
   
Hnrnph3 
   
Hnrnpu 
   
Hprt 
   
Hsp90b1 
   
Hspd1 
   
Ifrd1 
   
Ik 
   
Jph1 
   
Kif5b 
   
Larp7 
   
LOC100046079 /// Cox5b 
   
LOC100046628 /// Npm1 
   
LOC100642166 
   
LOC631286 /// Acp1 
   
Lsm6 
   
M6pr-ps /// M6pr 
   
Malat1 
   
Mat2a 
   
Mdm4 
   
Med21 
   
Metap1 
   
Mir297b 
   
Mir330 /// Eml2 
   
Mir598 
   
Mir669b 
   
Mir680-1 
   
Mir680-3 
   
 
124 
 
Mir692-1 
   
Mir9-1 
   
Mospd1 
   
Mrpl42 
   
Mrps14 
   
Mrps18c 
   
Myef2 
   
Myeov2 
   
Nasp 
   
Ncapg 
   
Ncbp2 
   
Ndufa4 
   
Ndufb6 
   
Nfu1 
   
Nono 
   
OTTMUSG00000016609 /// 100043387  
   
Otud6b 
   
Paip2 
   
Park7 
   
Pfdn2 
   
Ppia 
   
Ppp1cc 
   
Ppp6c 
   
Pramel7 
   
Prl4a1 
   
Psma1 
   
Psma3 
   
Psma4 
   
Psma5 
   
Psma6 
   
Psmc5 
   
Psmd10 
   
Ptp4a2 
   
Pttg1 
   
Purb 
   
Pydc3 
   
Rad21 
   
Rbbp6 
   
Rnf4 
   
Rnu2-10 
   
Rnu3a 
   
Rny3 
   
Rock2 
   
Rpl12 
   
Rpl17 
   
Rpl21 
   
 
125 
 
Rpl30 /// Gm6109 /// Gm7429 
   
Rpl32 
   
Rps18 
   
Rps23 
   
Rps25 
   
Rps7 
   
Sarnp 
   
Scarna17 
   
Sec61g 
   
Senp6 
   
Sf3b1 
   
Sfpq 
   
Slc30a1 
   
Slc44a1 
   
Snord14c /// Snord14d /// Hspa8 
   
Snord47 
   
Snrpd1 
   
Snrpd3 
   
Snx2 
   
Sod1 
   
Srsf3 
   
Stfa1 /// BC117090 /// BC100530 
   
Sub1 
   
Suclg2 
   
Sumo2 
   
Taf1d 
   
Tbca 
   
Tcea1 
   
Tceb1 
   
Tcp1 
   
Timm23 
   
Tpm4 
   
Tpt1 
   
Tra2b 
   
Trmt112 
   
Tspan8 
   
Txndc9 
   
Txnl1 
   
Uba3 
   
Ube2v2 
   
Uqcrb 
   
Utp3 
   
Vdac2 
   
Vdac3 
   
Wbp5 
   
Wtap 
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Xpo1 
   
Ywhae 
   
Ywhaz 
   
Zc3h15 
   
Zdhhc17 
   
Zfp534 /// Gm13051 
   
Zfp58 /// A530054K11Rik /// Zfp87 
   
Zfp706 
   
 
Suppl. Table S 6.2: Differentially regulated transcripts in oocytes of obese mice compared to oocytes of lean 
mice. Listed according to p-adj (adjusted p-value), starting with the lowest p-adj. All genes are significant with a p-
adj<0.05. Up-regulated genes first, followed by down-regulated genes. 
Upregulated genes 
      
Gene baseMean log2Fold   
Change 
lfcSE stat   p-value        p-adj 
  
Rpl41 164,84 3,44 0,66 5,24 1,63E-07 3,9822E-04 
Anapc13 50,32 3,55 0,68 5,25 1,51E-07 3,9822E-04 
2210417A02Rik 29,62 2,54 0,50 5,06 4,14E-07 6,7980E-04 
Ndufa11 391,96 3,22 0,64 5,06 4,17E-07 6,7980E-04 
Timm8b 2960,41 1,51 0,31 4,89 1,00E-06 8,6522E-04 
Sergef 88,38 1,71 0,35 4,89 1,00E-06 8,6522E-04 
Ndufb8 1045,11 1,82 0,37 4,89 1,02E-06 8,6522E-04 
Lsm7 846,58 1,83 0,37 4,88 1,06E-06 8,6522E-04 
Cox6a1 385,75 2,93 0,59 4,97 6,65E-07 8,6522E-04 
Acot13 157,91 3,45 0,70 4,94 7,72E-07 8,6522E-04 
Uba52 79,85 3,04 0,63 4,85 1,22E-06 9,2036E-04 
Rplp2 625,08 1,58 0,33 4,82 1,46E-06 9,4015E-04 
Znrd1as 51,76 2,02 0,42 4,80 1,62E-06 9,4015E-04 
Zfp935 22,71 2,25 0,47 4,82 1,42E-06 9,4015E-04 
Ccdc122 812,47 1,41 0,30 4,77 1,87E-06 1,0139E-03 
Nop10 641,58 1,66 0,35 4,70 2,64E-06 1,3588E-03 
Myl6 337,54 1,53 0,33 4,67 3,01E-06 1,4004E-03 
Acbd7 239,01 1,72 0,37 4,62 3,89E-06 1,6536E-03 
Lsm4 33,25 2,95 0,64 4,61 4,08E-06 1,6622E-03 
Ndufa1 299,37 2,95 0,65 4,57 4,86E-06 1,9023E-03 
Tma7 409,33 1,49 0,33 4,55 5,39E-06 2,0264E-03 
Rpl37 842,19 1,67 0,37 4,51 6,36E-06 2,2430E-03 
Hrsp12 147,01 1,99 0,44 4,51 6,49E-06 2,2430E-03 
Pop5 136,95 2,86 0,63 4,50 6,65E-06 2,2430E-03 
Myeov2 2719,50 1,49 0,33 4,49 7,19E-06 2,3461E-03 
Ndufa4 1739,21 1,88 0,42 4,46 8,33E-06 2,5456E-03 
Rwdd1 635,44 1,20 0,27 4,43 9,27E-06 2,7491E-03 
Cenpw 647,44 1,07 0,24 4,41 1,03E-05 2,8801E-03 
Rplp1 113,89 2,82 0,64 4,41 1,03E-05 2,8801E-03 
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Gm13826 1772,41 1,46 0,33 4,38 1,16E-05 3,0560E-03 
Cycs 931,28 1,65 0,38 4,36 1,28E-05 3,0560E-03 
Eef1e1 564,53 1,96 0,45 4,36 1,29E-05 3,0560E-03 
Cox14 464,54 2,08 0,48 4,37 1,22E-05 3,0560E-03 
1700021F05Rik 107,32 2,13 0,49 4,37 1,23E-05 3,0560E-03 
Dynlrb1 572,76 2,51 0,58 4,36 1,31E-05 3,0560E-03 
Wwtr1 57,85 2,57 0,59 4,37 1,25E-05 3,0560E-03 
Atp6v0e 1126,85 1,44 0,33 4,34 1,41E-05 3,0842E-03 
Ndufa3 93,40 2,51 0,58 4,33 1,47E-05 3,1259E-03 
Polr2f 1705,99 1,27 0,29 4,33 1,50E-05 3,1298E-03 
Gm10745 107,26 1,44 0,33 4,32 1,59E-05 3,2308E-03 
Pcbd2 344,41 2,18 0,51 4,30 1,74E-05 3,4707E-03 
Gm561 119,43 1,46 0,34 4,29 1,82E-05 3,5078E-03 
Polr2j 2617,42 1,64 0,38 4,28 1,83E-05 3,5078E-03 
1700018B24Rik 1590,64 1,53 0,36 4,26 2,01E-05 3,7018E-03 
Gm2694 345,83 1,80 0,42 4,25 2,16E-05 3,7335E-03 
Clec2f 73,80 1,92 0,45 4,25 2,12E-05 3,7335E-03 
2010107E04Rik 772,62 2,02 0,48 4,26 2,07E-05 3,7335E-03 
Cox6b1 278,87 2,03 0,48 4,24 2,20E-05 3,7335E-03 
Psmb2 1598,21 1,76 0,41 4,24 2,28E-05 3,7798E-03 
Rit2 104,30 1,18 0,28 4,20 2,62E-05 4,1034E-03 
Pcif1 451,61 1,25 0,30 4,21 2,57E-05 4,1034E-03 
Rpl23 94,58 2,48 0,59 4,21 2,52E-05 4,1034E-03 
Taf1d 600,70 1,10 0,26 4,18 2,87E-05 4,2129E-03 
Cpb2 330,61 1,42 0,34 4,18 2,90E-05 4,2129E-03 
Pate4 52,86 2,30 0,55 4,18 2,87E-05 4,2129E-03 
Paip2 1120,96 2,70 0,65 4,18 2,88E-05 4,2129E-03 
Ccdc28b 94,89 2,62 0,63 4,17 3,08E-05 4,3623E-03 
Myoc 390,89 1,82 0,44 4,13 3,61E-05 4,8996E-03 
Calm2 1293,77 2,38 0,58 4,13 3,68E-05 4,9369E-03 
Snrpd1 6952,84 1,11 0,27 4,12 3,81E-05 5,0020E-03 
Ttc1 1209,02 1,48 0,36 4,12 3,83E-05 5,0020E-03 
4930592A05Rik 15,42 2,71 0,66 4,11 3,92E-05 5,0505E-03 
1110001J03Rik 608,31 1,31 0,32 4,09 4,23E-05 5,0851E-03 
2610524H06Rik 373,79 1,32 0,32 4,08 4,49E-05 5,0851E-03 
Mycbp 748,49 1,32 0,32 4,08 4,57E-05 5,0851E-03 
Tbca 1076,73 1,40 0,34 4,08 4,41E-05 5,0851E-03 
Rbx1 7651,66 1,50 0,37 4,08 4,55E-05 5,0851E-03 
C530044C16Rik 46,14 1,57 0,38 4,09 4,41E-05 5,0851E-03 
Tasp1 57,62 1,61 0,39 4,10 4,21E-05 5,0851E-03 
Hmgn2 250,17 2,07 0,51 4,08 4,55E-05 5,0851E-03 
Ndufb3 154,27 2,25 0,55 4,09 4,26E-05 5,0851E-03 
Tm2d1 438,65 2,36 0,58 4,10 4,07E-05 5,0851E-03 
Uqcr11 277,32 3,17 0,78 4,08 4,44E-05 5,0851E-03 
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Rpl11 159,81 2,12 0,52 4,06 5,00E-05 5,5019E-03 
Gm5 167,22 2,51 0,62 4,05 5,19E-05 5,6380E-03 
Dynll1 677,54 2,41 0,60 4,04 5,27E-05 5,6684E-03 
Ndufab1 379,82 1,21 0,30 4,02 5,89E-05 5,8853E-03 
Sec62 3000,44 1,24 0,31 4,02 5,85E-05 5,8853E-03 
3110009E18Rik 1140,95 1,30 0,32 4,02 5,78E-05 5,8853E-03 
Dctpp1 138,45 1,91 0,47 4,02 5,78E-05 5,8853E-03 
Sec61g 86,61 2,18 0,54 4,02 5,76E-05 5,8853E-03 
Snx3 222,82 1,97 0,49 4,00 6,37E-05 6,2940E-03 
0610040F04Rik 358,88 1,65 0,41 3,99 6,50E-05 6,3622E-03 
Cox7a2 1078,32 1,60 0,40 3,99 6,60E-05 6,3958E-03 
Apoe 45,47 1,80 0,45 3,98 6,96E-05 6,6458E-03 
Ugt2b38 41,51 2,04 0,51 3,98 7,00E-05 6,6458E-03 
Rpl37a 88,71 1,56 0,39 3,96 7,37E-05 6,8119E-03 
Aig1 769,30 1,79 0,45 3,97 7,31E-05 6,8119E-03 
Lsm3 884,57 2,00 0,51 3,95 7,68E-05 6,8289E-03 
Ube2c 519,02 2,40 0,61 3,95 7,69E-05 6,8289E-03 
0610009B22Rik 247,79 2,61 0,66 3,95 7,74E-05 6,8289E-03 
AU019823 1147,83 0,99 0,25 3,92 8,71E-05 7,4772E-03 
Chchd1 124,41 1,98 0,51 3,91 9,10E-05 7,6666E-03 
Gm16497 1020,80 2,04 0,52 3,91 9,13E-05 7,6666E-03 
Serpinb12 116,40 2,34 0,60 3,91 9,17E-05 7,6666E-03 
Nedd8 704,27 1,80 0,46 3,90 9,74E-05 8,0725E-03 
Mrps31 230,33 2,41 0,62 3,90 9,82E-05 8,0730E-03 
Cox6b2 1464,29 1,45 0,37 3,89 0,000100283 8,1089E-03 
Ltc4s 243,53 2,09 0,54 3,89 0,000100278 8,1089E-03 
1700034K08Rik 118,06 1,40 0,36 3,89 0,000101128 8,1101E-03 
Hypk 5733,39 1,38 0,36 3,88 0,000102492 8,1259E-03 
Nsmce2 3751,51 1,02 0,26 3,87 0,000110908 8,4389E-03 
Rpain 220,38 1,23 0,32 3,87 0,000110278 8,4389E-03 
Mrps33 844,15 1,60 0,41 3,87 0,000109577 8,4389E-03 
Mien1 52,02 2,47 0,64 3,86 0,000111265 8,4389E-03 
Gabrr3 339,41 1,25 0,33 3,86 0,000114903 8,4814E-03 
Lactb2 275,07 1,27 0,33 3,86 0,000115293 8,4814E-03 
4931429P17Rik 90,80 1,47 0,38 3,86 0,000113637 8,4814E-03 
Coa3 218,92 1,16 0,30 3,85 0,000116898 8,5353E-03 
Uchl4 85,42 1,65 0,43 3,85 0,000119147 8,5841E-03 
Spcs1 606,58 1,93 0,50 3,84 0,000121568 8,6477E-03 
Tceb1 2785,40 2,15 0,56 3,83 0,000125917 8,8631E-03 
Dbi 1203,08 1,05 0,28 3,82 0,000133982 9,3439E-03 
7420461P10Rik 1205,95 1,75 0,46 3,81 0,00013948 9,5770E-03 
Cnih4 449,07 1,99 0,52 3,80 0,000146182 9,9323E-03 
Cadps 33,12 2,91 0,77 3,79 0,000149134 1,0063E-02 
Cox6c 897,89 1,52 0,40 3,79 0,000151756 1,0144E-02 
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Ube2t 1555,83 2,48 0,65 3,79 0,000152405 1,0144E-02 
Gm1673 44,37 1,89 0,50 3,78 0,000155198 1,0224E-02 
Mlip 22,57 1,92 0,51 3,77 0,000163854 1,0478E-02 
Plac8 3362,55 1,14 0,30 3,76 0,000172376 1,0797E-02 
Gm20741 24,92 2,08 0,55 3,76 0,000172042 1,0797E-02 
Ostc 527,07 1,05 0,28 3,75 0,000178717 1,0929E-02 
Polr2i 498,86 1,85 0,49 3,75 0,000177856 1,0929E-02 
Igflr1 15,80 2,41 0,65 3,74 0,000182496 1,1090E-02 
Tnni3 31,19 2,76 0,74 3,74 0,000185142 1,1182E-02 
Ubl5 4029,76 1,25 0,33 3,74 0,000186715 1,1207E-02 
Ndufaf2 1257,44 1,23 0,33 3,72 0,000197205 1,1379E-02 
A630095E13Rik 1038,29 1,38 0,37 3,72 0,000195817 1,1379E-02 
Atox1 277,87 1,68 0,45 3,72 0,000195319 1,1379E-02 
Rps28 48,93 1,74 0,47 3,72 0,000197361 1,1379E-02 
Srp19 1238,13 0,99 0,27 3,72 0,000201892 1,1514E-02 
Nmt1 442,26 1,36 0,37 3,71 0,00020425 1,1514E-02 
Glrx5 777,77 2,03 0,55 3,71 0,00020353 1,1514E-02 
Dera 53,06 2,08 0,56 3,71 0,000206985 1,1553E-02 
Rps27l 8076,57 1,34 0,36 3,70 0,000217925 1,2046E-02 
B2m 294,92 1,29 0,35 3,69 0,000226582 1,2307E-02 
Creb1 22,73 1,60 0,43 3,68 0,000231453 1,2307E-02 
Rpl32 256,45 1,85 0,50 3,68 0,000229222 1,2307E-02 
Rps24 112,43 1,94 0,53 3,68 0,000230655 1,2307E-02 
R3hdml 84,71 2,04 0,55 3,69 0,000228087 1,2307E-02 
Eny2 15328,76 1,31 0,35 3,68 0,000233339 1,2340E-02 
Minos1 1379,51 1,19 0,32 3,67 0,000239092 1,2577E-02 
Haus1 124,61 2,02 0,55 3,67 0,000242681 1,2697E-02 
Sar1a 553,45 1,36 0,37 3,67 0,000247073 1,2813E-02 
Sub1 26404,62 1,38 0,38 3,66 0,000250268 1,2813E-02 
Dad1 648,64 1,69 0,46 3,66 0,000255608 1,2813E-02 
Mnd1 135,96 2,01 0,55 3,66 0,000247694 1,2813E-02 
Szrd1 100,06 2,37 0,65 3,65 0,000258216 1,2824E-02 
Hscb 669,46 1,21 0,33 3,65 0,000265727 1,3131E-02 
5730522E02Rik 14,59 1,72 0,47 3,64 0,000270349 1,3225E-02 
A630077J23Rik 12,65 2,93 0,81 3,64 0,000277045 1,3419E-02 
Dll3 151,66 1,27 0,35 3,63 0,000278575 1,3427E-02 
Spata24 23,38 2,54 0,70 3,63 0,000280579 1,3457E-02 
1300002E11Rik 325,39 1,90 0,52 3,63 0,000285209 1,3612E-02 
Banf1 1631,96 1,13 0,31 3,63 0,000288303 1,3693E-02 
Rbm8a 303,76 1,92 0,53 3,62 0,000294693 1,3862E-02 
Gstk1 41,03 2,53 0,70 3,62 0,000293429 1,3862E-02 
Krt12 606,51 1,32 0,37 3,62 0,000297275 1,3916E-02 
Setd4 1032,45 1,94 0,54 3,62 0,000298692 1,3916E-02 
Mrpl34 274,28 1,67 0,46 3,61 0,000302187 1,4012E-02 
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Sp3os 76,91 1,48 0,41 3,61 0,000311953 1,4206E-02 
Mtus2 1797,42 1,56 0,43 3,60 0,000317976 1,4206E-02 
Rps14 373,91 1,57 0,44 3,60 0,000313874 1,4206E-02 
Cops5 327,67 1,57 0,44 3,60 0,000317231 1,4206E-02 
Gc 23,90 2,03 0,56 3,61 0,000311027 1,4206E-02 
Lage3 91,15 2,19 0,61 3,60 0,000313626 1,4206E-02 
Uqcrh 914,68 1,88 0,52 3,59 0,000329647 1,4483E-02 
Krtcap2 54,40 2,04 0,57 3,59 0,000330805 1,4483E-02 
Spcs3 19,25 2,56 0,71 3,59 0,000331582 1,4483E-02 
Mrpl57 395,81 1,45 0,41 3,58 0,000340848 1,4627E-02 
Uqcr10 306,80 2,00 0,56 3,59 0,000336885 1,4627E-02 
Atpif1 405,53 2,41 0,67 3,58 0,000339939 1,4627E-02 
Gm973 141,07 1,49 0,42 3,58 0,000346559 1,4799E-02 
Rps10 82,16 1,86 0,52 3,58 0,000347895 1,4799E-02 
Lamtor5 492,81 1,98 0,55 3,58 0,000349652 1,4810E-02 
Mrps21 289,90 1,60 0,45 3,57 0,000356668 1,4977E-02 
Pam16 536,26 1,60 0,45 3,57 0,000361985 1,5135E-02 
Cdk15 252,23 1,33 0,37 3,56 0,000369453 1,5320E-02 
Rpl35a 67,04 2,34 0,66 3,56 0,000369535 1,5320E-02 
Mrpl20 33,34 1,79 0,50 3,56 0,000377726 1,5564E-02 
Pafah1b3 82,27 2,15 0,61 3,55 0,000389156 1,5931E-02 
Prdx4 11,69 2,68 0,76 3,54 0,000394507 1,6083E-02 
C87198 171,66 1,06 0,30 3,54 0,000398438 1,6109E-02 
Ddit3 81,93 2,27 0,64 3,54 0,000397657 1,6109E-02 
Timm8a2 316,55 0,92 0,26 3,54 0,000403421 1,6243E-02 
BC068281 43,51 1,42 0,40 3,53 0,000409947 1,6438E-02 
Med6 680,17 1,46 0,41 3,53 0,000412853 1,6487E-02 
Eif3k 512,31 1,85 0,53 3,52 0,000432532 1,7133E-02 
Romo1 1722,57 1,22 0,35 3,51 0,000450378 1,7480E-02 
Mrps16 275,03 1,25 0,36 3,51 0,000453794 1,7480E-02 
Cetn2 398,01 1,87 0,53 3,51 0,000450837 1,7480E-02 
Sec11c 355,78 2,07 0,59 3,51 0,00044694 1,7480E-02 
Fcgbp 97,41 2,19 0,62 3,51 0,000450356 1,7480E-02 
Nsa2 390,44 0,76 0,22 3,50 0,000461712 1,7551E-02 
Ndufa6 352,90 1,70 0,49 3,50 0,000469227 1,7657E-02 
Mrpl42 343,00 1,63 0,47 3,50 0,000472587 1,7716E-02 
Mettl18 31,57 2,08 0,59 3,49 0,000482586 1,7817E-02 
Prcp 27,83 2,10 0,60 3,49 0,000481898 1,7817E-02 
Ms4a6d 175,19 2,17 0,62 3,49 0,000484734 1,7829E-02 
Idnk 43,72 2,09 0,60 3,49 0,000490135 1,7961E-02 
Rrh 80,39 1,63 0,47 3,48 0,000502449 1,8286E-02 
Emc6 530,20 1,62 0,47 3,48 0,000505504 1,8291E-02 
Pgbd5 21,90 1,96 0,56 3,48 0,000506621 1,8291E-02 
Oosp2 1827,64 1,56 0,45 3,47 0,000516917 1,8594E-02 
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Rgs10 406,49 1,54 0,45 3,47 0,000529144 1,8910E-02 
Rapsn 33,06 1,98 0,57 3,47 0,000529586 1,8910E-02 
Med21 2229,21 0,99 0,29 3,46 0,000537801 1,8986E-02 
Map3k6 1404,52 1,64 0,48 3,46 0,000541403 1,8986E-02 
Tmem251 214,69 2,03 0,59 3,46 0,000540617 1,8986E-02 
Malsu1 52,79 2,43 0,70 3,46 0,000535894 1,8986E-02 
Lbp 40,02 1,58 0,46 3,46 0,000548507 1,9166E-02 
Stra13 1524,51 1,16 0,33 3,45 0,000550861 1,9180E-02 
Psma6 556,45 1,79 0,52 3,45 0,000560992 1,9464E-02 
Ppil6 57,80 1,20 0,35 3,45 0,00056601 1,9549E-02 
2310036O22Rik 218,53 1,59 0,46 3,45 0,000567456 1,9549E-02 
Mrps14 3023,28 1,12 0,32 3,45 0,000570438 1,9583E-02 
Rpl36a 47,88 2,39 0,69 3,44 0,000573894 1,9633E-02 
Lsm8 199,11 1,03 0,30 3,44 0,000585651 1,9767E-02 
Tma16 233,24 1,07 0,31 3,44 0,000587011 1,9767E-02 
Rpp21 308,27 1,75 0,51 3,44 0,000581811 1,9767E-02 
Hspe1 653,69 1,12 0,33 3,43 0,000594582 1,9855E-02 
Fabp5 1624,95 1,24 0,36 3,43 0,000594073 1,9855E-02 
Rps20 45,85 2,41 0,70 3,42 0,000629462 2,0806E-02 
Sfta2 65,91 2,02 0,59 3,41 0,000638226 2,1025E-02 
Snrpg 2454,04 1,28 0,38 3,41 0,000647563 2,1194E-02 
Mrpl1 150,66 1,70 0,50 3,41 0,00064769 2,1194E-02 
Synj2bp 176,74 0,89 0,26 3,41 0,000654672 2,1260E-02 
Klhl14 105,03 1,19 0,35 3,40 0,000675176 2,1643E-02 
Atp5k 231,75 1,85 0,54 3,40 0,000681328 2,1643E-02 
Cdc123 347,54 1,29 0,38 3,39 0,000692222 2,1684E-02 
Manf 354,80 2,14 0,63 3,39 0,000689157 2,1684E-02 
Ppih 854,06 0,87 0,26 3,39 0,000702391 2,1747E-02 
Skp1a 11201,91 1,44 0,42 3,38 0,000716112 2,2033E-02 
Smim11 3869,91 1,19 0,35 3,38 0,000730477 2,2132E-02 
Batf3 57,33 1,77 0,52 3,38 0,000731919 2,2132E-02 
LOC101056136 18,10 1,80 0,53 3,38 0,000724516 2,2132E-02 
Coq4 15,48 2,51 0,74 3,38 0,000732915 2,2132E-02 
Snrpf 2081,33 1,12 0,33 3,38 0,000736018 2,2141E-02 
Pgm3 41,59 1,53 0,45 3,37 0,000740101 2,2144E-02 
Tmem258 488,09 1,36 0,40 3,37 0,000745918 2,2250E-02 
Txndc9 1622,69 1,90 0,57 3,36 0,000789069 2,3324E-02 
Gm9999 20,53 2,33 0,70 3,35 0,000793896 2,3329E-02 
Ptrhd1 171,08 1,62 0,48 3,35 0,000818688 2,3911E-02 
Gm2382 658,93 1,08 0,32 3,34 0,000831796 2,4073E-02 
C130060K24Rik 150,98 1,54 0,46 3,34 0,000842915 2,4073E-02 
2410021H03Rik 197,77 1,61 0,48 3,34 0,000835471 2,4073E-02 
2210011C24Rik 15,07 1,90 0,57 3,34 0,00084395 2,4073E-02 
Acn9 62,27 1,99 0,59 3,34 0,000828097 2,4073E-02 
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Haus7 78,28 2,24 0,67 3,34 0,000842852 2,4073E-02 
H3f3a 419,54 1,52 0,45 3,33 0,000856307 2,4150E-02 
2610203C22Rik 20,73 2,00 0,60 3,33 0,000856508 2,4150E-02 
Gabarapl2 168,49 0,81 0,24 3,33 0,000878363 2,4695E-02 
Rps21 81,73 1,83 0,55 3,33 0,00088239 2,4737E-02 
Asf1a 13914,50 0,95 0,29 3,31 0,000925428 2,5114E-02 
Atp5c1 1002,21 0,97 0,29 3,32 0,000916085 2,5114E-02 
Erh 768,45 1,01 0,30 3,32 0,000911741 2,5114E-02 
Snrpe 5732,10 1,08 0,33 3,31 0,00091999 2,5114E-02 
Gas5 194,47 1,13 0,34 3,31 0,000922656 2,5114E-02 
Npm2 5330,73 1,18 0,36 3,31 0,000930828 2,5114E-02 
Rgsl1 49,55 1,47 0,44 3,31 0,000919476 2,5114E-02 
Tyw5 253,65 0,83 0,25 3,30 0,00095319 2,5574E-02 
Nme1 95,16 1,63 0,49 3,30 0,000954053 2,5574E-02 
Sesn3 66,60 1,26 0,38 3,30 0,000963625 2,5690E-02 
Pdrg1 794,77 1,40 0,42 3,30 0,000963189 2,5690E-02 
Pdcd5 402,88 1,79 0,54 3,30 0,000968389 2,5747E-02 
Eif1ax 711,57 2,14 0,65 3,30 0,000976209 2,5884E-02 
Gas8 27,64 2,21 0,67 3,29 0,001002235 2,6431E-02 
Miox 1375,43 1,45 0,44 3,29 0,001013329 2,6592E-02 
Shfm1 485,51 1,71 0,52 3,29 0,001014834 2,6592E-02 
Ndufa12 52,70 2,33 0,71 3,29 0,001016507 2,6592E-02 
4921524J17Rik 3165,70 0,91 0,28 3,28 0,001046733 2,6601E-02 
Cetn3 1950,87 0,96 0,29 3,27 0,001056784 2,6601E-02 
Rpp30 173,94 1,03 0,32 3,27 0,001057618 2,6601E-02 
2810403D21Rik 372,05 1,09 0,33 3,28 0,001051382 2,6601E-02 
Dctn3 383,67 1,10 0,34 3,28 0,0010272 2,6601E-02 
Mrps24 155,22 1,89 0,58 3,28 0,001029905 2,6601E-02 
Ssr2 54,34 2,02 0,62 3,28 0,001049149 2,6601E-02 
Ccdc124 57,26 2,03 0,62 3,28 0,001022516 2,6601E-02 
Etfb 62,82 2,18 0,66 3,28 0,001025715 2,6601E-02 
Ndufa13 255,51 1,28 0,39 3,27 0,00106571 2,6736E-02 
Sptlc2 415,79 1,16 0,36 3,27 0,001078066 2,6976E-02 
B4galt4 684,43 1,48 0,45 3,27 0,001081028 2,6982E-02 
Trappc1 836,47 1,10 0,34 3,27 0,001085802 2,7032E-02 
Slc9a3r2 30,59 2,01 0,61 3,26 0,001098683 2,7214E-02 
Cyb5 575,26 2,23 0,68 3,26 0,00110273 2,7245E-02 
Gng5 1035,37 1,06 0,33 3,26 0,001113025 2,7361E-02 
Psma4 703,66 0,99 0,31 3,25 0,001151754 2,8172E-02 
Cnpy2 38,14 2,46 0,76 3,24 0,00117932 2,8631E-02 
Gfra4 130,41 1,65 0,51 3,24 0,00119436 2,8925E-02 
Ndufb6 1326,59 1,37 0,42 3,24 0,001200374 2,8999E-02 
Trappc6a 121,69 1,38 0,43 3,23 0,001227269 2,9358E-02 
Pfdn1 612,37 1,25 0,39 3,23 0,001242633 2,9653E-02 
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Rpf2 94,35 2,02 0,63 3,23 0,001247419 2,9669E-02 
Sdhb 164,64 1,85 0,57 3,22 0,00126678 2,9938E-02 
Prorsd1 68,47 1,07 0,33 3,22 0,001285952 2,9962E-02 
2010012O05Rik 82,76 1,14 0,35 3,22 0,001286174 2,9962E-02 
Gstm5 1694,89 1,54 0,48 3,22 0,00128385 2,9962E-02 
Rps12 61,39 1,73 0,54 3,22 0,001283822 2,9962E-02 
Ost4 107,02 2,08 0,65 3,22 0,001298387 3,0103E-02 
Zp4-ps 26,90 1,77 0,55 3,22 0,001303682 3,0154E-02 
Ppap2a 1241,84 1,06 0,33 3,21 0,001315492 3,0284E-02 
Polr1d 404,00 1,44 0,45 3,21 0,001313507 3,0284E-02 
Mrpl54 78,73 1,82 0,57 3,21 0,001340578 3,0503E-02 
Zcchc9 241,73 1,03 0,32 3,20 0,001364169 3,0683E-02 
3110045C21Rik 64,90 1,71 0,54 3,20 0,00135706 3,0683E-02 
Itgb3bp 21,51 2,14 0,67 3,20 0,001358521 3,0683E-02 
Ifitm3 1605,38 1,03 0,32 3,20 0,001377135 3,0814E-02 
Crcp 33,96 1,90 0,59 3,20 0,001379462 3,0814E-02 
Cisd1 548,82 1,91 0,60 3,20 0,001378966 3,0814E-02 
Mif 89,21 1,92 0,60 3,20 0,001387321 3,0919E-02 
Men1 16,00 2,19 0,69 3,19 0,001416054 3,1484E-02 
Rab3b 435,32 2,04 0,64 3,19 0,001422732 3,1493E-02 
Rasl2-9 47,34 1,69 0,53 3,18 0,001460036 3,1744E-02 
2610034M16Rik 462,21 1,58 0,50 3,18 0,001489282 3,2237E-02 
Mrpl32 929,31 1,23 0,39 3,18 0,001496062 3,2312E-02 
B230118H07Rik 132,13 1,40 0,44 3,17 0,001521144 3,2354E-02 
4933408N05Rik 178,40 1,48 0,47 3,17 0,001510682 3,2354E-02 
Acyp1 24,83 2,27 0,72 3,17 0,001519778 3,2354E-02 
Rin3 560,02 0,98 0,31 3,17 0,001535944 3,2598E-02 
Defb50 16,04 2,08 0,66 3,17 0,001540232 3,2618E-02 
Ift52 73,56 1,36 0,43 3,15 0,001607711 3,3828E-02 
Gm5083 107,80 1,11 0,35 3,15 0,001613947 3,3843E-02 
Ccl25 19,00 2,25 0,71 3,15 0,001618841 3,3843E-02 
Hmga2-ps1 39,73 1,83 0,58 3,15 0,001644244 3,4228E-02 
Ccdc38 1671,50 0,96 0,31 3,14 0,001665744 3,4428E-02 
Capns1 23,66 2,23 0,71 3,14 0,001667934 3,4428E-02 
Tcstv3 107,62 1,53 0,49 3,14 0,001677508 3,4481E-02 
Slco1a5 57,56 1,56 0,50 3,14 0,001675079 3,4481E-02 
Fen1 15,96 2,37 0,76 3,14 0,001707445 3,4949E-02 
Psma3 263,52 1,55 0,49 3,14 0,001717317 3,5038E-02 
Il10rb 64,75 1,90 0,61 3,13 0,001726097 3,5038E-02 
Prim1 113,54 1,75 0,56 3,13 0,001733594 3,5117E-02 
Trappc6b 314,95 1,27 0,41 3,12 0,001794122 3,5881E-02 
Cmc1 758,32 1,28 0,41 3,12 0,001781472 3,5881E-02 
Mocs2 319,72 1,55 0,50 3,12 0,001786591 3,5881E-02 
Wfdc15a 49,10 1,58 0,51 3,12 0,001796988 3,5881E-02 
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Mrpl15 61,53 1,69 0,54 3,12 0,00179596 3,5881E-02 
Pfdn4 9379,32 0,96 0,31 3,12 0,001809385 3,5942E-02 
Mrps17 362,33 1,63 0,52 3,12 0,001808222 3,5942E-02 
Cenpp 270,05 1,18 0,38 3,12 0,001820607 3,5986E-02 
Med31 3707,32 0,92 0,30 3,11 0,001848973 3,6181E-02 
Gm19299 861,29 0,99 0,32 3,12 0,001839431 3,6181E-02 
Ccnb1ip1 50,77 1,98 0,63 3,11 0,001842826 3,6181E-02 
Tekt4 131,49 2,01 0,64 3,11 0,001845401 3,6181E-02 
Pxmp2 162,45 1,28 0,41 3,11 0,001854747 3,6221E-02 
Cir1 680,57 0,91 0,29 3,11 0,001872606 3,6301E-02 
E330011O21Rik 1676,71 1,03 0,33 3,11 0,001868629 3,6301E-02 
Calm1 30078,35 1,08 0,35 3,11 0,001863023 3,6301E-02 
Naip1 77,69 2,01 0,65 3,11 0,001873646 3,6301E-02 
Tceb2 44,94 2,21 0,71 3,11 0,001879511 3,6342E-02 
Ndufb2 818,63 1,40 0,45 3,11 0,001887139 3,6368E-02 
Tmem29 335,80 1,94 0,62 3,10 0,001908846 3,6477E-02 
4930500J02Rik 401,12 0,95 0,30 3,10 0,001920182 3,6622E-02 
Sdhaf2 124,68 1,65 0,53 3,10 0,001932012 3,6747E-02 
Tctex1d2 68,14 1,67 0,54 3,10 0,001935692 3,6747E-02 
4933407G14Rik 35,61 1,27 0,41 3,10 0,001944772 3,6804E-02 
Srek1ip1 2266,39 1,22 0,40 3,09 0,001975366 3,7188E-02 
Hspb11 92,96 1,64 0,53 3,09 0,001973514 3,7188E-02 
Snupn 268,00 1,79 0,58 3,09 0,001976493 3,7188E-02 
4930524B15Rik 418,49 1,10 0,36 3,09 0,002034721 3,7704E-02 
Gnb5 72,30 1,27 0,41 3,09 0,002027297 3,7704E-02 
4930404A10Rik 41,87 1,90 0,62 3,09 0,002022528 3,7704E-02 
Mrpl18 1881,07 0,88 0,29 3,08 0,00205703 3,8045E-02 
Tusc2 29,37 1,98 0,64 3,08 0,002087594 3,8465E-02 
N4bp2l2 1307,45 0,76 0,25 3,08 0,002101047 3,8640E-02 
Lamtor1 270,36 1,48 0,48 3,07 0,002113732 3,8801E-02 
Mtcp1 1367,15 0,94 0,31 3,07 0,002149101 3,9286E-02 
Atraid 133,38 1,49 0,48 3,07 0,002152208 3,9286E-02 
1110008L16Rik 90,07 1,57 0,51 3,07 0,002166308 3,9470E-02 
Son 3553,26 1,06 0,35 3,06 0,002203097 3,9760E-02 
Hpd 19,47 2,10 0,69 3,06 0,002203045 3,9760E-02 
Gm11548 69,69 0,99 0,32 3,06 0,002212551 3,9793E-02 
Gpx1 398,84 1,05 0,35 3,04 0,002344349 4,1933E-02 
1700048M11Rik 28,53 1,25 0,41 3,04 0,002372207 4,1977E-02 
Apoo 205,89 1,39 0,46 3,04 0,002376379 4,1977E-02 
Nudt2 91,32 1,69 0,55 3,04 0,002352986 4,1977E-02 
Otub2 137,96 1,73 0,57 3,04 0,002376883 4,1977E-02 
Flad1 116,04 1,69 0,56 3,04 0,002390063 4,2058E-02 
2410004B18Rik 460,54 0,80 0,26 3,04 0,002400913 4,2173E-02 
Mlf1 197,97 0,93 0,31 3,03 0,002456502 4,2919E-02 
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Rora 1717,96 0,78 0,26 3,03 0,002462098 4,2940E-02 
Rnasek 209,74 1,69 0,56 3,03 0,002470352 4,3007E-02 
Fmnl3 110,83 1,50 0,50 3,03 0,00247787 4,3056E-02 
Pyurf 126,85 2,01 0,66 3,03 0,002481964 4,3056E-02 
Apip 1024,00 0,90 0,30 3,02 0,002500376 4,3146E-02 
Gstm6 20,88 2,08 0,69 3,02 0,00249424 4,3146E-02 
1810037I17Rik 2158,37 1,28 0,43 3,02 0,002536162 4,3610E-02 
Med28 5017,95 1,24 0,41 3,01 0,002577297 4,4027E-02 
Gskip 45,98 1,30 0,43 3,01 0,002578426 4,4027E-02 
Epc1 565,41 0,66 0,22 3,01 0,002618453 4,4247E-02 
Zfand6 2651,89 0,71 0,24 3,01 0,002612777 4,4247E-02 
Rpl39l 389,99 1,53 0,51 3,01 0,00261603 4,4247E-02 
Larp1b 19,53 1,68 0,56 3,01 0,002600825 4,4247E-02 
Rps4l 111,86 1,76 0,59 3,01 0,002603152 4,4247E-02 
Omt2a 53052,73 1,09 0,36 3,01 0,0026289 4,4347E-02 
Amz2 135,26 1,47 0,49 3,01 0,002645657 4,4426E-02 
2310009A05Rik 13,75 1,83 0,61 3,01 0,002654545 4,4426E-02 
Lemd1 11,38 2,41 0,80 3,00 0,002656302 4,4426E-02 
Sar1b 755,32 1,18 0,39 3,00 0,002673021 4,4620E-02 
AI463170 54,89 1,72 0,57 3,00 0,002677004 4,4620E-02 
Ccdc104 330,83 0,81 0,27 3,00 0,002699634 4,4920E-02 
Vdac2 487,80 1,01 0,34 3,00 0,002735081 4,5022E-02 
Polr2g 4239,98 1,07 0,36 3,00 0,002728419 4,5022E-02 
2210013O21Rik 148,49 1,18 0,39 3,00 0,002738123 4,5022E-02 
Mrps28 178,00 1,51 0,51 3,00 0,002739091 4,5022E-02 
Lsm6 325,98 1,81 0,60 3,00 0,002717718 4,5022E-02 
Dynlt1b 41,17 2,01 0,67 3,00 0,002725584 4,5022E-02 
Chst7 621,19 1,28 0,43 2,99 0,002762337 4,5109E-02 
Pdlim2 75,47 1,91 0,64 2,99 0,002779687 4,5109E-02 
Sec61b 1487,20 0,86 0,29 2,99 0,002823375 4,5617E-02 
Timm17b 68,22 1,61 0,54 2,99 0,002825395 4,5617E-02 
Commd1 550,38 1,50 0,50 2,99 0,002831866 4,5646E-02 
Dnajc19 388,20 0,99 0,33 2,98 0,002860663 4,5958E-02 
Nhp2l1 730,06 0,99 0,33 2,98 0,002856346 4,5958E-02 
2810408I11Rik 3486,52 1,08 0,36 2,98 0,002871977 4,6065E-02 
Magoh 8666,62 1,03 0,35 2,98 0,002894444 4,6349E-02 
Esrra 151,78 1,17 0,39 2,97 0,002954515 4,6499E-02 
Gm3219 50,08 1,24 0,42 2,97 0,002947936 4,6499E-02 
Cenpq 916,30 1,27 0,43 2,97 0,002959638 4,6499E-02 
Sptssb 128,38 1,49 0,50 2,97 0,002945271 4,6499E-02 
Tnrc6b 1468,70 0,94 0,32 2,97 0,002993265 4,6779E-02 
Macrod2 1763,44 0,96 0,32 2,97 0,003006464 4,6779E-02 
Tmc5 86,03 1,29 0,43 2,97 0,003007363 4,6779E-02 
Pdcl3 620,00 1,38 0,46 2,97 0,002991137 4,6779E-02 
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1600002D24Rik 154,36 1,72 0,58 2,97 0,003021429 4,6919E-02 
Cand2 58,08 1,66 0,56 2,96 0,003038838 4,7044E-02 
Ruvbl1 278,74 1,10 0,37 2,96 0,003048979 4,7052E-02 
Nrn1l 708,58 1,21 0,41 2,96 0,003066445 4,7247E-02 
Commd6 565,27 0,94 0,32 2,96 0,003075291 4,7309E-02 
6430710C18Rik 1123,24 1,09 0,37 2,96 0,003109498 4,7748E-02 
Snhg6 19,26 1,57 0,53 2,96 0,003125439 4,7748E-02 
Il2ra 16,85 1,65 0,56 2,95 0,003128221 4,7748E-02 
Sfr1 8582,03 0,75 0,25 2,95 0,003146771 4,7955E-02 
Tex26 416,01 1,41 0,48 2,95 0,00317435 4,8033E-02 
Gm19705 22,79 1,77 0,60 2,94 0,003247447 4,8806E-02 
Kera 185,58 1,15 0,39 2,94 0,003322267 4,9442E-02 
Cd96 31,21 2,08 0,71 2,94 0,003325132 4,9442E-02 
Txndc17 374,76 0,89 0,30 2,94 0,003330471 4,9447E-02 
Auh 3497,71 0,69 0,24 2,93 0,003350538 4,9594E-02 
Gtf2a2 5059,77 0,96 0,33 2,93 0,003365772 4,9669E-02 
Ptplad2 174,67 1,22 0,42 2,93 0,003362722 4,9669E-02 
 
Downregulated genes 
      
Gene baseMean log2Fold 
Change 
lfcSE stat p-value p-adj 
Plcl1 25,73 -4,36 0,76 -5,75 9,16E-09 8,96E-05 
Ung 521,53 -1,85 0,34 -5,41 6,19E-08 3,03E-04 
Prps2 73,38 -3,31 0,69 -4,79 1,63E-06 9,40E-04 
4930512B01Rik 48,53 -2,31 0,49 -4,68 2,93E-06 1,40E-03 
Sh2d3c 619,50 -1,95 0,42 -4,66 3,16E-06 1,40E-03 
E2f4 1960,77 -1,44 0,32 -4,48 7,56E-06 2,39E-03 
Trim75 3780,23 -1,72 0,40 -4,35 1,37E-05 3,08E-03 
Ube2s 734,60 -1,10 0,25 -4,34 1,42E-05 3,08E-03 
Naa40 1172,22 -1,36 0,32 -4,28 1,91E-05 3,60E-03 
Pla2g15 264,54 -1,32 0,31 -4,24 2,21E-05 3,73E-03 
Myt1 183,74 -1,11 0,26 -4,20 2,64E-05 4,10E-03 
Gm15787 40,78 -1,66 0,40 -4,18 2,93E-05 4,21E-03 
Pkmyt1 453,81 -0,94 0,23 -4,16 3,14E-05 4,39E-03 
Tbc1d10a 153,28 -1,02 0,25 -4,15 3,26E-05 4,49E-03 
Wasf1 239,80 -1,19 0,29 -4,10 4,08E-05 5,09E-03 
Snx9 1506,12 -1,38 0,34 -4,04 5,42E-05 5,76E-03 
Srebf2 30,11 -2,04 0,51 -4,02 5,84E-05 5,89E-03 
Ncoa4 991,96 -1,55 0,39 -3,96 7,38E-05 6,81E-03 
Sh3bgrl2 586,28 -1,54 0,39 -3,96 7,64E-05 6,83E-03 
Patz1 278,52 -1,49 0,38 -3,95 7,75E-05 6,83E-03 
Zbtb24 223,82 -1,38 0,35 -3,94 8,27E-05 7,23E-03 
Gpr3 532,01 -1,31 0,33 -3,93 8,50E-05 7,36E-03 
Cstf1 402,83 -1,50 0,39 -3,88 0,000103313 8,13E-03 
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Traf4 650,91 -1,11 0,29 -3,88 0,000103817 8,13E-03 
Actn4 611,55 -1,42 0,37 -3,86 0,000115098 8,48E-03 
Kat7 1234,67 -1,31 0,34 -3,85 0,000119321 8,58E-03 
Api5 1114,30 -1,56 0,41 -3,84 0,000121972 8,65E-03 
Nedd1 3047,63 -1,36 0,36 -3,82 0,000134658 9,34E-03 
Arrdc2 1679,09 -1,24 0,32 -3,81 0,000139975 9,58E-03 
Scml2 1126,63 -1,36 0,36 -3,78 0,000155703 1,02E-02 
Kif20a 1760,49 -1,28 0,34 -3,78 0,000157253 1,03E-02 
Trafd1 622,92 -1,27 0,34 -3,77 0,000160571 1,04E-02 
Lypd3 63,59 -2,43 0,64 -3,77 0,000162238 1,04E-02 
Hace1 202,14 -1,40 0,37 -3,76 0,000169584 1,08E-02 
Smad5 104,91 -1,16 0,31 -3,76 0,000173251 1,08E-02 
Wdr1 983,83 -1,24 0,33 -3,75 0,00017853 1,09E-02 
Klhl24 117,26 -1,44 0,38 -3,73 0,000189262 1,13E-02 
Dtx2 1727,09 -1,63 0,44 -3,73 0,000192122 1,14E-02 
Tex19.1 1309,80 -1,38 0,37 -3,72 0,000197713 1,14E-02 
Fa2h 437,17 -1,53 0,41 -3,71 0,000204767 1,15E-02 
Abcf2 1365,83 -1,14 0,31 -3,71 0,000207822 1,16E-02 
Elmo1 22,82 -2,18 0,59 -3,69 0,000223543 1,23E-02 
Nupl1 343,14 -1,42 0,38 -3,69 0,000225749 1,23E-02 
Mynn 1185,69 -1,37 0,37 -3,66 0,000256687 1,28E-02 
Nlrp9a 5597,04 -1,34 0,37 -3,66 0,000254641 1,28E-02 
Rnf14 3798,00 -1,19 0,33 -3,66 0,000254844 1,28E-02 
Fpgs 2684,81 -1,12 0,31 -3,66 0,000252966 1,28E-02 
Dab2 572,15 -1,03 0,28 -3,66 0,000249954 1,28E-02 
Dlg1 437,02 -1,11 0,30 -3,64 0,000269487 1,32E-02 
Ube3c 342,11 -1,12 0,31 -3,64 0,000272783 1,33E-02 
Ttc17 168,12 -1,51 0,42 -3,61 0,000304022 1,40E-02 
Ppp2r1b 275,70 -1,34 0,37 -3,60 0,000316596 1,42E-02 
A230046K03Rik 163,78 -1,48 0,41 -3,60 0,000321447 1,43E-02 
Nlrp4b 3435,08 -1,03 0,29 -3,59 0,000329713 1,45E-02 
Klhl13 509,77 -1,09 0,30 -3,58 0,000340663 1,46E-02 
Raf1 3931,52 -1,34 0,38 -3,57 0,000354732 1,50E-02 
Far1 1031,92 -1,24 0,35 -3,55 0,000378602 1,56E-02 
Abhd4 2013,78 -1,20 0,34 -3,53 0,000417779 1,66E-02 
Tpst2 29,28 -1,65 0,47 -3,52 0,000439479 1,73E-02 
Cdt1 574,25 -0,90 0,26 -3,51 0,000452622 1,75E-02 
Slc25a40 155,07 -1,09 0,31 -3,51 0,000455967 1,75E-02 
Phf1 1525,46 -1,01 0,29 -3,50 0,000459147 1,75E-02 
Ptprr 1713,93 -0,85 0,24 -3,50 0,000462814 1,76E-02 
Ect2 1483,72 -1,29 0,37 -3,50 0,000465384 1,76E-02 
BC005764 62,19 -1,81 0,52 -3,49 0,000474748 1,77E-02 
Pygo2 68,84 -1,64 0,47 -3,49 0,00048143 1,78E-02 
Champ1 744,95 -1,03 0,30 -3,48 0,000502739 1,83E-02 
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Zfp964 72,76 -1,43 0,41 -3,46 0,000537801 1,90E-02 
Nup107 1113,38 -1,21 0,35 -3,44 0,000587915 1,98E-02 
Itsn2 2745,66 -1,03 0,30 -3,44 0,00058554 1,98E-02 
Itgb1 256,08 -1,05 0,31 -3,43 0,000605167 2,01E-02 
Rbm38 1690,57 -1,21 0,35 -3,42 0,000620218 2,06E-02 
Fstl5 705,58 -1,66 0,49 -3,41 0,000658413 2,13E-02 
Piga 790,45 -1,25 0,37 -3,41 0,000656997 2,13E-02 
Plekhg1 631,89 -0,87 0,26 -3,41 0,000657844 2,13E-02 
Mcm4 1620,92 -1,46 0,43 -3,40 0,000681124 2,16E-02 
Cdc42se2 14528,54 -1,25 0,37 -3,40 0,000674108 2,16E-02 
Rnf185 3877,49 -1,12 0,33 -3,40 0,000677439 2,16E-02 
Zfp735 2262,21 -1,35 0,40 -3,40 0,000683912 2,17E-02 
Reep1 71,45 -2,17 0,64 -3,39 0,000694299 2,17E-02 
Exoc2 30,73 -1,99 0,59 -3,39 0,000695922 2,17E-02 
Ints4 306,19 -1,20 0,35 -3,39 0,000692966 2,17E-02 
Tada3 266,19 -0,96 0,28 -3,39 0,000702287 2,17E-02 
Cse1l 177,95 -1,42 0,42 -3,39 0,000710272 2,19E-02 
Stk38 731,79 -1,14 0,34 -3,38 0,000720913 2,21E-02 
Aqp9 478,79 -1,16 0,34 -3,38 0,000730275 2,21E-02 
Hsf1 1171,76 -1,25 0,37 -3,38 0,000737744 2,21E-02 
Inpp5e 32,70 -1,61 0,48 -3,36 0,000775344 2,30E-02 
Zbtb33 227,55 -1,07 0,32 -3,36 0,000776722 2,30E-02 
Lrrc8b 664,57 -1,36 0,41 -3,35 0,000794006 2,33E-02 
Parp12 9336,38 -1,05 0,32 -3,35 0,000818624 2,39E-02 
Trove2 39,66 -1,37 0,41 -3,34 0,000838452 2,41E-02 
Gtpbp10 300,82 -1,10 0,33 -3,34 0,000840271 2,41E-02 
Lamp2 153,66 -1,70 0,51 -3,33 0,000856003 2,42E-02 
Khdrbs1 112,58 -1,10 0,33 -3,34 0,000852733 2,42E-02 
Thsd7b 67,54 -1,66 0,50 -3,32 0,000885688 2,48E-02 
Pde3a 85,60 -1,42 0,43 -3,32 0,000907898 2,51E-02 
Kbtbd8 6651,41 -1,39 0,42 -3,31 0,000923781 2,51E-02 
Zbtb41 288,38 -1,21 0,36 -3,32 0,000904017 2,51E-02 
Usp9x 1061,22 -1,13 0,34 -3,31 0,000931748 2,51E-02 
Taf6 822,91 -1,07 0,32 -3,31 0,000927886 2,51E-02 
Usp21 929,27 -0,96 0,29 -3,31 0,000919239 2,51E-02 
Myo5b 1783,97 -0,94 0,29 -3,29 0,000999441 2,64E-02 
Flcn 1147,44 -1,18 0,36 -3,28 0,001053742 2,66E-02 
Calu 481,44 -1,16 0,35 -3,28 0,001033395 2,66E-02 
Stat3 532,92 -1,12 0,34 -3,28 0,001049408 2,66E-02 
Rrm1 438,88 -1,10 0,34 -3,28 0,001037125 2,66E-02 
Klhl8 5063,03 -0,97 0,30 -3,28 0,001039889 2,66E-02 
Sytl4 2553,14 -0,88 0,27 -3,28 0,001033356 2,66E-02 
Add3 598,88 -1,36 0,42 -3,27 0,001088839 2,70E-02 
Gsk3a 131,43 -1,03 0,32 -3,26 0,001107366 2,73E-02 
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Ddi2 197,68 -1,75 0,54 -3,26 0,001130553 2,77E-02 
Aph1b 81,71 -1,62 0,50 -3,25 0,001155721 2,82E-02 
Dhx32 1242,19 -0,97 0,30 -3,25 0,001160514 2,82E-02 
Ctps 3639,78 -1,04 0,32 -3,24 0,001206032 2,91E-02 
Ptbp1 980,94 -1,13 0,35 -3,24 0,001209993 2,91E-02 
Scarb1 412,26 -0,88 0,27 -3,23 0,001225613 2,94E-02 
Bzw1 709,88 -0,98 0,30 -3,23 0,00124933 2,97E-02 
Hiatl1 640,92 -1,34 0,42 -3,23 0,001253281 2,97E-02 
Ttll5 184,86 -1,31 0,41 -3,22 0,001278767 3,00E-02 
Ctdspl2 818,96 -1,08 0,34 -3,22 0,001283162 3,00E-02 
Gas2l3 638,57 -1,13 0,35 -3,22 0,001291261 3,00E-02 
4833439L19Rik 241,78 -1,14 0,35 -3,21 0,001325711 3,04E-02 
Tfdp1 1083,88 -0,94 0,29 -3,21 0,001323916 3,04E-02 
Vps35 1914,87 -1,05 0,33 -3,21 0,001336318 3,05E-02 
Mcm7 707,74 -0,88 0,28 -3,21 0,001339819 3,05E-02 
Papss1 419,28 -1,01 0,31 -3,21 0,001348698 3,06E-02 
Smyd4 59,52 -1,27 0,40 -3,20 0,001362547 3,07E-02 
Zfp60 1708,07 -1,29 0,41 -3,19 0,001419092 3,15E-02 
Dmxl2 303,21 -0,99 0,31 -3,19 0,001426638 3,15E-02 
Polk 174,66 -1,47 0,46 -3,19 0,001441841 3,17E-02 
Gyk 1791,24 -1,01 0,32 -3,19 0,00144203 3,17E-02 
Ythdf3 2675,81 -1,08 0,34 -3,18 0,00145537 3,17E-02 
Tnpo1 812,48 -1,01 0,32 -3,18 0,001452305 3,17E-02 
Nlrp4a 6380,84 -1,00 0,31 -3,18 0,001459126 3,17E-02 
Haus5 349,23 -0,93 0,29 -3,18 0,001447985 3,17E-02 
Gjb2 29,57 -1,91 0,60 -3,18 0,001486013 3,22E-02 
Xpo6 269,33 -1,55 0,49 -3,17 0,001520387 3,24E-02 
Ipo11 41,77 -1,52 0,48 -3,17 0,001520976 3,24E-02 
Skp2 288,96 -1,29 0,41 -3,17 0,001503622 3,24E-02 
Fam126b 1177,49 -1,06 0,33 -3,17 0,001513271 3,24E-02 
Scyl2 1047,02 -1,12 0,35 -3,16 0,001554249 3,28E-02 
Pcid2 2357,34 -1,05 0,33 -3,16 0,001587903 3,35E-02 
Dis3l2 63,39 -1,06 0,34 -3,15 0,0016179 3,38E-02 
Pola2 446,68 -0,90 0,29 -3,15 0,001624541 3,39E-02 
Arhgap19 185,58 -1,28 0,41 -3,15 0,00165958 3,44E-02 
Fpgt 593,74 -1,12 0,36 -3,14 0,00166344 3,44E-02 
Inpp5a 247,15 -0,82 0,26 -3,14 0,001697761 3,48E-02 
Gm13242 58,49 -1,18 0,38 -3,13 0,001725077 3,50E-02 
Cul4b 2813,80 -0,82 0,26 -3,13 0,001722532 3,50E-02 
Fbxl5 3309,32 -1,10 0,35 -3,13 0,001759712 3,56E-02 
Cttnbp2 164,79 -1,11 0,35 -3,12 0,001791274 3,59E-02 
Cbl 35,55 -1,49 0,48 -3,12 0,001811039 3,59E-02 
Trim11 535,28 -0,98 0,31 -3,12 0,001819949 3,60E-02 
Zfp942 750,41 -1,23 0,40 -3,12 0,001837848 3,62E-02 
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Ndufs1 95,60 -1,18 0,38 -3,11 0,001888459 3,64E-02 
Med15 1310,53 -1,15 0,37 -3,11 0,001893707 3,64E-02 
Pacsin2 2047,06 -1,01 0,32 -3,11 0,001895726 3,64E-02 
Zfp235 194,25 -1,34 0,43 -3,10 0,001902825 3,64E-02 
Cdc23 785,07 -0,76 0,25 -3,10 0,001938032 3,67E-02 
Ust 120,66 -1,69 0,55 -3,09 0,001992543 3,74E-02 
Adck3 13,12 -2,01 0,65 -3,09 0,002017537 3,77E-02 
Wdr35 11,72 -1,80 0,58 -3,09 0,002011956 3,77E-02 
Prps1l3 173,94 -1,13 0,36 -3,09 0,002025864 3,77E-02 
Zfand2a 804,83 -1,11 0,36 -3,09 0,002031163 3,77E-02 
Hspa9 2277,58 -0,86 0,28 -3,08 0,002070611 3,82E-02 
Fbxo18 676,67 -0,97 0,32 -3,07 0,002126377 3,90E-02 
Otogl 42,02 -1,89 0,62 -3,06 0,002178307 3,95E-02 
Prkcb 38,55 -1,73 0,57 -3,06 0,00217824 3,95E-02 
Kcnip4 82,35 -1,17 0,38 -3,06 0,002199374 3,98E-02 
Tgfbr3 211,83 -1,09 0,35 -3,06 0,002206642 3,98E-02 
Mark2 1363,98 -1,35 0,44 -3,06 0,002244488 4,03E-02 
Ncstn 714,36 -1,53 0,50 -3,05 0,002285339 4,10E-02 
Gm4944 48,64 -1,49 0,49 -3,04 0,002371177 4,20E-02 
Ubqln1 4458,79 -1,11 0,36 -3,04 0,002365666 4,20E-02 
Cry1 2535,49 -1,08 0,35 -3,04 0,00236112 4,20E-02 
Birc3 10023,94 -0,97 0,32 -3,04 0,002389359 4,21E-02 
Lrp2bp 59,24 -1,11 0,37 -3,03 0,002407809 4,22E-02 
Kif23 7111,11 -1,04 0,34 -3,03 0,002451693 4,29E-02 
Trim37 410,51 -1,06 0,35 -3,02 0,002497272 4,31E-02 
Mcm10 331,39 -0,88 0,29 -3,02 0,002511898 4,33E-02 
Cmtr2 548,16 -1,26 0,42 -3,02 0,002566937 4,40E-02 
Nlgn1 277,01 -0,95 0,32 -3,01 0,002572858 4,40E-02 
Tjap1 330,34 -0,99 0,33 -3,01 0,002611841 4,42E-02 
Zfp616 2081,74 -1,23 0,41 -3,01 0,002649374 4,44E-02 
Zfp74 239,48 -0,88 0,29 -3,01 0,002652699 4,44E-02 
Hps3 54,44 -1,27 0,42 -2,99 0,002744479 4,50E-02 
Gpatch1 566,51 -1,00 0,33 -2,99 0,002747123 4,50E-02 
Gm15941 491,00 -0,99 0,33 -3,00 0,002716769 4,50E-02 
Stard7 2323,70 -0,72 0,24 -2,99 0,002754808 4,51E-02 
Foxj2 40,07 -1,73 0,58 -2,99 0,002777968 4,51E-02 
Zfp750 747,75 -1,03 0,34 -2,99 0,002774316 4,51E-02 
Asun 655,32 -0,82 0,28 -2,99 0,002780115 4,51E-02 
Pde4a 62,21 -1,37 0,46 -2,99 0,002802948 4,54E-02 
Nlrp4f 14444,10 -0,99 0,33 -2,98 0,002906133 4,64E-02 
Acbd5 774,17 -0,85 0,29 -2,98 0,002906357 4,64E-02 
Exoc1 1483,66 -1,05 0,35 -2,98 0,00292798 4,65E-02 
Kdm7a 2114,01 -1,04 0,35 -2,97 0,002933188 4,65E-02 
Sh2b3 75,82 -1,02 0,34 -2,98 0,002920669 4,65E-02 
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Mtmr14 2775,72 -0,83 0,28 -2,97 0,002937988 4,65E-02 
Dcaf8 1881,60 -0,79 0,27 -2,97 0,002930771 4,65E-02 
Fbxo43 2449,07 -0,79 0,27 -2,97 0,00296084 4,65E-02 
Pggt1b 390,43 -1,06 0,36 -2,97 0,003002899 4,68E-02 
Hsdl1 193,61 -0,96 0,32 -2,97 0,003005912 4,68E-02 
Nlrp4g 4591,44 -1,01 0,34 -2,97 0,003025925 4,69E-02 
Ehd3 66,09 -1,26 0,43 -2,96 0,003047728 4,71E-02 
Ampd3 691,68 -1,50 0,51 -2,96 0,003124021 4,77E-02 
Slain1os 92,97 -1,12 0,38 -2,96 0,003125805 4,77E-02 
Phtf2 1514,50 -1,10 0,37 -2,95 0,003151601 4,80E-02 
Pspc1 19,25 -1,51 0,51 -2,95 0,003176371 4,80E-02 
Fam118a 2201,15 -0,99 0,34 -2,95 0,003174924 4,80E-02 
Mcm2 919,97 -0,89 0,30 -2,95 0,003167951 4,80E-02 
1700017B05Rik 134,41 -1,45 0,49 -2,95 0,003187706 4,81E-02 
Csde1 2026,30 -1,01 0,34 -2,94 0,003232403 4,87E-02 
Cs 1922,75 -0,93 0,31 -2,94 0,003244774 4,88E-02 
Tug1 169,60 -1,27 0,43 -2,94 0,003264094 4,90E-02 
Atl2 6031,51 -1,06 0,36 -2,94 0,003298633 4,94E-02 
Gpcpd1 1113,79 -1,00 0,34 -2,94 0,003305129 4,94E-02 
Slc7a6os 1197,28 -0,77 0,26 -2,94 0,003303365 4,94E-02 
6330409D20Rik 13,51 -1,69 0,58 -2,94 0,00331328 4,94E-02 
Klhl15 97,65 -1,03 0,35 -2,93 0,003343395 4,96E-02 
 
 
